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UGT1A gene family members encode for phase II metabolic enzymes that play a 
crucial role in the biotransformation of endogenous and exogenous compounds into 
highly active, lower activity or inactive compounds that are easily excreted from the 
body.  Many of these compounds include clinically administered drugs, hormones, 
bile acids and environmental toxins.  Compromised or excess expression of the 
UGT1A genes is commonly associated with adverse consequences such as 
hyperbilirubinemia, cancer progression or undesired drug-drug interactions.  Whilst a 
substantial amount of research has linked hepatic UGT1A gene expression to activated 
pregnane X receptor (PXR), upcoming research has evidenced extrahepatic UGT1A 
activity as very clinically relevant, although influenced by vitamin D receptor (VDR).  
Research in this direction is still at its infancy, the extent, clinical consequences and 
molecular mechanisms are not well understood.  This project aims to characterize 
VDR in the detoxification processes, particularly, the regulation of UGT1A gene 
family members and the molecular mechanisms involved.  Therefore, to address this 
issue, LS180 cells, that imitate 1,25D’s colonic physiological responses were used to 
investigate the regulation of the entire family at mRNA, protein and functional level.  
A series of reporter-based assays were implemented to define a functional and VDR 
specific binding motif. Upon identification of UGT1A4 as the most responsive to VDR 
ligands, novel tools such as CRISPRi genome editing, molecular cloning and 
characterization of the UGT1A promoter region were employed to examine putative 
binding motifs.  To extend upon this study, novel molecular mechanisms, to 
investigate the reciprocal effects of cross-talk between VDR and NRF2 signalling 
pathways were examined.  This interplay has direct implications for a range of 
physiological and pathological consequences, including enhanced detoxification, 
cancer prevention and anti-aging properties.  Contrary to previous findings, we 
identified that VDR was in this case dependant upon intact NRF2 signalling. 
Furthermore, the interaction of both NRF2 and VDR signalling pathways did not 
significantly enhance UGT1A gene expression, although, surprisingly, inhibitory 
effects were observed.  Although LS180 cells were predominantly used in our novel 
approaches, future studies should incooperate other cell model systems were NRF2 





Collectively this study contributes towards our understanding of VDR and its co-
operative activities that influence UGT1A gene expression and NRF2 signalling 
pathways. Whilst the study highlights the impact of VDR ligand co-administration 
with glucuronidation susceptible drugs, this study reinforces the importance of 
maintaining optimal 1,25D levels for chronic disease prevention, management of 
hereditary hyperbilirubinemia and neonatal jaundice. Perhaps, employing novel 
approaches using these findings will be the best advancement, where UGT1A 
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1 Introduction  
 
1.1 Vitamin D and its bio-synthesis  
 
The structural characterization of Vitamin D led to the isolation of Vitamin D2 from 
an irradiation mixture and Vitamin D3 from 7-dehydrocholesterol (7-DHC) (Askew et 
al., 1932).  Holick et al., (1981) revealed a new Vitamin D concept signifying that pre-
Vitamin D3 was formed in the skin via ultra violet (UVB) irradiation.  To date, the skin 
is the most important source of Vitamin D3, which is dependent upon UVB intensity 
(290-320nm), melanin (which blocks UVB from reaching 7-DHC), sunscreen, 
clothing, season and latitude (Holick, 2004).   With regards to the latter, the further 
from the equator, the less solar exposure to produce Vitamin D3 (Jelinek et al., 2015).  
UVB disrupts a b-ring on the 7-DHC, found in the epidermal layer of the skin. This 
forms the thermo-sensitive pre-Vitamin D3 (Webb et al., 1989).  Reacting to the 37°C 
body heat in a non-catalytic process, pre-vitamin D3 isomerizes to form Vitamin D3 
(cholecalciferol) (Webb et al., 1989) (See Figure 1.1).  Vitamin D can also be acquired 
through a limited selection of dietary foods including fatty fish and UVB irradiation 
of the ergosterol in plants (green leafy vegetables and fungi) forming Vitamin D2 
(Holick et al., 2008).     
 
The difference between Vitamin D3 and D2 is that the latter has a double bond between 
Carbon 22 (C-22), C-23 and in addition, a methyl group at C-24 in the side chain 
(Hollis et al., 1984). These differences affect catabolism capabilities; hence, a higher 
Vitamin D2 dose is required to reach comparable amounts of Vitamin D3 in the blood 
stream (Hollis et al., 1984).  Furthermore, Vitamin D2 has a lower affinity for 
association with Vitamin D Binding Protein (VDBP) and faster clearance from the 
circulation (Delanghe et al., 2015).  A major proportion of Vitamin D is bound to the 
VDBP, which functions to transport Vitamin D metabolites between the liver, kidney 
and various other target tissue (Delanghe et al., 2015). 
 
1.1.2 Hepatic and Renal Metabolism of Vitamin D  
 
Both Vitamin D3 and Vitamin D2 are not biologically active, and as such, go through 




2012).  Transported by VDBP, the first site of metabolism is the liver, where the 
hepatic endoplasmic reticulum (ER) phase I metabolic enzyme,  cytochrome P450 2R1 
(CYP2R1) facilitates in C-25 hydroxylation  producing the 25-hydroxyvitamin D3 
(25(OH) D3), which is the major circulating form of Vitamin D, serving as a 
biomarker for Vitamin D status (Zerwerk, 2008).  The 25(OH) D3/VDBP complex is 
filtered in the kidney (glomerulus) were the VDBP binds to the lipoprotein known as 
megalin, resulting in the endocytotic internalization of 25(OH) D3 (Kalousovu et al., 
2015).  25(OH) D3 is further hydroxylated at the C-1 position of the α-ring by the 
CYP27B1 forming 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) (referred to as 1,25D 
hereafter), the functional form of Vitamin D, responsible for all of its biological actions 
(Kalousovu et al., 2015) (See Figure 1.1).   
1.1.3 Homeostatic control of Vitamin D  
 
1,25D homeostatic control is facilitated by a strict balance between its 1α-
hydroxylation and 24-hydroxylation, by the mitochondrial CYP24A1 enzyme (Jones 
et al., 2011).  The latter results in 1,24,25-dihydroxyvitamin D3, a target for excretion 
(Jones et al., 2011).  Both enzymes are rigorously controlled by 1,25D, serum calcium 
and phosphate levels (Veldurthy et al., 2016).  Low calcium or 1,25D causes 
parathyroid hormone (PTH) secretion by the parathyroid glands (Veldurthy et al., 
2016). This stimulates increased expression of CYP27B1, resulting in 1,25D synthesis 
(Anderson et al., 2004).  On the other hand, PTH inhibits CYP24A1 enzymatic activity 
whilst inducing fibroblast growth factor 23 (FGF23) synthesis in osteoclast and 
osteocytes, causing a reduction in sodium phosphate transporters (Shigematsu et al., 
1986). Interestingly, FGF23 controls 1,25D levels by suppressing CYP27B1 
enzymatic activity, while increasing that of CYP24A1 (Haussler et al., 2012).  In this 
case, 1,25D and calcium are reduced under hyperphosphatemia conditions.  Klotho is 
highly expressed in the distal tubule of the kidney, and acts as an obligate co-receptor 
for FGF23 and as such required by FGF23 to activate fibroblast growth factor 
receptors (FGFRs) (Donate-Correa et al., 2019). Similar to FGF23, klotho also 
suppress the expression of CYP27B1 and induces CYP24A1, thereby inhibiting the 
synthesis and promoting the catabolism of 1,25D (Bachetta et al., 2013).  The actions 
of CYP24A1 increase with age, hence the increase in 1,25D catabolism, which is a 




mediates intracellular 1,25D as it is also expressed in cells containing VDR (Osanai 
and Lee, 2016).  These findings have been the forefront of Vitamin D analogue design 














Figure 1.1: Chemical Structures and Vitamin D Biosynthesis. Pre-Vitamin D3 is 
synthesized in the epidermal layer of the skin from 7-dehydrocholesterol by the action 
of UVB light from sunlight. Thermal isomerization converts pre-Vitamin D3 to Vitamin 
D3 , which is transported to the liver.  Hepatic CYP2R1 and CYP27A1 enzymes 
catalyse 25-hydroxylation of Vitamin D3 and the plant-based Vitamin D2. The product 
is further transported to the kidney for a further 1α-hydroxylation to the biologically 
active form, 1α,25-dihydroxyvitamin D3 by CYP27B1. Holick et al., 1987) (Image 






1.2 Actions of Vitamin D  
 
1.2.1 Regulation of Mineral Homeostasis (Classical Role of Vitamin 
D)   
 
1,25D regulates calcium and phosphate levels by facilitating absorption, renal 
excretion and calcium bone utilization (Mundy and Guise, 1999).    Diminished 
calcium levels lead to PTH secretion and 1,25D synthesis, resulting in the stimulation 
of calcium renal re-absorption (Blaine et al., 2015).  If the calcium levels are in excess, 
the parafollicular cells on the thyroid secrete calcitonin, block calcium mobilization 
and increase calcium and phosphorus excretion (Morris and Anderson, 2010).  This 
process regulates calcium levels.  Conversely, an increase in serum calcium levels 
reduces PTH secretion, 1,25D synthesis and calcium utilization (Morris and Anderson, 
2010).   
 
Additionally, 1,25D targets three tissues for mineral homeostatic control (Fleet, 2017). 
In intestinal tissue, 1,25D stimulates intestinal calcium absorption, though affected by 
intestinal solubility, diet and absorption capacity (Fleet and Schoch, 2011).  Optimum 
calcium levels are required for trans-cellular calcium transportation (Christakos et al., 
2011).  Hoenderop et al., (2003) characterized member of the transient receptor 
potential cation channel subfamilies V (TRPVs) including TRPV6 as important 
calcium transport channels. The expression of these and other transporters (calbindin-
D9K, and Plasma membrane Ca2+ ATPase 1b (PMCA1b)) are highly regulated by 
1,25D (Choi and Jeung, 2008).  Secondly, 1,25D along with PTH induces renal distal 
tubule reabsorption of calcium (Blaine et al., 2015).   1,25D stimulates calcium cellular 
influx through the apical membrane, calbamicin-mediated calcium diffusion and its 
transportation through the basolateral membrane (Wong and Ko, 2002).  Renal 
phosphate reabsorption is inhibited by 1,25D (Haussler et al., 2012). This is an indirect 
consequence of FGF23 and klotho induction in osteocytes (Haussler et al., 2012).    
 
Additionally, 1,25D mobilizes calcium from the bone through the involvement of PTH 
(Gil et al., 2018).  Diminished calcium levels lead to PTH mediated 1,25D activation 
(Tebben et al., 2016). Vitamin D Receptor (VDR)-induced differentiation of 




by stimulating the secretion of receptor activator for nuclear factor kappa-β ligand 
(RANKL) which acts as a precursor for osteoclasogenesis and bone resorption (Boyce 
and Xing, 2008). Moreover, 1,25D inhibits mineralization through the increase of 
pyrophosphate levels and osteopontin (Gil et al., 2018).  1,25D also promotes growth 
and bone formation through the activation of chondrocyte differentiation and 
increasing serum calcium and phosphate levels (Bikle, 2013).   Evidently, Vitamin D 
deficiency results in inadequate mineralization of skeletal bones. 1,25D defiant 
individuals means bone health is diminished due to calcium and phosphate depletion.  
1,25D suppresses the parathyroid gene expression and parathyroid cell proliferation, 
again reinforcing its control of calcium regulation (Bikle, 2013).     
 
1.3 Clinical Recommendation of Vitamin D  
 
1,25D is implicated with numerous clinical consequences (discussed in section 
1.5).Therefore maintaining optimum levels within the global population is evidently 
vital.  What is challenging to scientists are the many factors that impact optimum 
1,25D levels.  Even though 1,25D has been under scrutiny for most part of the century, 
there is still much controversy regarding its daily-recommended allowance (RDA), 
because the above-mentioned factors and many others need to be considered.  Prior to 
2010, the recommended RDA for an adult was 200IU/day (Glerup et al., 2000).  
However, the USA Institutes of Medicine (IOM) refuted this because it only 
considered optimum levels for rickets prevention and not the other physiological 
benefits (Holick et al., 2011).  The IOM then recommended 600IU/day for an average 
adult and at least 800IU/day for adults over the age of 70, one reason being its 
increased catabolism rate (Boucher, 2012). Priemel et al., (2010) recommended 
20ng/ml 25(OH)D3 serum concentration for adequate physiological health.  This was 
challenged by Garland et al., (2015) who observed that 30ng/ml 25(OH)D3 yielded a 
better prognosis for chronic illnesses, although a limitation to this and similar studies 
is they point towards higher concentrations  as the minimal for physiological webb-
being. Consequently, even the IOM’s recommendations were suggestive as a better fit 
for subclinical osteomalacia prevention (Bischoff and Willet, 2010).  Modern societal 
habits prevent sunlight exposure from which 80% of Vitamin D is derived, and as 




(Spiro and Buttris,2014). The current European guidelines recommend 30-50ng/ml. 
This was also in line with the guidelines for 25(OH)D3 in United Arab Emirates and 
Gulf population (Haq et al, 2018). These guidelines, unlike that of IOM do consider 
the pleotropic actions of 1,25D (Haq et al., 2018).  The challenge with setting uniform 
RDA guidelines on a global scale depends of several clinical and environmental 
factors, including skin pigmentation, latitude of residence, diet, clothing and exposure 
to sunlight.  Table 1.1 however, provides the recommended 1,25D daily intake 
guidelines taken from the IOM, European Food and Safety Authority (EFSA) and 
Scientific Committee or Food (SCF) (Spiro and Buttriss, 2014). Furthermore, 
authorities have since based their recommendations on the following blood levels 
(Norman, 2008): 
 
• Severe Vitamin D Deficiency  <5ng/ml 
• Vitamin D Deficiency 5-10ng/ml 
• Vitamin D insufficiency 10-20ng/ml 
• Sufficient 25(OH)D3 > 30-60ng/ml 
• Risk of toxicity >150ng/ml 
 
While there is an urgent need to combat 1,25D deficiency, the RDA guidelines are 
critical, as excessive intake leads to toxicity, resulting in hypercalcemia and as such, 









Table 1.1:  The recommended daily intake for Vitamin D, taken from EFSA and 
IOM (Spiro and Buttriss, 2014) 
 
1.4 Genomic Mechanisms of Vitamin D 
 
1.4.1 Introduction to Nuclear Receptors 
 
The biological responses of 1,25D are mediated by its actions as a ligand to the 
Vitamin D receptor (VDR) (Ryan et al., 2015). VDR also known as nuclear receptor 
subfamily 1 group 1, member 1 (NR1I1), forms part of the 49 Nuclear Receptor (NR) 
superfamily members that evolved from common ancestry (Krasowski et al., (2005) 
(Examples shown in Table 1.2).  NRs are divided in to seven sub-families according 
to their homology in the ligand and DNA binding domains (Kwasowski et al., 2005).  
Pregnane X Receptor (PXR, NR1I2) is the closest relative to VDR. Both share a 
common modular structure and also derived from a duplication of a single ancestral 
gene following examination of the Ciona intestinalis gene in the genome of chordate 
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Figure 1.2: A schematic representation of VDR functional domains.  (A) VDR 
domains (B) Ligand binding domains (C) The binding mode of Vitamin D in the 
binding domain (D) The DNA binding domain of VDR. (Image from Iqbal and Khan, 
2017).   
 
1.4.2 Vitamin D Receptor (VDR) 
 
The past two decades of 1,25D examination have seen its influence on nearly every 
tissue and organ, across numerous species, including mammals, birds, amphibians, 
and reptiles (Krasowski et al., 2011).  At least all mammalian genomes analysed to 
date express the VDR gene (Reschly et al., 2007). Human VDR expression ranges 
from brain, gut, skeletal muscle and immune cells. Detection in the liver and Central 
Nervous System (CNS) has been a challenge (Reschly et al., 2007).  
 
The 472 amino acid VDR protein encompasses two functional units, the DBD and the 
LBD. (See Figure 1.2) (Campbell et al., 2010).  Evidence from an x-ray 
crystallographic structure determined that the α-helical sandwich-like structure allows 
VDR surfaces to form heterodimers with retinoid x receptor- (RXRα, RXRβ or 
RXRγ), following its liganding with 1,25D (Dawson et al., 2012).  Only the liganded 
VDR/RXR heterodimeric complex is able to access and recognize the Vitamin D 




Meyer, 2010).  VDREs commonly consists of either direct repeat of two half elements 
with three nucleotides spacers (DR3) with an AGGTCA consensus sequence 
(Thummel et al., 2001). Everted repeat of two half-elements with 6 nucleotide spacers 
(ER6) are the less common responsive motifs (Thummel et al., 2001).  PXR also 
employs RXR as its heterodimeric partner. The complex also recognizes the DR3 and 
ER6 motifs (Wallace et al., 2013). VDREs are typically positioned proximally in the 
promoter region of target genes, although this is not always the case (Pike and Meyer, 
2010). For example, human CYP3A4 VDRE is located close to 7.5kb upstream of its 
transcription start site (TSS) (Gombart et al., 2012 and Thompson et al., 2002).  The 
genomic mechanism of 1,25D/VDR signaling results in either target gene 
transactivation or repression (Carlberg et al., 2013). Following the heterodimeric 
complex binding to the VDRE, gene expression is mediated through the ability to 
recruit transcriptional complexes (Stees et al., 2012). The co-regulatory complexes 
primarily bind to the AF-2/H12 domain of the VDR (Kraichely et al., 1999).   These 
include p160 co-activators, steroid receptor activators 1, 2 and 3 (SRC-1, SRC-2 and 
SRC-3) (Teichert et al., 2009).  SRC co-activators contain Leucine (L-xxL, x is any 
amino acid) motifs that facilitate binding to VDR and multiple other NRs (Teichert et 
al., 2009).  SRC co-activators recruit other secondary protein, for example, a large 
macromolecular co-activator complex, DRIP/TRAP, the CBP/p300 complex, SMAD-
3 and NCoA62, which in addition to p160 co-activators have histone acetylase 
transferase (HAT) activity (Rachez et al., 2000). Further emerging evidence of 
individual gene regulatory activities has so far detailed how the machineries operate 
to enhance or suppress the expression of target genes.  Crystallographic analysis 
identified 1,25D inhabiting the hydrophobic pocket and molecular modelling 
identified lithocholic acid (LCA) to associate compatibly with VDR, also confirming 
the NR involvement in bile acid (BA) biology (Masuno et al., 2013). Haussler et al., 
(2016) further identified numerous low affinity VDR ligands including ω3‐ and ω6‐
essential polyunsaturated fatty acids (PUFAs), docosahexaenoic acid (DHA), 
arachidonic acid, and γ‐tocotrienol (Vitamin E derivative). New knowledge on novel 
concepts will further the understanding of 1,25D/VDR signaling to develop 
sustainable nutritional solutions to prevent or treat diseases, particularly where VDR 






1.4.3 Genome-wide studies of VDR/RXR binding in various cell lines  
 
Transcriptome-wide analysis on numerous in-vitro and in-vivo models indicated more 
than 1000 genes are direct VDR target genes (Vukic et al., 2015 and Pike et al., 2016). 
On a genome-wide level, chromatin immunoprecipitation –sequencing (ChIP-seq) 
data has also expanded insight on the genomic VDR binding loci, with emerging data 
on B-lymphocytes, T+HP-1 monocytic cells and colon cancer cells (Meyer et al., 
2012).  Beyond mineral homeostasis, 1,25D has been implicated with a global network 
of genes such as Cyclin Dependent Kinase Inhibitor 1A (CDKN1A), Glutamate-
cystein ligase catalytic subunit (GCLC) in addition to the  Growth arrest and DNA-
damage-inducible protein (GADD45A), (involved in cell cycle, glutathione synthesis 
and growth regulation respectively) that function to maintain cellular as well as overall 
physiological health (Protiva et al., 2009).  Classically, much of 1,25D’s physiological 
mechanisms have been investigated in whole organisms, however within the last 
decade, scientists have implemented powerful tools such as genome-wide 
microarrays, large-scale genome sequencing and genomic approaches for molecular 
characterization. Initially, the 1,25D-induced transcriptome by microarray analysis 
reported a small number of target genes from the colon, prostate and breast (Palmer et 
al., 2003, Krishnan et al., 2004 and Swami et al., 2003).  Although still in the early 
phase, Wang et al., (2005) further identified 913 1,25D responsive genes by 
oligonucleotide microarray in SCC25 cells. In the same study, a combination of 35,000 
gene microarrays and genome-wide screens identified that 65% of the VDREs 
identified within 1,25D target genes were within -10 to 5kbp of the 5’-region 
(transcription start site ; TSS) of the gene.  A study by Ramagopalan et al., (2010) later 
determined 2776 VDR binding motifs in lymphoblastoid cells, with enriched sites 
within Cyclin-C gene (CCNC), the intronic region of Arachidonate 5-lipoxygenase 
(ALOX5), and VDR gene itself.  The ChIP-seq analysis further determined significant 
changes in expression of genes such as Interferon regulatory factor 8 (IRF8) and 
Tyrosine-protein phosphatase non-receptor type 2 (PTPN2) following 1,25D exposure 
(Ramagopalan et al., 2010). Further genome-wide investigation of 1,25D’s actions 
was focused on osteoblasts in view of its bone anabolic activity (Meyer et al., 2010).  




that gene regulation occurs near the transcriptional start site (TSS). 43% binding sites 
occupied by VDR, RXR and H4 acetylation were distal, 44% within introns and exons 
(Meyer et al., 2010) Only 13% motifs were proximally occupied (Meyer et al., 2010)  
Interestingly, majority of basal VDR binding overlap those defined following 1,25D 
exposure, suggesting that selective occupancy by VDR does not require the ligand for 
activation (Meyer et al., 2010). This is contrary to other TFs such as PXR where DNA 
binding is a principle characteristic.     Another intriguing finding from the ChIP-seq 
data set is that RXR pre-occupies VDR binding motifs, suggesting that RXR is a good 
indicator of potential VDR activity (Meyer et al., 2012). However, the fundamental 
nature of this binding is still not fully understood.  De novo sequence motifs that 
represent both VDR/RXR complex binding motifs have since been implemented.  The 
most common DR3-type VDRE consensus sequence, first identified by Kerner et al., 
(1989) is frequently defined.  In most experiments, the multiple VDREs on the genome 
have correlated with synergistic activation mechanism (Kim et al., 2006). 
Additionally, Campbell (2014) suggested that the linking of distal with proximal 
VDREs via DNA chromatin looping creates a single platform that supports this 
synergistic transcriptome machinery (Figure 1.3). Chromatin configuration and the 
utilization of multiple VDREs works as an advantage in that, many co-regulatory 
complexes are recruited simultaneously, fine-tuning and contributing towards 
combinatorial synergistic transactivation (Campbell, 2014) Contrary to this, Onal et 
al., (2016) suggested that unique distal enhancers are linked to transactivation. For 
example, enhancers RL-D5 and RL-D6, are involved in the induction of RANKL, but 
the same was not observed for RL-T1 enhancer (Onal et al., 2016).  More relevant to 
our study are genome-wide data sets from LS180 cells where 1,25D activities closely 
recapitulate intestinal and colon physiology (Meyer et al.,2012).  In this study, 262 
VDR binding motifs were identified under basal conditions; however, the ChIP-seq 
data reveals a 2209 increase following 1,25D treatment (Meyer et al.,2012)  RXR 
binding also increased by 6-fold in a 1,25D dependant manner in the same study 
(Meyer et al., 2012). RXR binding occupied over 75% VDR binding sites Meyer et 
al., (2012).  In addition to VDR/RXR binding motifs, transcription factor 7-like 2 
(TCF7/L2/TCF4)/β-catenin cistromes and the genes these TFs regulate were also 
identified (Meyer et al., 2012). Amongst these genes were c-MYC, c-FOS and 




(Meyer et al., 2010).  Our laboratory and others have since defined functional VDREs 
within the genes’ (CYP3A) promoter region. Investigations are still rudimentary; 
however, it is clear that 1,25D is of uttermost significance in malignancies and 
detoxification pathways.  Altogether these and subsequent studies applying advanced 
molecular approaches will provide a new insight into cell and tissue specific 1,25D 













Figure 1.3: Gene transcription activity. Gene transcription is tightly controlled. As 
shown here, the liganded transcription factor complex binds to proximal response 
elements and distal enhancers within the gene’s promoter region. Co-regulatory 
complexes and RNA polymerase II recruitment initiate gene transactivation 










1.5 Non-classical Roles of Vitamin D  
 
1.5.1 Vitamin D and Immunology  
 
Lagishetty et al., (2011) identified that 1,25D stimulates innate immune responses. 
The first evidence being the treatment of tuberculosis with cod liver oil (Green, 2011). 
This involved macrophages and monocytic scavenging of Mycobacterium 
tuberculosis (Green, 2011). Additionally 1,25D regulates antimicrobial protein levels 
and may be crucial in infection control. These include the expression of defensin β2 
(DEFB) and cathelicinin antimicrobial peptide (hCAP18) (Gombart et al., 2009).  Jean 
et al., (2017) also linked low 1,25D levels to increased mortality in end-stage renal 
patients with severe infection. 1,25D has also proven its importance in association 
with influenza and allergic asthma (Ali et al., 2017).  Dendritic cells (DC) are also an 
important target for immune modulatory effects of 1,25D (Prietl et al., 2013). 1,25D 
alters the function and morphology of DC, inducing immature DCs with decreased 
major histocompatibility complex (MHC) class II and co-stimulatory molecule 
expression that reduces antigen-presenting process (Prietl et al., 2013).  Animal 
models studies by Adzemovic et al., (2013) found that 1,25D ameliorates Type 1 
Diabetes (TID) and Multiple Sclerosis (MS) Furthermore, VDR knockout mice 
showed an increase in inflammation and development of TID and Crohn’s disease, 
along with disturbed T-cell homing and lack of host protection from bacterial 
infections (Ardesia et al., 2015).    
 
1.5.2 Vitamin D and Cardiovascular Diseases 
 
1,25D, through UVB light exposure was linked to decrease blood pressure (BP), 
resulting in the suppression of renin (McMullan et al., 2017).  Additionally, Xiang et 
al., (2005) observed that mice with abolished VDR expression were hyperreninemic 
and presented with high BP and hypertrophy.  Additionally Pilz et al., (2009) 
identified 1,25D’s ability in regulating BP through the prevention of secondary 
hyperparathyroidism.  Molecular mechanisms further revealed 1,25D’s inhibitory 
effects on the renin –angiotensin system and nuclear factor β pathway (NFKβ) which 





1.5.3 Vitamin D and Neurodegenerative Disorders  
 
Adding to the on-going evidence of 1,25D’s extra-skeletal roles, Littlejohns et al., 
(2014) confirm that 1,25D deficiency is associated with a substantial increased risk of 
dementia and Alzheimer disease.  Contrary to this finding, Olsson et al., (2017) found 
in a cohort study that there was no association between baseline 1,25D status, dementia 
or cognitive impairment. Zündorf and Reiser, (2011) concluded that calcium 
dysregulation is influential on brain cell death , Parkinson’s disease, Huntington’s 
disease and Alzheimer’s disease development.     
 
1.5.4 Vitamin D and Malignancies 
 
1,25D deficiency is frequently correlated with high incidence and mortality in 
malignancies (Grant et al., 2009). As observed in numerous cancer cell types, 1,25D 
stimulates cellular differentiation and inhibits proliferation by regulating Cyclin 
dependant kinase inhibitors (CDKIs) (Jensen et al., 2001).  CDKI are key proteins 
involved in cell cycle initiation (Jensen et al., 2001).  Flores et al., (2010) also 
identified that 1,25D regulates the DNA damage 45α (GADD45A) gene which 
induces cell cycle arrest in G0/G1.  The c-MYC oncogene, whose products promote 
cell proliferation, immortalization and reverse differentiation, is repressed by 1,25D 
(Saleh-Tabar et al., 2012). Additionally Levresse et al., (2002) identified that in non-
small cell lung cancer (NSCLC) c-JUN overexpression correlated with primary and 
metastatic lung tumour cases, contrary to normal tissue, which did not express c-JUN. 
Likewise, c-FOS was associate with high-grade lesion and poor prognosis (Liu et al., 
2016).  
 
Colorectal cancer (CRC) and 1,25D have in recent years been a topic of interest, 
particularly because CRC is becoming a critical health problem and there is a 
worldwide need for effective chemopreventative/chemotherapeutic measures. With a 
significantly high VDR expression profile in intestines, researchers such as Ferrer-
Mayorga et al., (2019) have since evaluated the effects of 1,25D in CRC. So far, it is 
known that the Wnt/β-catenin signalling pathway, involved in CRC progression is 
antagonized by 1,25D through various events (Larriba et al., 2013).  These include 




1,25D also abrogates nuclear β-catenin content by promoting binding of β-catenin to 
E-cadherin which is regulated by 1,25D (Larriba et al., 2013). Furthermore, Larriba et 
al., (2013) noted that in CRC patients, 1,25D suppressed β-catenin whilst inducing E-
cadherin.  Furthermore, angiogenesis, migration and invasiveness are repressed by 
1,25D through the downregulation of genes such as Dickkopf 4 (DKK-4) (Aguilera et 
al., 2007). Angiogenesis is abrogated through control of vascular endothelial growth 
factor (VEGF), inhibitor of differentiation (ID)-1/2 and thrombospondin (TSP)-1 
genes, an effect that was observed in both human in vitro and rat model systems ( 
Shibuya, 2011).  MicroRNAs  (miR) such as miR-22 induced by 1,25D were found to 
be involved in antiproliferative, anti-migratory, tumour growth inhibition and 
suppressed invasion effects in several cancer cell lines (Alvarez-Diaz et al., 2012).  
With the above-mentioned and many more findings associated with 1,25D and 
malignancies, there seems to be potential in VDR agonist use as a chemotherapeutic, 
or better yet, chemo-preventative measure.   
 
1.5.5 Vitamin D and Metabolism  
 
Xenobiotic metabolism involves a set of specialized enzymatic pathways that facilitate 
in the biotransformation of toxic substances such as drugs, carcinogens, environmental 
toxins and endogenous compounds into easily excretable forms (Penner et al., 2012). 
There are three phases of xenobiotic metabolism, namely phase I reactions which 
introduce reactive or polar groups to susceptible substances. Phase II reactions 
catalyse conjugation reactions of phase I metabolites and Phase III transporters 
facilitate in the basolateral efflux of conjugated metabolites for excretion in the bile or 
urine (Xu et al., 2005) (See Figure 1.4).  The nuclear receptor subfamily 1 group I 
(NR1I) family members (e.g. VDR, PXR and CAR) play a central role in the 
xenobiotic metabolism, integrating a network of transcriptional target gene products 
that orchestrate the defence against toxic endogenous and exogenous substances 
(Prakash et al., (2015). While a broad spectrum of chemicals serve as prototypical 
ligands for PXR, VDR agonists are restricted to 1,25D, its hydroxylated metabolites 
and secondary bile acids. (Khedkar et al., 2017; Makishima et al., 2002).  We and 
others have defined VDR activity to induce phase I CYP3A expression (Maguire et al., 
2012, Doherty et al., 2014).  In expanding upon our knowledge was the earlier 




(Thompson et al., 2012). Seo et al., (2013) also observed VDR mediated SULT2B1 in 
prostatic cancer cells, an effect thought to suppress disease progression.  Shen and 
Kong, (2009) and our laboratory-based evidence has correlated multidrug resistant 
protein 1 (MDR1) and multidrug resistant associated protein 2 (MRP2) phase III 
transporters expression with VDR activation.    
 
Much of our attention is on our unpublished data that links the phase II metabolic gene, 
Uridine 5’diphsophoglucuronosyltransferase 1 A (UGT1A) induction to VDR 
activation.  Although extensive extrahepatic UGT1A gene profile regulation by VDR 
has not yet been conducted, multiple VDR/RXR binding sites have been identified 
within the UGT1A locus. Additionally, attempts by Wang et al., (2016) identified 13 
putative VDREs within the 10kb UGT1A8 and UGT1A10 promoter region.  Whilst 
significant attempts have been employed, the regulatory mechanisms have not been 
examined fully; therefore, this study aims to fully characterize this at a molecular level 
as further discussed below.   
 
 
Figure 1.4: A representation of cellular detoxification. Phase I metabolism involves 
oxidation, reduction and hydroxylation reactions of hydrophobic substances.  The 
metabolites usually undergo further conjugation reactions by phase II metabolic 
enzymes, converting water-soluble forms that can be easily exported by phase III 





1.6 UDP-Glucuronosyltransferases 1A (UGT1As) 
 
Of the above-mentioned phase II detoxification processes, glucuronidation, mediated 
by UGT1As is the most significant, representing the pathway of critical compounds, 
which, if disrupted leads to serious clinical consequences (Section 1.6.4).   
Glucuronidation occurs following transfer of the glucuronic acid moiety from a 
ubiquitous co-substrate uridine diphosphoglucuronic acid (UDPGlcA) to susceptible 
substrates, forming a glucuronide derivatives (-G) which are consequently more easily 
excreted from the body due to the carboxyl group’s ionized state at physiological pH, 
thus increase water solubility of the otherwise hydrophobic substance (Mottino and 
Rodriguez, 1987) (Figure 1.5).  The glucuronide is transported by the biliary and renal 
organic anion efflux system, leading to secretion in the bile and urine respectively 
(Fujiwara et al., 2010).  Glucuronidation alters the chemical structure of xenobiotics 
and therefore; their biological function is diminished (Fujiwara et al., 2010).   
Glucuronidation is critical in the detoxification and clearance of endogenous 
hydrophobic substances including sex hormones, bile acids, bilirubin and fatty acids 
(Rowland et al., 2013). This mechanism maintains homeostasis and regulates the 
biological activity of these substances.  Interestingly, these substances are able to 
regulate the expression of UGT1A genes, thus generating a feedback loop and the 





















Figure 1.5: The endoplasmic reticulum (ER) glucuronidation pathway.  1. Substrate 
depicted as X-OH diffuses into the ER lumen. 2. The co-factor UDPGA is also 
transported into the lumen and transfers a molecule of glucuronic acid (GA) to the 
substrate. 3. This results in a conjugated substrate that is easily excreted by efflux 
transporters (Image edited from Liu and Coughtrie, 2017). 
 
Due to the UGT’s inherent localization within the luminal side of the endoplasmic 
reticulum (ER) membrane, rich in UDPGla, the structural analysis of UGTs to 
determine catalytic mechanisms is still being researched, however UGT cDNA 
cloning has enabled DNA based expression of individual gene family members for 
substrate specificity (Liu and Coughtrie, 2017). Izukawa et al., (2009) identified two 
UGT superfamilies, namely UGT1A and UGT2.  The UGT2 superfamily is further 
sub-divided into UGT2A and UGT2B, which contains three and seven individual 
isoforms respectively.  UGT2B gene family members within 4q13 gene loci contain 
six specific exons (Strassburg et al., 1997).  HEK293 cells stably expressing UGT2B 
isoforms demonstrated glucuronidation towards endogenous substances including sex 
hormones and bile acids (Strassburg et al., 1997).  Turgeon et al., (2001) and 




significantly expressed in prostatic cancer cell lines, and mainly catalyze testosterone 
and dihydrotestosterone glucuronidation.  These findings suggest the important role 
of glucuronidation in fine-tuning androgen signaling. As with endogenous 
compounds, UGT2B7 metabolizes epirubicin (hepatocellular carcinoma anti-cancer 
drug), an effect that contributes to acquired chemotherapeutic resistance (Hu et al., 
2014).  Nevertheless, the focus of this study, UGT1A gene family members encoded 
on chromosome 2q37.1, spans approximately 200kbp (Fujiwara et al., 2016). Their N-
terminal amino acid sequence contains isoform specific first exons, which exhibit 
significantly low amino acid sequence similarity (24-49%), and contribute towards 
substrate specificity (Strassburg et al., 1997.) The N-terminal is spliced to the highly 
conserved C-terminal amino acid sequence encoded by common exons (2-5), 
generating nine functional isozymes (UGT1A1, UGT1A3, UGT1A4, UGT1A5, 
UGT1A6, UGT1A7, UGT1A8, UGT1A9 and UGT1A10) (Fujiwara et al., 2016). 
(Figure 1.6).  The involvement of both N- and C-terminal in substrate binding was 
demonstrated by Radominska-Pandya et al., (2010) through a series of point 
mutations.  The findings demonstrated abrogated affinity towards substrates and 
UDPGlcA (Radominska-Pandya et al., (2010).  Interestingly, alternative splicing of 
exon 5 (exon 5b) resulting in the generation of UGT1A variant were recently observed 
(UGT1A_b) which generates a shorter amino acid sequence (Girard et al., 2007).  
Bellamare et al., (2010) later identified that the UGT1A_b protein is 45kDa compared 
to the main variant ranging from 50-55kDa. Moreover, the alternative products 
interact with the enzymatically active proteins, subsequently inhibiting their in vitro 
glucuronidation (Bellamare et al., (2010). However, the relative abundance activity of 
these variants needs further investigation to determine the extent of inhibition and its 





Figure 1.6: The genomic organization of the UGT1A loci on chromosome 2q37. The 
locus contains 9 unique first exons that are alternatively spliced at the 5’-end of the 
mRNA with common exons 2-5.  There is a TATA-box approximately 30bp upstream 
of each unique first exon sequence, which implies individual transcriptional 
regulation.   
 
1.6.1 UGT1A Tissue Distribution  
 
UGT1A mRNA expression profile was first quantified in human tissue samples using 
conventional RT-PCR and more recently by real-time RT-PCR (Nakamura et al., 
2010; Cengiz et al., 2015).  Findings by Court, (2010) and Nakamura et al., (2008) 
have shown a tissue specific distribution and inter-individual differences in UGT1A 
mRNA levels in various tissue types.  More precisely, UGT1A expression was detected 
predominantly in the liver, a major detoxification site, but also kidney, gastrointestinal 
tract, pancreas, lung, breast, brain, prostate and bladder (Tang et al., 2012) (Figure 
1.7).  Izukawa et al., (2009) successfully quantified UGT1A mRNA transcripts, 
although protein expression in human liver only correlated with UGT1A1 out of all 
the hepatic UGT1As.    Nonetheless, we and others have been able to correlate UGT1A 
mRNA transcripts with protein expression in extrahepatic cell line models (Wang et 
al., 2014 and Strassburg et al., 1998). Alas, isoform specific protein expression 
analysis has been impossible due to UGT1A gene family member’s high amino acid 




isotope-labelled peptide-based UGT1A expression by use of liquid chromatography-
tandem mass spectrometry (LC-MS/MS). Although this methodology has proven to 
be better than the standard western blot, the approach does not distinguish between 
UGT1A variants that occur due to alternative splicing.   So far, UGT1A1, UGT1A3, 
UGT1A4, UGT1A6 and UGT1A9 expression have been detected in human liver.  
UGT1A7, UGT1A8 and UGT1A10 were not detected in human liver microsomes 
(Strassburg et al., 1999 and Nakamura et al., 2005).  Extrahepatic exclusive UGT1As 
include UGT1A7, UGT1A8, UGT1A9 and UGT1A10, although mRNA expression of 
other isoforms were also detected (Tukey and Strassburg, 2000). The UGT1A6 and 


















Figure 1.7: Differential expression of UGT1A and UGT2B genes in normal human 
tissue.  Basal UGT1A isoform expression in normal human tissue including liver, lung, 
stomach, small intestine, colon, kidney, bladder, adrenal gland, breast, ovary, uterus, 
and testis were investigated by RT-PCR.  Liver, as a major glucuronidation site houses 
majority of expression. As shown UGT1A7, UGT1A8 and UGT1A10 are exclusive 





1.6.2 Transcriptional regulation of UGT1A gene family members 
 
Numerous transcription factors (TFs), are linked to UGT1A gene induction. For 
example, 2, 3,7,8-tetrachlordibenzo-p-dioxin (TCDD) activated Aryl Hydrocarbon 
Receptor (AhR), which  induced UGT1A8 and UGT1A10 in KYSE70 (human 
esophageal squamous carcinoma) cell line (Kalthof et al., 2010).  Xenobiotic 
Response Element (XRE) motif mutagenesis significantly abrogated this induction 
(Kalthof et al., 2010). Furthermore, Ugt1a6 and Ugt1a7 mRNA expression and 
glucuronidation activity acetaminophen was observed in rat brain samples in response 
to β-Naphthoflavone induced AhR activation (Sakakibata et al., 2016).  Constitutive 
Androstane Receptor (CAR), signaling is also evidenced to induced UGT1A induction 
(Xie et al., 2003).    Buckley and Klaassen, (2009) observed Ugt1a1 and Ugt1a9 
induction mRNA expression was induced by CAR prototypical ligand, 1,4-bis[2-(3,5-
dichloropyridyloxy) benzene (TCPOBOP).   Guo et al., (2003) exposed FXR-null and 
PXR-null mice models to TCPOBOP which were fed 1% cholic acid.  Metabolic gene 
products including hepatic CYP2B, CYP3A, MRP2 and most importantly UGT1As 
were significantly elevated (Guo et al., 2003). These findings represent CAR clinical 
significance in bile acid detoxification.  CAR is also a member of the NR superfamily 
similar to VDR and PXR (Krasowski et al., 2011). PXR is a key hepatic UGT1A1 
inducer, mainly responsible for bilirubin clearance (Sugatani et al., 2012).  Raynal et 
al., (2010) observed that PXR-expressing LS174T, SW480 and SW620 cells induced 
UGT1A1, UGT1A9 and UGT1A10 mRNA expression.   PXR-mediated UGT1A1 
transactivation was robustly enhanced compared to CAR and AhR (Sugatani et al., 
2012). Following the discovery of PXR in the 1990s, it has mostly been implicated 
with abrogating clinical consequences that include hyperbilirubinemia (Saini et al., 
2005). However, UGT1A enhanced induction, amongst other metabolic genes means 
that PXR is implicated with enhanced DDI, or reduced drug toxicity (Guo et al., 2003).  
Lamotrigine metabolism by UGT1A4 was enhanced by rifampicin exposure, which 
activated PXR.   (Chai et al., 2013).  The oxysterol-activated NR, Liver X-Receptor 
alpha (LXRα) is also a known UGT1A gene inducer (Edwards et al., 2002).  UGT1A3 
enhanced induction was observed in hepatic cells and Tg-UGT1A mice (Chen et al., 
2012).  The involved LXR response element (LXRE) was identified by ChIP assay 




expression abrogation and reduced LCA glucuronidation (forming LCA-24G) (Chen 
et al., 2012). Bedi et al., (2017) identified that, following LXRα activation, RXR 
heterodimer formation and binding to the LXRE, the LXRα recruits the SRC-1α and 
NcoR co-regulatory proteins for direct UGT1A3 transactivation.  In addition, 
Farnesoid X receptor (FXR), predominantly expressed in the liver is implicated with 
bile acid metabolism (Sun-Gi et al., 2016).  FXR also forms a heterodimer with RXR 
prior to the complex binding to FXR response element (FXRE), recruiting co-
activators and inducing gene expression (Sun-Gi et al., 2016).  Researchers including 
Erichsen et al., (2010) also observed FXR-mediated UGT1A3 induction, in addition 
to the identification of an FXR element within the gene’s 5’ upstream promoter region.  
This regulation was also confirmed by electrophoretic mobility shift assay (EMSA) 
following GW4064 exposure in colonic cells (Erichsen et al., (2010).  FXR mediated 
chenodeoxycholic acid (CDCA) glucuronidation further confirmed the biological 
relevance of FXR in the human bile acid detoxification (Chiang et al., 2013).   
Peroxisome proliferator-activated receptor alpha and gamma (PPARα and PPARγ) are 
ligand-activated TFs also belonging to the NR superfamily (Barbier et al., 2003). 
Barbier et al., (2003) identified that these NRs both induced UGT1A9 following 
prototypical ligand exposure using human hepatocytes, macrophages and murine 
adipocytes (Barbier et al., 2003).  PPARα mutagenesis abrogated UGT1A9 expression 
and enzymatic activity.  The direct mediation of this gene confirmed by a response 
element at the -719 to 706bp position of the UGT1A9 gene (Barbier et al., 2003).  This 
induction suggest that PPAR is clinically relevant in the genotoxic catecholestrogen 
metabolism and the control of fibrates.  The Nuclear factor erythroid 2-related factor 
2/Kelch-like ECH-associated protein 1 (NRF2/KEAP1) signaling pathway described 
in Section 1.7 induces UGT1A1 expression (Yueh and Tukey, 2007).  In this case, 
HepG2 cell lines exposed to NRF2 ligands implicated UGT1A1 with neutralization of 
oxidative and electrophilic stress.  In addition to UGT1A1/NRF2 induction in Tg-
UGT1A mice models, the ARE was identified at position -3328/-3323bp from the TSS 
(Yueh and Tukey, 2007).  Both UGT1A8 and UGT1A10 were also induced by NRF2 
in KYSE70 cell lines (Kalthof et al., 2010).  Likewise, in Tg-UGT1A mice exposure 
to coffee, which has been identified to activate NRF2 signaling, resulted in a 10-fold 
and 14-fold UGT1A induction in the liver and stomach respectively (Kalthof et al., 




in Section 1.6.3). As such, drugs, including Phenobarbital (PB) are widely used to 
restore UGT1A1 activity (Sugatani et al., 2001).  In fact, the use of PB led to the more 
extensive research on 5’ flanking region of UGT1A1 promoter region.  Termed the PB 
responsive enhancer module (gtPBREM), this 290bp fragment located at position -
3499 to -3210, and was characterized to contained multiple NRs binding sites 
including that for PXR, CAR and AhR.  Sugatani et al., (2001) also identified that 
Glucocorticoid Receptor (GR) regulates UGT1A1 and as such, GR responsive 
elements (GRE1 and GRE2) were also identified within the gtPBREM (Figure 1.10).  
Studies by Eeckhoute et al., (2004) also identified that major liver-enriched TFs, 
Hepatocyte Nuclear Factor 1 alpha (HNF1α) and HNF4α induce UGT1A expression.  
Following concerns over the TFs’ contribution in inter-individual variability, 
Aueviriyavit et al., (2007) further characterized this induction. UGT1A1, UGT1A3, 
UGT1A4, UGT1A6, UGT1A9 induction was altered in human liver samples by the two 
TFs.   
On the other end of the spectrum UGT1A regulation can be suppressed through post-
translational involvement of microRNAs such as miR-103b, miR-141–3p, miR-200a-
3p, and miR-376b-3p. This also suppresses glucuronidation acitivity by approximately 
30% (Papageorgiou and Court, 2010).  Dluzen et al., (2015) further confirmed UGT1A 
mediated miR-491-3p regulation in HepG2 cells.  Nonetheless, controlled 
glucuronidation by the above-mentioned factors ensures homeostatic balance of 
endogenous compounds and elimination of toxic foreign substances.  Compromised 


























Figure 1.8:  The phenobarbital responsive enhancer module nucleotide sequence.  
Shown here is the 290bp sequence at position -3499/-3210 upstream of the UGT1A1 
promoter region.  The fragment contains multiple NR response elements including 
DR3-type and DR4-type motifs which are recognised by NR heterodimeric complex 
binding and lead to subsequent UGT1A1 transcription.  Sugatani et al., (2005).   
 
1.6.3 UGT1A clinical relevance  
 
Diminished UGT1A enzymatic activity has highlighted its biological relevance.  
Single nucleotide polymorphisms (SNPs), resulting from a nucleotide mutations often 
lead to variants that confer reduced or increased UGT1A enzymatic phenotypes (Cox 
et al., 2013; Ehmer et al., 2012).   The wild-type UGT1A1*1 allele normally includes 
six thymine-adenine (TA6) repeats, referred to as the TATA box (Du et al., 2019). 
However, the most commonly studied variant, UGT1A1*28 is characterized by seven 
TA (TA)7TAA7) repeats and presents with impaired proper transactivation, resulting 
in close to 30% decrease in glucuronidation activity (Du et al., 2019).  UGT1A1 is the 
only enzyme associated with bilirubin metabolism.  Diminished metabolism results in 
increase serum bilirubin (hyperbilirubinemia) (Wagner et al., 2018). This clinical 
concern is usually a benign consequence of Gilbert’s Syndrome (GS) were serum 
bilirubin levels are above 5mg/dL (Yueh et al., 2017).  GS symptoms are very mild 




Other symptoms include tiredness, weakness, abdominal pains and nausea. The link 
between the latter symptoms and high serum bilirubin levels is still unclear (Sampietro 
and Iolascon, 1999 and Wagner et al., 2018).  GS diagnosis typically requires 
genotyping, liver function tests and measurement of serum bilirubin (Sampietro and 
Iolascon, 1999).  There currently is no treatment for GS, mostly due to its benign 
nature (Sampietro and Iolascon, 1999).  However, undesirable clinical consequences 
such as toxic effects from use of certain drugs such as irinotecan, metabolised by 
UGT1A1 may manifest (Singh and Jialal, 2019).  With over 3% of the global 
population as carriers and 1 in 3 individuals unaware, it is increasingly important to 
be aware of potential GS management avenues, to prevent devastatine consequences 
such as drug toxicity (Wagner et al., 2018).   
On the other hand, Crigler Najjar Type 1 (CNS1) disease is a serious form of 
hyperbilirubinemia, where individuals are homozygous or heterozygous carries of a 
completely inactive UGT1A1 allele (Viveksandeep and Savio, 2019). If left untreated, 
CNS I is fatal, due to irreversible fatal encelopathy (Fujiwara et al., 2017). A milder 
phenotype, CNS II results from mild UGT1A1 enzymatic activity following mutations 
with the UGT1A1 gene (Fujiwara et al., 2017). Hyperbilirubinemia in this case is 
usually treated by PB, however if left untreated, kernicterus (bilirubin build up in brain 
tissue) may still develop due to trauma or sepsis may develop (Aggarwal et al., 2001).  
CNS I usually requires phototherapy or even liver transplantation (Hammad et al., 
2017).  
Additionally variants such as UGT1A1*37 have eight TA repeats and its enzymatic 
activity is significantly lower than the UGT1A1*28 variant, whereas UGT1A1*36 has 
five TA repeats and results in increased enzymatic activity (Reira et al., 2018).  
Moreover, in Asian and African populations the UGT1A1*6 variant is the most 
common (Gao et al., 2013). This variant results in approximately 30% lower 
enzymatic activity and so carriers present with GS and neonatal hyperbilirubinemia 
(Ullah et al., 2016).   Currently, there are more than 113 UGT1A isoform variants, 
which either diminish or increase glucuronidation activity (Barbarno et al., 2014).  
Many of these variants have also been linked to malignancies (Barbarno et al., 2014).  
For example, UGT1A7*3 variant exhibited a highly significant association with 
colorectal cancer (Strassburg et al., 2002).  Benzo (α) pyrene-7, 8-dihydrodiol-9, 10-




Furthermore, Vukovic et al., (2018) found that UGT1A1*28 allele correlates with the 
development of colorectal and breast cancer risk in Asian and European populations. 
UGT1A1*6 specifically increases the risk of colorectal cancer in Chinese populations 
(Tang et al., 2005).  In addition to this, Lucy-Driscoll syndrome, a rare metabolic 
disorder, increases UGT1A1 activity inhibitors, also resulting in familial neonatal 
hyperbilirubinemia (Singh and Jailal, 2019).   
UGT1A7 is predominantly expressed in the oral cavity and as such, diminished 
expression is linked to oropharyngeal cancer development (Lacko et al., 2009).  
Additionally estrogen is a UGT1A10 substrate; therefore, cases of reduced 
glucuronidation have been associated with estrogen-related cancers (Lazarus et al., 
2009).  Glucuronidation also plays a role in the elimination of over 50% of clinically 
administered drugs (Yang et al., 2017).  For example, Irinotecan (used to treat colon 
cancer) is activated by phase I hydrolysis reaction to 7-Ethyl-10-hydroxycamptothecin 
(SN-38) (Wang et al., 2012). SN-38 is topoisomerase I inhibitor and thus prevents 
inhibition of both DNA replication and transcription (Wang et al., 2012).  SN-38 is a 
known UGT1A1 substrate.  The effects of reduced UGT1A1 expression lead to 
undesireably high amounts of unconjugated SN-38, leading to adverse effects such as 
diarrhoea and immunosuppression (Wang et al., 2012 and Ramchandani et al., 2007). 
 Furthermore, UGT1A8 and UGT1A10 are known substrates of mycophenolic acid 
(MPA), an immunosuppressant usually prescribed to kidney transplant patients (Wang 
et al., 2014).  An increase in their expression enhances drug clearance. This has 
become a major problem within the pharmaceutical industry due to inter-individual 
variability, drug-drug interactions and reduced drug efficacy (Wang et al., 2016).   
On the other hand, Wang et al., (2014)’s findings of 25(OH)D3-3-glucuronides in 
human plasma suggest that UGT1A3 and UGT1A4 enzymes may contribute towards 
homeostatic control of 1,25D in humans, although these findings are still limited, this 
may suggest a link between UGT1As and the 1,25D/VDR signaling pathway which 







Table 1.3: Differential glucuronidation of endogenous and exogenous substrates.   
UGT1A Sub-family  Endogenous Substrates  Exogenous Substrates  
UGT1A1 Bilirubin  
Cathecols 
































UGT1A7 Triiodothyronine (T3) 
Tetraiodothynine (T4) 
Glutaric Acid  





























 examples of susceptible substances commonly metabolised by the UGT1A gene 
family members (Franklin, 2007, Wang et al.,2014) Due to high sequence homology, 
there is evidence of substrate overlap; however the differential expression significantly 
contributes towards distinct clearance of these substances.  UGT1A5 is the least 
studied isoform; however, Finel et al., (2005) did confirm its glucuronidation 
capabilities of bile acids and a number of drugs.   
Table 1.4: Examples of UGT1A single nucleotide polymorphism (SNP) and their 
associated clinical concequences.   
UGT1A SNP Increased Risk  References 
UGT1A1*27  Irinotecan-induced toxicity  Fukuda et al., 2018 
UGT1A1*28 Hyperbilirubinemia,  Irinotecan 
toxicity  
Iyer et al., 2002 
UGT1A1*6 Gilbert’s Syndrome  Iyer et al., 2002 
UGT1A1*34 Crigler Najjar Syndrome I  Marques et al., 2010 
UGT1A1*35 Crigler Najjar Syndrome II Marques et al., 2010 
UGT1A1*37 Gilbert’s Syndrome Marques et al., 2010 
UGT1A3*1/3/5 Estrogen related cancers  Cailier et al., 2007  
UGT1A4*3 Haematological malignancies  Joeng et al., 2018 
UGT1A6*1/2 Lung Cancer  Kua et al., 2012 
UGT1A7*2/3 Orolaryngeal Cancer Zheng et al., 2001 
1.7 NRF2: The master regulator of oxidative stress   
 
Following oxidative stress (OS) insults, a number of signalling pathways, converging 
in the regulation of TFs, including NF-κβ, SP1, cAMP responsive element binding 
protein 1 (CREB-1) and Nuclear factor erythroid 2-related factor 2 (NRF2) are 
provoked (Belleza et al., 2018; Morgan and Liu, 2011; Ryu et al., 2003 and Ichiki et 
al., 2003) .  Their activation induces the expression of genes required for 




(Tonelli et al., 2015).  OS neutralization mediated by TFs can take place by protein 
synthesis or degradation, cytoplasm to nuclear trafficking or DNA binding and 
transcriptional activation (Sun et al., 2015).  In this study, NRF2, and its contributory 
role in the co-operative matrix with the VDR signalling pathway in OS protection, 
particularly UGT1A induction will be evaluated.   
 
1.7.1 NRF2 Discovery and Function  
 
Moi et al., (1994) was the first to successfully clone and characterize NRF2 gene 
based on its ability to bind to the tandem nuclear factor erythroid 2/ activating protein 
1 (NF-E2/AP1) repeats on β-globin promoter region.  NRF2 is a member Cap ‘n’ 
collar (CNC) leucine b-zipper TFs. Other CNC members include NRF1 and NRF3, 
the former being involved in cholesterol homeostatic control (Chowdhury et al., 
2017).  Proteomics identified 605 amino acid in human NRF2 protein, compared to 
597 amino acids in rodents (Hayes and McMahon, 2009).  Characterization of the 
NRF2 protein architecture revealed seven highly conserved domains referred to as 
NRF2-ECH homology (Neh) domains (Figure 1.9), each with a distinct role (Sun et 
al., 2015).  Neh1 is characterized by a DNA binding domain encompassing CNC-
type basic-region leucine zipper (Canning et al., 2015). Kelch-like ECH-associated 
protein 1 (Keap1), a known ubiquitin ligase substrate adaptor responsible to NRF2 
suppression binds to the Neh2 domain of NRF2 (Canning et al., 2015).  Neh2 consists 
of two highly conserved sequences at the N-terminal, namely  high affinity ETGE 
motif and the low affinity DLG motif to which Keap1 binds, subsequently allowing 
cullin -3 (Cul3) to facilitate NRF2 ubiquitination and subject it to proteosomal 
degradation (Tong et al., 2006). Lysine residues between the two motifs make it 
susceptible for NRF2 to undergo ubiquitination (Villeneuve et al., 2010).  The 
carboxyl – terminal Neh2 domain is a transactivation domain that is able to interact 
with components of the transcriptional apparatus (Nioi et al., 2005). This 
characterization was identified by Nioi et al., (2005), who deleted 16 amino acids of  
Neh3, resulting in diminished ability to induce both gene and reporter-based activaty.   
Furthermore, these experiments did not alter DNA binding capabilities, confirming 
the independent Neh2 and Neh3 roles (Nioi et al., 2005).  The work of Hayes et al., 
(2017) demonstrated that Neh4 and Neh5 domains mediate the recruitment of 




genes. Additionally, Katoh et al., (2001) identified that both domains co-operatively 
bind to cyclin adenosine monophosphate (cAMP) response element-binding protein 
(CREB) thereby increasing transactivation through gene promoter interaction.  
Chowdhry et al., (2013) identified, through boitinylated-peptide pull-down assays 
that Neh6 domain encompasses serine resides and two β-transducin repeat containing 
protein (β-Trcp), namely DSGIS and DSAPGS that function to negatively regulate 
NRF2.  Gycogen synthase kinase-3 (GSK-3) phosphorylation to the DSGIs motif 
initiates this regulation (Beurel et al., 2016). To date, Wu et al., (2014) have advanced 
knowledge into Neh7 domain role. Experiments on A579 cell line demonstrated 
RXRα inhibited NRF2 transactivity through Neh7 domain, an effect that was 
independent of Keap1 (Wu et al., 2014).  
  
Figure 1.9: NRF2 structural domain. NRF2 comprises an N-terminal hydrophobic 
domain, followed by a Keap1-binding domain, transcriptional activation domain, 
CNC domain and basic leucine zipper domain.  NRF2, through its leucine zipper 














Figure 1.10  The domain structure of small Maf proteins. This comprises of a 
extended homology region (EHR) and a bZIP domain (Image edited from Hayes et 
al., 2010).   
 
1.7.2 NRF2 activation and repression 
 
Keap1, using the Neh2 domain of the NRF2 protein is the principal negative regulator, 
by so doing, keeping its basal levels under control (Tonelli et al., 2018). Keap1 first 
characterized by Itoh et al., (1999) using yeast two-hybrid assay also identified 27 
cysteine residues.  Its dimeric module encompasses tram track and brica-brac (BTB) 
domain which facilitates the recruitment of Cul3, and intervening region (IVR), a 
cysteine-rich domain and a C-terminal Kelch-repeat domain consists of subdomains 
including Gly-Gly motifs, which form β-propeller with anti-parallel β-strands that 
form twisted β-sheet (Itoh et al., 1999). These are required for Keap1/NRF2 
interaction via the Neh2 domain (Itoh et al., 1999).  The human Keap1 comprises 624 
amino acids has multiple OS sensitive cysteine based sensors (Wakabayashi et al., 
2004).  Watai et al., (2007) have since defined the localization of Keap1 in the 
cytoplasm contrary to NRF2 which is also found in the nucleus. Under basal 
conditions, NRF2 is bound to Keap1 and undergoes constant ubiquitylation by the 
Cul3 E3 ubiquitin ligase, and subsequently degraded by the proteasome (Villeneuve 
et al., 2010).  OS inducers such as Sulforaphane (SFN: a isothiocynate compound 
obtain from cruciferous vegetables e.g. broccoli), curcumin, tert-butylquione (tBHQ), 
environmental toxins, UV rays, and ROS prompt a Keap1 conformational change 
(Wu et al., 2010; Kraft et al., 2004; Osburn and Kensler, 2008).  Cys-151 then 
prompts NRF2 activation pathway by allowing Keap1 to bind to Cul3 instead 
(Canning et al., 2015).  An important discovery was by Luo et al., (2007) who 




Cysteine (Cys)-151, -226, -273,-434, -288 and -613 in Keap1 are key cysteine 
residues responsible for NRF2 activation.  
 
NRF2 then translocates into the nucleus where it forms a heterodimer with small Maf 
proteins (sMafF, sMafG and sMafK), which are also members of the bZip family of 
TFs that recognize distal and proximal anti-oxidant response elements (ARE) within 
the genome (Nguyen et al., 2009).  However, ChiP-seq data revealed the absence of 
ARE binding, suggesting that NRF2 may also interact with other DNA binding 
protein (Hirotsu et al., 2012).  This leads to the recruitment of ATP-dependent 
nucleosome remodeling complexes including the SWI/SFN chromatin-remodeling 
complex (Kansanen et al., 2013).  Furthermore, the chromo-domain helicase DNA 
binding protein 6 (CHD6), receptor-associated co-activator 3 (RAC3) and Sirtuin 6 
(SIRT6) are recruited, prompting chromatin remodeling and recruitment of RNA 
polymerase II, leading NRF2 target gene transactivation (Tonelli et al., 2018).   
 
1.7.3 NRF2 and Target genes 
 
Several studies have implicated NRF2 activation with genes involved in protein 
transport, cell cycle, cell growth, and phosphorylation (Ma´rton et al., 2018; Fan et 
al., 2017).  ChIP-seq data from mouse embryonic fibroblasts and human 
lymphoblastoid cell line models showed that amongst the common OS responsive 
genes, adipogenesis genes were  also induced (Chorley et al., 2012). Over 240 novel 
NRF2 genes were further characterized using qPCR and short interfering RNA 
(siRNA) following sulforaphane exposure (Chorley et al., 2012).  ARE motif sites 
were the most enriched following de novo motif analysis (Nioi et al., 2003).  
Additionally activated NRF2 mediates Notch1 mouse gene involved in osteoblast 
differentiation (Wakabayashi et al., 2015) There is also enough reason to speculate 
NRF2 has a role in retinoid-mediated pathways following evidence of its ability to 
also regulate RXRα (Chorley et al., 2012).   Nevertheless, the most common element 
of the novel NRF2 genes is their role in preventing cellular damage, ROS 
detoxification, NADPH production and GSH synthesis (Tonelli et al., 2018. 







Figure 1.11: Examples of NRF2 target genes. Depicted are the co-ordinated effects 
of NRF2 signalling involving OS neutralization through GS production, in addition to 
ROS and xenobiotic detoxification, NADPH regeneration and lastly Haem and iron 
metabolism.  NRF2 signalling pathway ensures cyto-protection through the 
enhancement of a network of genes regulating the processes as shown (Tonelli et al., 
2018). Glutamate cysteine ligase (GCLM);Glutathione reductatse 
(GSR1);Glutathione peroxidase 2 (GPX2); Glutathione S-transferase P 
(GSTP1);NAD(P)H dehydrogenase (quinone) 1 (NQO1); Glucose-6-phosphate 
dehydrogenase (G6PD);Malic Enzyme 1(ME1); Phosphogluconate dehydrogenase 
(PGD); Heme Oxyhenease 1 (HMOX1);Ferritin (FTH) and Terminal Flower (TFL). 
 
1.7.4 NRF2 in Health and Disease 
 
Research over the past two decades has established that NRF2 suppresses 
carcinogenesis, especially during the early stages (Ma et al., 2015).  The use of Nrf2 -
/- mice exposed to carcinogens has shown that activated NRF2 is chemo-preventative, 
through the induction of detoxification pathways and sequestering of ROS (Khor et 
al., 2008).  NRF2 activators such as sulphorafane (SFN) have been evidenced to 
inhibit carcinogenesis in the gastrointestinal tract, skin, lung, bladder and breast tissue 
(Melba et al., 2013; Chen et al.,2014 and Lu et al., 2017).   Other cancer prevention 
studies implementing oleanane triterpenoids, a synthetic NRF2 ligand have showed a 




Her2 (Bishayee et al., 2013).  Furthermore, lung carcinogenesis was suppressed 
following oleanane triterpenoids exposure (To et al., 2015).  Contrariwise, somatic 
mutations in NRF2 that result in its overexpression positively correlate with 
tumorigenesis, indicating the selective advantage to cancer cells which are susceptible 
to proliferation induced OS (Kitamura and Motohashi, 2018).  Additionally the NRF2 
protective effects against OS that characterizes neurodegenerative diseases have been 
exemplified in vitro and mice models of Parkinson’s disease (PD) (Lui et al., 2017).  
Furthermore, SFN was evidenced to protect against mitochondrial complex I 
inhibitors 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced death of 
nigral dopaminergic neurons and also decrease of astrogliosis and inflammatory 
cytokine release, which is associated with neurodegenerative disorders (Sita et al., 
2017).  
1.8 Vitamin D – ‘A custodian for phenotypic stability’  
 
Emerging evidence has linked 1,25D to the regulation of vital signalling pathways that 
are important for cellular health (Nakai et al., 2014; Chen et al., 2013 and Wang et al., 
2012).  The cellular antioxidant defences maintain a highly reduced internal state 
(Birben et al., 2012).   An imbalance of this steady state is caused by reactive oxygen 
species (ROS) due to trauma, hypertoxia, infection or excessive exercise increases free 
radicals (e.g. superoxide, hydrogen peroxide and peroxynitrite) (Valko et al., 2007). 
Furthermore, exposure to UV, environmental toxins, carcinogens and dietary 
compounds disrupts this steady state, causing oxidative stress, thus cells become 
susceptible to damage or cellular death (Dunning et al., 2006).  In addition, 
carcinogenesis, diabetes mellitus, age-related disease and neurodegenerative disease 
have been implicated with ROS (Berridge, 2015).  The fundamental basis of ROS 
signalling is its reversibility.  1,25D in conjunction with Klotho and Nrf2 has been 
linked to the modulation of antioxidant systems that prevent OS by removing ROS 
(Berridge, 2015).  In expanding upon the ‘defensome’ properties of 1,25D, Gaucion 
et al., (1999) were the first to observe gamma-glutamyl transpeptidase (γ-GT) gene 
expression and enzymatic activity were augmented by 1,25D in primary cultures of 
newborn rat astrocytes, although Ito et al., (2014), observed contradicting findings in 
LLC-PK1 porcine renal tubular epithelial cells.  Additionally 1,25D abrogates 




generation, an effect observed in human renal arteries Dong et al., (2012).  Glucose-
6-phosphate dehydrogenase (G6PD) glutamate cysteine ligase (GCLC) and 
glutathione reductase (GR) all increase GSH and their increased expression is linked 
to 1,25D exposure (Jain and Micinski, 2014).   NRF2, the cellular modulator of over 
300 genes involved in the neutralization of oxidative stress is also regulated by 1,25D 
(Chorley et al., 2012).  Moreover, bipolar disorder treatment such as valproate and 
lithium known to inhibit HDAC, also enhance NRF2 expression (Correa et al., 2011). 
Epigenome regulation by 1,25D was also observed in the mediation of DNA 
methyltransferases such as Jumonji Domain Containing 3 (JMJD3) (Fetahu et al., 
2014).  The ‘defensome’ properties of 1,25D and involvement in diabetic 
cardiomyopathy were investigated by Lee et al., (2014) using diabetic induced rats.  
Upon 1,25D exposure, the diabetic effects on receptor advanced glycation end 
(RAGE) products, mediated by Angiotensin II receptor type 1 (AT1R), anti-
inflammatory and anti-oxidative responses were decreased (Torino et al., 2017).  
Higher than normal RAGE levels are also observed in Alzheimer’s disease, 
osteoarthritis and malignancies, all of which have been linked to 1,25D deficiency 
(Torino et al., 2017).  1,25D is also involved in the regulation of Klotho, a 
transmembrane bound anti-aging protein, crucial for homeostatic function of 
numerous organs Tsujikawa et al., (2003).  There is also enough evidence to speculate 
that insulin, tumour necrosis factor (TNF), Wnt signalling pathway and cytokines are 
amongst the different signalling pathways regulated by 1,25D (Larriba et al., 2013).  
The above-mentioned classical, non-classical, cellular protective properties together 
with cell cycle properties, further highlight the need to maintain optimum 1,25D 
levels. 
 
 Additionally, its (1,25D) ability to modulate hepatic and extrahepatic properties, it is 
reasonable to speculate this beneficial function also in the blood brain barrier (BBB) 
and placenta (Shin et al., 2010). The former was confirmed by Takahashi et al., (2017)  
who observed that 1,25D decreased damage to the BBB in following treatment of the 
human brain microvascular endothelial cell line. Consequently, Berridge (2015) 
proposed a hypothesis, in which 1,25D was defined as a ‘custodian for phenotypic 




also, their manifestation correlates with dysregulation of calcium, redox signalling, 
including NRF2 and Klotho modulation.  
 
Expanding upon Berridge’s (2015) hypothesis, our study also focuses on examining 
the co-operative effects of enhanced detoxification responses, through UGT1A 
induction mediated by VDR and NRF2 (Figure 1.11).  As already mentioned, NRF2 
increases the expression of multiple UGT1A isoforms that include the UGT1A7-
UGT1A10 cluster (Kalthof et al.,2010; Sakakibata et al., 2015 and Wu et al., 2012). 
Interestingly, Wu et al., (2012) identified that NRF2 increases the mRNA expression 
of UDP-glucose-6 dehydrogenase (UGDH) and solute carrier family 35 member D1 
(SLC35D1). These enzymes are involved in the synthesis and transport of UDPGlcA 
into the ER respectively (Wu et al., 2012). UDPGlcA is the co-factor that facilitates 
glucuronidation of UGT1A susceptible subtrates (Fujiwara et al., 2010).  These 
findings suggest that NRF2 is a key factor in the bioavailability of UDPGlcA and 
glucuronidation processes altogether.   Since activation of VDR increases NRF2 
mRNA expression, it is reasonable to speculate that the interplay between both TFs is 
likely to enhance UGT1A expression and activity (Nakai et al., 2014).  We and others 
have correlated VDR to the modulation of pivotal metabolic (e.g. CYPs) and 
transporter-related activities (e.g. MDR1) (Maguire et al., 2012 and Chow et al., 2011). 
Furthermore, our unpublished data has also confirmed UGT1A up-regulation by VDR 
ligands in colon cancer cells.  Altogether, there is compelling evidence that suggests 
that UGT1A regulation may be further enhanced by VDR acting in concert with NRF2 






Figure 1.12: A proposed model of Vitamin D and NRF2 co-operative effects. A 
concept based upon Berridge’s phenotypic stability hypothesis, we propose that that 
modulation of metabolic gene products, and NRF2 it’s self by VDR signalling 















1.9 Research Aims and Objectives 
 
Taking into consideration the above-mentioned evidence, it is reasonable to speculate 
that VDR may be a potent inducer of vital extrahepatic metabolism.  This project aims 
to fully define the impact of VDR induced UGT1A.  Our findings will be of biological 
significance particularly where UGT1A expression is compromised (e.g. neonatal 
jaundice). Additionally, our findings will re-inforce the implications of drug-drug 
interactions, whilst also at a functional level, this study will also re-inforce the co-
operative effects of VDR in the redox-signaling pathway.  Using LS180 cells as our 
main model system, we aim to:  
1. Investigate the regulation of extrahepatic UGT1A gene family 
members by VDR.  
Transcriptomic characterization through mRNA and protein expression profile and 
reporter-based activity under various conditions, in cells exposed to VDR ligands will 
be examined. For the latter, this will also involve the identification of VDREs within 
the UGT1A promoter regions, following which confirmation of its functionality by 
mutagenesis experiments will be implemented, where diminished activity will signify 
a functional VDRE.  Functional read-out experiments measuring glucuronidation 
activity will examine the ability to translate our transcriptomic evidence into a clinical 
setting.   
2. Examine whether there is an interaction between VDR and NRF2 
signalling pathways that encompasses UGT1A gene regulation.  
 
Here also transcriptomic characterization through mRNA levels, protein expression 
and reporter-based activity of cells exposed to VDR and NRF2 prototypical ligands 
will be examined.  Inter-dependency of NRF2 signalling upon VDR signalling 
pathway will be determined through mutation of response elements, followed by 
measurement of promoter activity.  Growth inhibitory assay as a functional study will 
fundamentally measure whether 1,25D enhances chemo-protective features where 
both pathways are activated. This will also be translated in a prostatic cancer cell 




3. Characterize VDR/RXR binding motifs within the  UGT1A locus 
 
Due to the dramatic UGT1A4 responsiveness by VDR ligands, this project also aims 
to conduct a more focused evaluation of the UGT1A locus to delineate the contribution 
of potential binding motifs that may contribute to this unique response. The cloning 
of UGT1A locus will allow further manipulation of the identified binding sites that 
will then be used for UGT1A4 transcriptomic characterization.  The use of Clustered 
Regularly Interspaced Short Palindromic Repeats Interference (CRISPRi) technique 
will allow simultaneous VDRE deactivation in a native context, thereby characterizing 
the effects of UGT1A transactivation through a series of gene expression and reporter-






































2: Chapter 2 















2.1 Reagents  
Ethanol was purchased from Romil Pure Chemistry (E314), EB1089 was obtained 
from Enzo Scientific and Calcitriol (1,25D) was purchased from Tocris Biosciences, 
Bristol, UK.  Methanol was purchased from Fisher Scientific (M/H056/17), Trypan 
Blue Stain 0.4% was purchased from GIBCO, UK (15250), GW474064A was 
purchased from Gaskosmithkline and Cas9-Dead-NLS, produced in E.coli, expressing 
a Streptococcus pyogenes Cas9 gene with two amino acid substitutions in the protein 
(D10A and H840A) was purchased from Eupheia Biotech, Germany.  Rifampicin 
(R3501), 5β-Cholanic acid 3-one (3kLCA, C6271), Dimethyl sulfoxide (DMSO, 
D2650), Sulforaphane (574215), tert-butyhydroquione (tBHQ, 112941), phosphate 
buffered saline (PBS, P4417), Nuclease-free water (W4502) and TO901316 (T2320) 
were all purchased from Sigma-Aldrich, Dorset UK. 
2.2 Cell Culture  
 
2.2.1 LS180 Cells  
 
LS180 cells are derived from a 58-year-old Caucasian female with Dukes type V 
adenocarcinoma of the colon (Public Health England, 2020).  This cell line was 
evaluated as a suitable in vitro model for investigating VDR signaling as they mimic 
1,25D extrahepatic, in addition to (Aiba et al., 2005) who observed the suitability of 
LS180 cells in elucidating mechanisms that regulate intestinal metabolic gene 
products. Additional cell line models were used to evaluate VDR signaling in a 
different context.  LS180 cells were obtained from the European Collection of Cell 
Cultures at passage 52 (ECACC, LOT06/C/039).  Cells were maintained in complete 
media made up of Minimum Essential Medium (MEM) (Invitrogen, UK) 
supplemented with 10% fetal bovine serum (FBS) Invitrogen) 50 units/ml penicillin 
G, 50μg.ml streptomycin (P/S) (Invitrogen,UK),  1% MEM Non-Essential Amino 
Acid Solution (NEAA) (Invitrogen, UK) and 1% Sodium Pyruvate (Invitrogen, UK).  
For experiments using steroid depleted conditions, MEM was supplemented with 5% 






2.2.2 Human Embryonic Kidney cells (HEK293 cells)  
 
HEK293 cells were generated from normal human embryonic kidney cells exposed to 
sheared fragments of human adenovirus type 5 DNA (Ad5) in by Alex van der Eb et 
al., (1973).  Although direct comparison to kidney tissue may be questionable, this 
cell line model is standard and very efficient co- transfection. In this study, HEK293 
cells were used to evaluate precise VDR effects.  The cells were obtained from 
(ECACC, 8512062).  For maintenance, High Glucose (4.5%) Dulbecco’s Minimum 
Essential Medium (DMEM, supplemented with 10% FBS, 1% L-glutamine and 1% 
P/S.   
 
2.2.3 LNCaP cells  
 
LNCaP cell line was isolated from a needle aspiration biopsy of the left supraclavicular 
lymph node of a 50 year of Caucasian male (blood type B+) with metastatic prostate 
carcinoma.  This cell line was use to evaluate VDR mediated metabolic gene product 
regulation and cross talk with NRF2 signaling in a prostatic context and how it 
compares to the gastrointestinal context. LNCaP cell line were obtained from (ECACC 
89110211, LNCaP clone FGC). Cells were maintained in RPMI 1640 with 10% FBS, 
1% P/S and 1% L-Glutamine (Invitrogen).   
 
2.2.4 Sub-culture Routine  
 
Cells were split to sub-confluent cultures between 70 to 80% (1:3 to 1:6), seeding at 4 
x 106 cells/ T175 cells.  LS180 cells were split by use of non-supplemented MEM and 
0.5 EDTA. HEK293 and LNCaP cells were split but by 0.05% Trypsin (Invitrogen).  
Cells were incubated at 37oC and 5% CO2 atmosphere.   
 
2.2.5 Cell Storage 
 
For cell storage, cells were centrifuged at 1,500rpm for 5 minutes and the supernant 
was discarded and re-suspended in 1ml freezing solution/4 x 106 cells, comprising of 
5% DMSO and 95% FBS.  Cells were transferred to Nalgene 5100-0001 PC/HDPE 




then transferred to a permanent storage box at -80oC or liquid nitrogen for long-term 
storage.   
 
2.2.6 Thawing cells 
 
Cells were removed from the -80oC freezer and immediately thawed in a 37oC 
waterbath.  5ml media was added to the cells drop-wise, followed by centrifugation at 
1,500rpm for 5 minutes.  Supernatant was discarded and the cell pellet was re-
suspended in 5ml media. Cells were transferred to a T75 cell culture flask and 
maintained as described in Section 2.2.4.   
 
2.2.7 Cell Density  
 
Cell density and viability for seeding determined using a haemocytometer (See Table 
2.1). Following detachment from culture flasks, cells were centrifuged at 1200prm for 
5 minutes (RT).  The supernatant was discarded and the pellet was re-suspended in 
5ml media. 14μl cell suspension was mixed with 14μl Trypan Blue Stain 0.4% (Sigma-
Aldrich, Dorset, UK) 12μl of the 1:1 suspension was pipetted on to a coverslip.  Cell 
viability is determined by the absence of Trypan Blue staining. Unstained cells were 
visualized using the an automated cell counter which also determined the percentage 
cell viability and quantification of live cells.  The total number of cells in suspension 
were calculated per ml were the total number of cells is multiplied by the dilution 















Table 2.1:  Common seeding densities  
Cell 
Line  
Plate  Volume 
of Media  
Cell Density 
(Cells/ml) 
LS180 100mm dish 10ml 1.5x106 
LS180 6-well 2ml 4x105 
LS180 24-well 500μl 1x105     
LS180 96-well 100μl 18x103 
HEK293 24-well 500μl 1x105 
LNCaP 6-well 2ml 4x105 
LNCaP 24-well 500μl 1x105 
LNCaP 96-well 100μl 4x103 
 
2.2.8 Dosage with Ligands 
 
1,25D (10-8M), the biologically active form of Vitamin D which activates VDR was 
used in the investigation of all VDR signalling experiments.  3-ketolithocholic acid 
(3KLCA), a major metabolite of the cytotoxic secondary bile acid (BA), lithocholic 
acid was also used in our experiments as it also a VDR ligand, although less potent.  
Our interest in using this ligand was to identify the role of VDR in controlling the 
bioavailability of BA as a chemo-preventative measure through the regulation of 
extrahepatic UGT1A gene family members.  EB1089, a Vitamin D synthetic analogue 
was included in our experiments to also examine the effects of UGT1A regulation.  
EB1089 is a very potent VDR ligand and also has been synthetically  modified such 
that, if VDR induced UGT1A is clinically relevant, EB1089 may be a safer alternative 
dude to the absence of side effects such as hypercalcemia, which are often observed 
upon administering Vitamin D.  PXR is a well-known UGT1A regulator and is a close 
relative of VDR. PXR activation by rifampicin was included as a positive control, in 
addition to establishing the most potent extrahepatic UGT1A inducer.  Also included 
in this study were well-known LXR and FXR ligands TO901317 and GW474066 
respectively.  Both NRs are known to enhance UGT1A gene expression.  These were 
included in our experiments to confirm VDR specific activities in our chosen cell 
model systems. Tert-butylhydroquinone (tBHQ) and sulphorafane (SFN), both 






Ligand stock concentration was diluted in media in a 1:1000 dilution. All experiments 
were treated with ligands as stated in table 2.2.  
 
Table 2.2: Ligands and common concentrations used in this study 





Ethanol - 100% 100% Vehicle 
DMSO - 100% 100% Vehicle 
Methanol - 100% 100% Vehicle 
1,25D Ethanol 105M 10-8M Biological 
VDR ligand 
EB1089 Ethanol 10-5M 10-8M  Synthetic 
VDR ligand  
3kLCA Ethanol 10-2M 10-5M Secondary 
bile acid  
known to be a 
VDR ligand  
tBHQ Ethanol 40mM 40μM NRF2 ligand  
SFN DMSO 6mM 6μM NRF2 ligand 
TO901317 DMSO 10-2M 10-5M LXR ligand  
GW474066 DMSO 10-2M 10-5M FXR ligand  
Rifampicin Methanol 10-2M 10-5M PXR ligand  
 
2.3 Polymerase Chain Reaction (PCR)  
 
2.3.1 RNA Extraction  
 
Following ligand exposure at appropriate time points for each experiment, RNA 
extraction from cells was performed using the Qiagen RNAeasy® Plus Mini Prep Kit 
(Qiagen, Sussex, UK).  The procedure was carried out using the manufacturer’s 
instructions.  Briefly, media with ligands was discarded and cells were dislodged by 




for 5mins.  Cell pellet was lysed using 350μl Buffer RLT containing β-
Mercaptoethanol (Sigma-Aldrich, Dorset, UK).  Lysate homogenization was 
performed by passing through a 20-gauge needle with RNAase free syringe.  DNA 
was removed by passing be lysate through a gDNA Eliminator column. For each 
sample, 350μl of 70% Ethanol was added, and the solution was passed through an 
RNAeasy mini column. Bound RNA was washed using RW1 buffer, then RPE buffer. 
Total RNA was eluted in 30µL RNase free H2O. RNA concentration was determined 
by nanodrop using an ND-1000 Spectrophotometer (Labtech, Ringmer, UK).  
Approximately 1μl was loaded and the absorbance was measured at 260/280nm. RNA 
quantification was given in ng/μl. All samples were stored at -80oC to avoid 
degradation.   
 
2.3.2 Ethanol Precipitation  
 
 
Ethanol precipitation was performed were RNA purity was significantly low.  It 
concentrates RNA and de-salts nucleic acids in an aqueous solution.  Briefly, 0.1 
volume of 3M sodium acetate (NaOHC) pH 5.2 was pipetted into RNA sample, 2.5μl 
of ice cold 100% Ethanol was mixed thoroughly into the solution, which was then 
incubated at -20oC for 1 hour. Centrifugation at 12,000 rpm for 15 minutes at 4°C was 
carried out and the supernatant was discarded. The pellet was washed by adding 300μl 
of 70% Ethanol, then briefly centrifuged for 10minutes at 12,000rpm at 4oC.  The 
supernatant was discarded and the pellet was left to air dry prior to dissolving in 
RNAase free H2O (30μl).   
 
2.3.3 cDNA Synthesis  
 
For each cDNA conversion, 2000ng of RNA was diluted with 1μl Oligo dT primers, 
1μl 10mM dNTP mix (Invitrogen, UK) and distilled H2O (ddH2O), made up to a 12μl 
volume.  The mixture was heated on the Multi-Block System (MBS) for 5 minutes at 
65oC to ensure Oligo dT primer annealing to RNA, then cooled for 2 minutes at 4oC.  
Subsequently, a 7.5μl mixture containing 4μl 5Xfirst Strand Buffer (Invitrogen), 2μl 
of 0.1M DTT and 1.5μl of ddH2O.  This was heated at 42°C for 2 minutes to optimize 
the temperature for the reverse transcriptase to work.  To each sample, 0.5μl 




transcription was carried out at 42°C for 50 minutes, then then halted by heating to 
70°C for 15 minutes.  cDNA is was then diluted to 1:10 using ddH2O to a total 
concentration of 200ng. cDNA is more stable than RNA and was stored at -20oC.   
 
2.3.4 Primer Design and preparation  
 
Custom primers that only code for specific upstream or downstream sites of gene 
sequences being amplified were designed using Primer3 version 4.1.0. Software 
available online (Untergasser et al., 2012).  The sequence for each designed primer is 
listed in table 2.4.  The gene mRNA sequence was retrieved from the NCBI database 
which was then inputted to the Primer3 software. The criteria for each primer pair 
included the following optimum parameters:  
 
Table 2.3: Optimum parameters for endpoint PCR primer design 
Primer length        20 nucleotides 
Primer melting temperature  (Tm)        60°C 
Primer GC% content 60% 
Product Size  150-250bp 
 
Each primer pair was designed to span to exons, with one of the primers spanning 
across two exons itself. This minimized the chances of DNA contamination and the 










Table 2.4: Endpoint primer oligonucleotide sequences 




β-Actin Forward    AAACTGGAACGGTGAAGGTG 
Reverse     TCAAGTTGGGGACAAAAG 
CYP24A1 Forward    CAGCGAACTGAAAATGGTCG 
Reverse     TCTTCTCATACAACACGAGGCAG 
CYP3A4  Forward    FCGTGGCCCAATCAATTATCT 
Reverse      GCTGAATCTTTCAGGGAGGA 
CYP3A5 Forward      GGAGATGTTCCCCATCATTG 
Reverse      CGTTGAGGCGACTTTTCTTC 
UGT1A1 Commercially available at Thermo Fischer Scientific, UK 
UGT1A3 Commercially available at Thermo Fischer Scientific, UK 
UGT1A4 Commercially available at Thermo Fischer Scientific, UK 
UGT1A5 Commercially available at Thermo Fischer Scientific, UK 
UGT1A7 Commercially available at Thermo Fischer Scientific, UK 
UGT1A8 Commercially available at Thermo Fischer Scientific, UK 
UGT1A10 Commercially available at Thermo Fischer Scientific, UK 
VDR Forward    CCAGTTCGTGTGAATGATGG 
Reverse      GTCGTCCATGGTGAAGGACT 
PXR Forward     TGTCAACGCAGATGAGGAAG 
Reverse       TCCCTGTCCGTTCACTTTTC 
FXR Forward       GTCAGCAGGGAGGATCAAAG 
Reverse        CTGCATGCTGCTTCACATTT 
LXRα Commercially available at Thermo Fischer Scientific, UK 
LXRβ Commercially available at Thermo Fischer Scientific, UK 
G6PD Forward    TTGCCAACAGGATCTTCGGC 
Reverse    GGTCGTCCAGGTACCCTTTG 
NQO1 Forward    GAAAGGATGGGAGGTGGTGGTGG  
Reverse    CGTGGATCCCTTGCAGAGAG 
GCLC Forward   ACCCAAACCATCCTACCCTT 
Reverse   GGCTTGGAATGTCACCTGGA 
SOD1 Forward   GCAGAAGGAAAGTAATGGACCA 




GSR Forward   TGCGTGAATGTTGGATGTGT 
Reverse    TATTCCTAAGCTGGCACCGG 
GPX2 Forward    TGAATGGGCAGAACGAGCAT 
Reverse      CCAGCAGTGTCTCCTGAAGG 
 
2.3.5. Endpoint PCR 
 
Endpoint PCR was performed prior to initial gene expression analysis to detect house-
keeping gene, β-actin as a quality control in addition to detection of genes of interest 
listed in Table 2.4 All primers were supplied by Invitrogen, UK and all for the PCR 
recipe (Table 2.5), reagents were supplied by Promega (Madison, USA). The dNTP 
mixture was from Invitrogen (Paisley, UK).   
 
Table 2.5: Endpoint PCR reaction mixture  
Reagent  Volume (μl) 
5X PCR Buffer  5 
25mM MgCl2 1.5 
10mM dNTP mix 0.5 
10μM Forward Primer 0.5 
10μM Reverse Primer 0.5 
Taq Polymerase  0.1 
ddH2O Up to 20μl 
 
20μl of the reaction was added to each 0.5ml Eppendorf and 5μl of 200ng cDNA 
template or ddH2O for negative control were added to each mixture.  The samples 











Step  Conditions  
Initial Denaturation  94°C for 2 minutes  
Denaturation 94°C for 30 seconds   
30 to 35 cycles Annealing Tm 60°C for 30 seconds  
Extension 72°C for 3 minutes  
Final Extension  72°C for 10 minutes  
Hold  Hold  
 
2.3.6 Gel Electrophoresis  
 
1.5% agarose gel was prepared with 1.5g of agarose electrophoresis grade powder 
(BIA1176 Apollo Scientific, UK) was added to 100ml of 1X Tris Acetate Buffer 
(TAE). The powder was completely dissolved by heating the mixture. Once the 
mixture cooled down to approximately 60°C prior to adding 3μl of the fluorescent 
nucleic acid Gel Red dye (Sigma-Aldrich, UK).   The solution was poured on to a 
casting tray and allowed to solidify.  The cell was transferred into an electrophoresis 
tank immersed in 1X TAE buffer.  8μl pf PCR product was added to each well of the 
gel and run alongside 100bp or 1Kb DNA ladder (Invitrogen, Paisley, UK) depending 
on the expected product size.  Electric current was run at 100V for approximately 15 
minutes.  PCR product was visualized using a UV transluminator and images captured 
using the Sygene G BOX Chemi system.   
 
2.3.7. Real Time PCR  
 
For this study, real time PCR using using Taqman® mono colour hydrolysis probes 
(Applied Biosystems) was the method of choice for gene expression analysis.  
 
 This allowed direct comparison of relative mRNA expression changes induced by the 
above-mentioned ligands the chosen cell model systems.  Each hydrolysis probes 








Reagent  Volume  (𝝁l)  
2 PCR H2O 2 
Probe 0.5 
1 2X Probes Master 5 
 
For each reaction, 2.5μl of cDNA was added to the PCR master mix, then, loaded to 
each well on a white 96 LightCycler® 480 Multi-well plate. Each PCR sample was 
performed in triplicates. Negative controls consisted of RNAase free H2O.  An Optical 
adhesive cover (Applied Biosystems) was used to cover the well to avoid evaporation.  
The plate was plus centrifuged to 800rpm for approximately 10 seconds using Hettich 
Rotanta 460R centrifuge.  The plact was placed in the Light Cycler 480 system set 
according to the manufacturer’s User Manual.  Relative gene expression in samples 
was calculated relative to vehicle control treated samples using the equation below:  
ΔΔCt = 2^-(ΔCtTARGET – ΔCtCONTROL) 
 
The Ct value is the raw output from the LightCycler 480 system. The ΔCt is the 
difference in Ct values between the target gene and house-keeping gene (HPRT).  Fold 








































2.4 DNA Extraction  
 
To collect the pellet 5 x 106 LS180 cells were obtained by washing with ice cold PBS 
and scrapping from a T175 flask.   Cells were then recovered by centrifugation at 
1500g for 10 minutes at 4°C. The supernatant was discarded and re-suspended in 
500μl of ice cold PBS. Added to the cell suspension also was 500μl of ice-cold C1 
lysis buffer (Qiagen, UK) and 500μl ddH2O.  Cell lysates were centrifuged at 1300g 
for 15 minutes at 4°C.  The supernatant was discarded and 250μl of C1 lysis buffer 
(Qiagen, UK) and 750μl of ice-cold ddH2O.  The pellet was re-suspended by vortexing 
and again centrifugation at 4°C for 15 minutes at 1300g following which the 




Culture Mini Kit (Qiagen: 13323) using the manufacturer’s protocol. DNA 
concentration was determined by nanodrop using an ND-1000 Spectrophotometer 
(Labtech, Ringmer, UK).  Approximately 1μl was loaded and the absorbance was 
measured at 260/280nm DNA quantification was given in ng/μl, thereafter stored at -
80oC.  
 
2.4.1 DNA amplification  
 
ChIP-seq data by Meyer et al., (2012) evidenced multiple 1,25D dependent VDR/RXR 
binding motifs within the UGT1A loci in LS180 cells. In this study, we evaluated one 
of these enhancer regions. The sequence was obtained from the National Centre of 
Biotechnology Information (NCBI) website and was used to design primers for the 
UGT1A loci region of interest as described in Section 2.13.  
 
Table 2.9: UGT1A enhancer region primer sequencers amplify a 1532bp product.  
Primer  Oligonucleotide sequence 5’-3’  
UGT1A enhancer 
region  
Forward   GGAGTTGGCCGTGATGACA         
Reverse   ACCTCTAGACACTGCCGGT 
Endpoint PCR technique was used to generate copies of the targeted sequences.  The 
extracted DNA was used as a template for PCR to amplify the UGT1A promoter region 
using Q5 High Fidelity DNA Polymerase (See Table 2.9) (PCR reagents supplied by 
NEBLabs, UK (M0491).  The PCR reaction was run under the conditions described 
in Table 2.9. The PCR product was visualized in 0.9% agarose gel as described in 









Component  Volume (µl)  
5 x Q5 Reaction Buffer 5 
10mM dNTPs 0.5 
10µM Forward Primer 1.25 
10µM Reverse Primer  1.25 
DNA Template 200ng 
Q5 High Fidelity DNA Polymerase  0.25 
Nuclease Free Water  to 25 
 
Table 2.11: DNA amplification thermocycler conditions. 
Step Condition 
Initial Denaturation 98°C for 1 minute 
seconds 
Denaturation 98°C for 1 minute  
30 
cycles 
Annealing  60°C for 30 seconds  
Extension  72° for 90 seconds 
Final Extension  4°C  
 
 
2.4.2 Gel Excision and DNA purification  
 
The agarose gel was placed on an open Ultra Violet (UV) box and was set at 70nm 
wavelength. This visualized the desired DNA fragment, which was sliced and placed 
in a clean 1.5 Eppendorf. DNA purification, which removes chaotropic salts and non-
specific fragments was carried out using an alcohol-based wash using the Wizard® 
SV Gel and PCR Clean-Up System, following the manufacturer’s instructions. DNA 
was eluted in TE buffer and concentration determined using the nanodrop using an 









Western Blot analysis was used to determined UGT1A protein induction following 
ligand exposure to LS180 cells. The effects of VDR prototypical ligands was 
compared to various ligands in their ability to induce this protein.   
 
2.5.1 Extraction of Protein from Whole Cell Lysates 
 
To collect whole cell lysates, LS180 cells were scrapped using non-supplemented 
MEM and 0.5M EDTA.  The pellet was collected by centrifugation at 1,200rpm for 5 
minutes. The supernatant was discarded and re-suspended in ice cold PBS, followed 
by centrifugation at 1000g for 5 minutes at 4oC.  The supernatant was removed at 
250μl of Radio-immunoprecipitation assay (RIPA) buffer consisting of  1M  Tris-HCl 
(pH 7.5) , 5M NaCl, 10% Igepal CA630, 10% sodium deoxycholate, 10% SDS, 0.5M 
EDTA (pH 8.0), 0.1M DTT, 80% Glycerol, 1% Protease inhibitor cocktail and ddH2O. 
Each sample was sonicated at 4 amplitude microns for 3 cycles at 10 seconds. 
Centrifugation at 15,000g for 15 minutes at 4oC to remove cellular debris. The 
supernatant was transferred to a new pre-chilled 1.5ml Eppendorf.  For long-term 
storage, protein samples were stored at -80oC.   
 
2.5.2 Extraction of Protein from Microsomal fractions 
 
The microsome Isolation Kit (ab206995: Abcam) was used to isolate microsomal 
fractions from LS180 cells for UGT1A protein profiling and enzymatic activity.  
Briefly, the cells were seeded in 100mm dishes as described previously and treated for 
a further 24 hours.  The next day, cells were washed in 1ml ice cold PBS, then 
centrifugation at 700xg for 5 minutes at 4°C.  Supernatant was discarded and the pellet 
was re-suspended in 500μl ice-cold homogenization buffer followed by 
homogenization using a chilled Dounce homogenizer.  The homogenate was 
transferred to a microcentrifuge tube and vortexed for 30 seconds prior to chilling on 
ice for 1 minute, followed by centrifugation at 10,000xg for 15 minutes at 4°C.  A 
thin, floating lipid layer was aspirated using a Pasteur pipette. The supernatant was 
transferred to a new pre-chilled microcetrifuge tube and centrifuged at maximum 
speed >20,000xg for 20 minutes at 4°C.  Supernatant was discarded and pellet was 
gently washed with homogenization buffer, then re-suspended in pre-chilled storage 





2.5.3. Quantification of protein  
 
Protein concentration was determined using the Bio-Rad DC protein assay (Bio-
Rad,UK) following the manufacturer’s protocol.  Each LS180 whole cell lysate 
sample was diluted in 1:10 dilution with ddH2O.  The assay was performed in a 96 
well plate where absorbance at 750nm was measured using FLUO star Omega 
microplate reader (BMG Labtech).  A standard curve was calculated using the serial 
dilutions on the standard Bovine Serum Albumin (BSA;Bio-Rad;0206). BSA stock 
(2mg/ml) was diluted 1:2 in PBS.  DC™ Protein Assay Reagent S was added to DC™ 
Protein Assay Reagent A in a 1:50 dilution, followed by 200μl of DC™ Protein Assay 
Reagent S (all reagents from Bio-Rad 500113-115). Then added to both BSA and 
LS180 protein samples. This was incubated for 15 minutes at room temperature prior 
to an absorbance reading at 750nm using the UV spectrophotometer.  LS180 protein 
was quantified from the standard curve using the formula Y=mX+C.   
 
2.5.4 Blotting  
 
Western blot reaction mixtures was prepared as shown in Table 2.13.  Protein was 
denatured in a 95oC heat block for appoximately 5minutes.  The denatured samples 
were transferred in a 4-12% NuPage® Bis-Tris Mini Gel (IM-8042: Thermo 
Scientific) along with 7.5μl of Spectra of SpectraTM Multicolour Broad Range 
Protein Ladder (Fermentas, 26628). For electrophoresis the X-cell sure Lock TM 
novex mini cell kit (Invitrogen), using 1X NuPage SDS MOPS running buffer 
(NP001: Invitrogen) at 200Volts constant for 47 minutes with an expected current 
of 100-125mA/gel start; 60-80mA/gel end was utilized.   After protein distribution 
on the gel, the protein fragments were placed on a Nitrocellulose blotting 
membrane (Amersham Biosciences; 10600018) using semi dry transfer 
methodology.   The transfer buffer comprised of 100% Methanol, 10X Tris-
Glycine buffer and ddH2O.   This was run in a Trans-Blot SD Semi-Dry Transfer 
cell (Bio Rad) for 60 minutes at 20Volts.  Subsequent transfer of protein was 
distinguished via Ponceau S Solution (Sigma-Aldrich; P71701L). The stain was 
carefully removed by washing the membrane with 1X TBS-T (Tris-buffered 




semi-skimmed milk (Marvel, UK) dissolved in 1X TBS-T for one hour at room 
temperature, then washed with 1XTBS-T prior to incubation with antibody.   
 
2.5.5 Probing with antibody  
 
The membrane was incubated with primary antibody as depicted in table 2.12 for 
14 - 16 hours at 4oC, then washed with 1XTBS-T three times for approximately 
10 minutes, followed by secondary antibody incubation at room temperature for 1 
hour.  The secondary antibody was subsequently detached using 1X TBS-T.  For 
protein development, the membrane was incubated in Immunbilon® Western 
Chemiluminescent HRP Substrate (Millipore; WBKLS0050) for approximately 5 
minutes.  The membrane was placed on a black screen inside the G-Box Chemi 
XRQ system where the GeneSys software and Kodak X Omat camera captured 
images of the protein. 
 
  Table 2.12: Western Blot sample preparation recipe 
Reagent  Volume (μl) 
Protein Lysate (30μg)  
NuPage LDS Loading buffer 
(4X) 
7 
NuPage Reducing Agent (10x) 3 










Table 2.13: List of primary antibodies used in this study  






Santa Cruz Sc-271268 1:5000 
Rat Anti-VDR 
9A7 
Thermo Fisher MA1-710 1:5000 
Mouse Anti-β-
Actin 
Sigma A2228 1:20000 
Rabbit Anti-
HPRT  
Santa Cruz Sc-20975 1:2000 
 
Table 2.14: List of secondary antibodies used in this study 
Antibody Source Catalogue ID Dilution 
Goat anti-Mouse 
IgG HRP  
Abcam Ab205719 1:5000 
Goat anti-Rat 
IgG HRP 
Santa Cruz Sc-2006 1:10000 
Mouse anti-
Rabbit 1gG HRP 
Santa Cruz  Sc-2357 1:3000 
 
In order to re-probe the membrane with another antibody, either mild or harsh 
stripping (See Table 2.14) to remove the previously detected antibodies. For the harsh 
stripping, the membrane was incubated at 60°C for 30 minutes with bouts of agitation. 
The protein was blocked using 0.5% semi-skimmed milk (Marvel) dissolved in 1X 
TBS-T for one hour at room temperature, then washed with 1xTBS-T and probed with 
primary, then secondary antibody as described in above.   
 
Table 2.15: Recipe for antibody stripping.  
Mild Antibody Stripping  Harsh Antibody Stripping 
O.1M Glycine-HCl pH 2.5 50mM Tris-HCl pH6.8 
1% SDS 50mM DTT 
 2% SDS 





Glucuronidation activity investigated in LS180 cells following the methodology 
outline by Dellinger et al., (2012), briefly described below.   
 
2.6.1 Preparation of cell homogenates  
 
Cells were seeded in 100mm (See Table 2.1) for 24 hours prior to dosage with VDR 
prototypical ligands.  Media from cells was discarded and cells were collected by 
scrapping after adding 5ml of ice cold PBS.  Once detached, LS180 cells collected and 
centrifuged for 1,200rpm for 5 minutes. The supernatant was discarded and the pellet 
re-suspended in 200μl Tris Buffered Saline (TBS) homogenate buffer consisting of 
25mM Tris base, 138mM NaCl, 2.7mM KCl pH 7.4 and 5% protease inhibitor cocktail 
(P8340; Sigma Aldrich, UK).  The cell lysates subdued a series of freeze thaw cycles 
using dry ice with ethanol for freezing and a 37oC water bath to thaw the samples.  
Each homogenate was transferred into a 2ml glass Dounce homogenizer and forcefully 
disrupted using a homogenizing plunger. Each homogenate was transferred into a pre-
chilled 1.5 Eppendorf and was subject to protein quantification was per section 2.5.3 
or stored at -80oC.   
 
2.6.2 Glucuronidation Assay using UGT-glo 
 
1μl of alamethicin (BML-A150-0005, Enzo) was added to each well in an opaque 96-
well plate, then incubated at 37°C for 1 hour to evaporate the ethanol.  50μg of each 
homogenate was added to each well containing alamethicin in triplicate.  (Although 6 
wells per sample in order to compare basal levels were UDPGA, the co-factor of 
glucuronic acid transfer is absent).  UGT multi-enzyme was prepared as depicted in 
table 2.15 and added to each well.  The reaction was incubated for 10 minutes on ice.   
 
Table 2.16: Multi-Enzyme Substrate reaction mixture 
Reagent Volume (μl) 








Following incubation, 10μl of UDPGA (16mM) was added to half of the wells and 
ddH2O in all – UDPGA samples.  The plate was incubated for 90 minutes at 37°C. 
 
2.6.3 UGT Activity Detection 
 
Luciferin detection solution was prepared by mixing both reconstitution buffer and 
Luciferin detection agent.  1X D-Cysteine was added to the detection solution. After 
1-hour incubation, 40μl of Luciferin Detection reagent was added to each well 
followed by stabilization of luminescent signal by incubating plate for 20 minutes at 
room temperature.  Luminescence signal was detected using FLUO star Omega micro 
plate reader (BMG Lab tech).  The values were reported in percentage (%) relative 
light units increase.   




To investigate UGT1A1 promoter activity induction by VDR ligands, the firefly 
luciferase based pGL3-UGT1A1-2K which contains 2kbp (-5193/-3092) and the 
pGL3-UGT1A1-290 (-3483/-3194) which contains 290bp distal enhancer sequence 
were kindly gifted by Professor Masahiko Negishi (Research Triangle Park, North 
Carolina).  The pGL3-UGT1A1-290 mutant was produced previously in the laboratory 
by site directed mutagenesis (Agilent,UK) (See section 2.8). This contained a 2bp 
mutation of the DR3 putative VDRE within the 290bp fragment.   CYP3A4 is 
significantly induced by VDR and so in this study, the firefly luciferase based pGL3-
CYP3A4 reporter which contains 10kbp of the CYP3A4 promoter region (-10466/+53) 
(Bertilsson et al., 2001) was kindly gifted by Dr Patrik Blomquist (Karolinska 
Institute, Sweden). pSG5-hVDR, pSG5-hPXR, pSG5-hRXRα and pSG5-LXRα were 
gifted by Professor Mark Haussler, University of Arizona, from which V5 based 
constructs were then generated using the gateway cloning system (Thermo Fisher 
Scientific, UK).  In addition, V5-hFXR was also previously generated by LR clonase 
reaction using an existing pDONER entry clone for hFXR.  The VDRE minimal 
promoter was previously constructed through VDRE oligonucleotide insertion in to 
the pGL3-promoter vector (Promega, UK).  The vector was cut with Nhel and Xhol 




oligonucleotides were inserted. The ARE minimal promoter 
(pGL4.37[luc2P/ARE/Hygro]) (See Figure 2.1) which contains four copies of the 














Figure 2.1: The pGL4.37[luc2P/ARE/Hygro] Vector depicted contains multiple 
AREs derived from that induce Photinus pyralis luciferase gene transcription.  The 
vector backbone comprises an ampicillin resistance gene that allows E.coli selection 


















Figure 2.2: The pGL3- Luciferase Reporter Vector contains Photinus pyralis firefly 
luciferase gene used to measure transcriptional activity in successfully transfected 
cells.  The basic vector also contains restriction enzyme sites utilized to clone a 
promoter sequence of interest. (Promega, 2020) 
 
2.7.2 Transformation of plasmids into Library Efficiency® DH5α 
E.coli (Invitrogen) 
 
40μl Library Efficiency® DH5α E.coli (Invitrogen Cat: 18263-012) were added to 1μl 
of plasmid. The mixture was incubated on ice for 35minutes prior to heat-shock at 
42°C water bath for 45 seconds, followed by 2 minutes chill on ice.  600μl of SOC 
media (Invitrogen Cat: 15544-034) was added to the culture which was then incubated 
at 37°C in a 200rpm shaker for 1 hour.  The culture was centrifuged at 13,000rpm for 
1 minute at room temperature, following which 400μl of the supernatant was 
discarded. The pellet was then re-suspended in the remaining 200μl and plated onto 
LB Amp plate and streaked using beads. The plates were incubated at 37°C overnight 
for 8 to 10 hours. Individual colonies were then observed on the plate were inoculated 
into LB Amp broth which was grow overnight.  PureLink™ HiPure Plasmid Filter 






2.7.3 Transfection Methodology 
 
2.7.3.1 Lipofectamine Transfection  
 
For Lipofectamine transfection, LS180 and LNCaP cell lines were seeded in 24 well 
plate or 100mm (See Table 2.1 for seeding density) for 24 hours to reach 
approximately 70% confluency. This was followed by DNA transfection using 
Lipofectamine 2000 Invitrogen, 11668-019) in a 1:3 ratio (See Table 2.16 for DNA 
concentrations). The DNA-Opti-MEM® was added to the Lipofectamine- Opti-MEM® 
mixture and incubated for 45 minutes at room temperature.  The DNA-Lipofectamine 
mixture was added to cells and incubated for 5 hours at 37°C, following which fresh 
media containing ligands. The cells were treated for 24 hours unless stated for 
individual experiments.   
 
Table 2.17: Concentration of transfected DNA  
Plasmid DNA  Concentration per well (ng) 
pGL3-UGT1A1-2K 650 











pcDNA.3.1 Promoter vector control 
 
2.7.3.2 Calcium Phosphate transfection  
 
Calcium phosphate transfection, developed by Graham and van der Eb (1973) is less 
expensive and easy to master.   However, the cytotoxic effects meant it was unsuitable 
for LS180 and LNCaP cell line models used in this study. However, HEK293 cells 





HEK293 cells were seeded in 24-well plate for 24 hours to reach approximately 70% 
confluency (See Table 2.1 for seeding density).  The required plasmid DNA was added 
to 2M CaCl2 (Sigma, C8106) (See Table X). The mixture was added drop-wise to 2X 
HBS (50mM HEPES, 280mM NaCl, 1.5mM Na2HPO4) in a 1:1 ratio (See Table 2.17).  
The mixture was incubated for 30 minutes at room temperature.  Cells were exposed 
to the mixture for 16 hours at 37°C.  Cells were washed with PBS prior to treatment 
with designated ligands after 24 hours. 
 


















.25X 35 4.3 1 0.5 
 
2.7.4 Reporter Assay Reading 
 
Following treatment at specified time points for each experiment, media was removed 
and the cells were washed with PBS. 150μl of 1X passive lysis buffer (Promega, E941) 
and plate was placed on a shaker for 15 minutes.  After which, 80μl of cell lysates 
were transferred into 96-well opaque plate. 50μl of Dual-Glo® Luciferase reagent 
(Promega, E195A) was added to each well and left to equilibrate at room temperature 
for 5minutes. Luminescence was measured FLUO star Omega micro plate reader 
(BMG Lab tech).  50µl of Dual Glo®- STOP &GLO® reagent (Promega, E641A) 
which detects pRL-TK vector, signifying transfection efficiency was then added to 
each well and left to equilibrate for 5 minutes prior to detecting luminescence.  
Furthermore, this reading was used to normalize the former luciferase readings.   
2.8 Site-directed Mutagenesis  
 
Yueh and Tukey (2006) previously identified three AREs within the UGT1A1 
promoter, which when mutated reduced NRF2 mediated induction. Upon in silico 




study (Sequence in Figure 2.3).  Mutagenesis primers introducing a 2bp mutation on 
the ARE were designed using the Agilent Quik-change primer tool (Table 2.18).  The 
mutagenesis mixture was depicted in table 2.20 was then subjected to PCR reaction 
with the thermocycler conditions depicted in (Table 2.21). The reagents were from the 









Figure 2.3: UGT1A1 promoter sequence (Tukey and Yueh, 2010) 
 
 
Table 2.19: UGT1A1-290 primers designed for site-directed mutagenesis.   
Primer  Oligo sequence 5’ to 3’ 
UGT1A1 290bp Forward gttacataacctgaaacccggactaagcacttggtaagcac 
UGT1A1 290bp Reverse  gtgcttaccaagtgcttagtccgggtttcaggttatgtaac 
 
 
Table 2.20: Site-directed mutagenesis PCR reaction recipe 
Reagent  Amount  
10X reaction buffer  5μl 
Forward Primer  200ng 
Reverse Primer  200ng  
pGL3-UGT1A1-290 reporter plasmid (Wild-
type, WT)  
 
dNTPs 1μl 
Pfu Polymerase  1μl 









Table 2.21: Site Directed Mutagenesis PCR conditions 
Step Conditions 
Initial Denaturation  95°C  for 30 seconds  
Denaturation  95°C for 30 seconds   
18 
Cycles 
Annealing  60°C for 1 minute 
Extension  68°C for 10 minutes  
Hold  4°C  
 
1μl of Dpnl restriction enzyme (Agilent, UK) was added to the PCR product, then, 
incubated at 37°C for 90 minutes. 1μl of the sample was transformed into 40μl of 
XL1-Blue super competent cells (Agilent, 200249). The reaction was left on ice 
for 30 minutes, then subjected to heat shock (42°C temperature).  NZY+Broth with 
NZ amine (casein hydrolysate (Sigma C0626), 0.5g of yeast extract (Sigma, 
Y1625), 0.5g of NaCl (Sigma, S7653) dissolved in 100ml deionised water and pH 
adjusted to 7.5. To this 12.5 µl of 1 M MgCl2, 12.5 µl of 1M MgSO4, 20µl of 
20% (w/v) glucose was added to 1 ml of the NZY broth, freshly prior to 
transformation and incubated in a waterbath. The reaction was streaked on LB 
agar plates with 50μg/ml ampicillin and incubated at 37°C overnight.  Plasmid 
DNA was extracted using Pure-LinkTM Quick plasmid mini-prep kit, then 
sequenced as described in Section 2.9, prior to a maxi prep extraction as describe 
previously.   
2.9 Sequencing  
 
Plasmid DNA sequencing was performed using the Applied Biosystem 3100 Genetic 
Analyser with Bing Dye Terminator version 3.1 Cycle Sequencing Kit (Applied 
Biosystems Cat: 4337-457). To confirm the presence of ARE mutation, UGT1A 










Table 2.22: Sequencing mixture 
Reagent Volume (μl) 
Big Dye Ready Reaction Mix  2 
5X sequencing buffer 3.5 
UGT1A Sequencing Primer 
Forward   (3.2pmol/μl) 
1 
UGT1A Sequencing Primer Reverse  
(3.2pmol/μl) 
1 
Plasmid DNA Template  300ng 
Nuclease free water  Up to 20μl 
 
The sequencing mixture was run under the following cycling conditions  
 Table 2.23: Thermocycler conditions for sequencing mixture 
Step Conditions  
Initial Denaturation  96°C for 1 minute  
Denaturation  96°C for 30 seconds   
30 cycles Annealing  55°C for 30 seconds 
Extension  60°C for 4 minutes 
Hold  4°C 
 
The PCR product was subjected to ethanol precipitation by the addition of 16μl 
nuclease free ddH2O and 64μl of ethanol (95%). The reaction was incubated overnight 
at -20°C, followed by centrifugation at 14,000rpm for 20 minutes.  The supernatant 
was discarded the pellet re-suspended in 250μl of ethanol (70%), then centrifugation 
for a further 10 minutes and supernatant discarded.  The sample was placed on a 95°C 
heat blot for 2 minutes to ensure ethanol evaporates, prior to chilling on ice for a 




heat shock (95°C) and chilling for 3 minutes.  The sequencing reaction (Table 2.21) 
was loaded to the DNA sequencing 96 well plate, which was then loaded on to the 
Applied Biosystem 3100 Genetic Analyser, which works on a capillary 
electrophoresis basis. Bound DNA fragments migrate through a polymer and the 
fluorescence emissions are measured.  Each fluorescence signal is represented by a 
different colour which correlates which one of the nucleotides.  
2.10 Cell Viability Assay 
 
Cell Viability was conducted using CellTiter-Glo® Luminescent Cell Viability Assay 
(Promega: G7570) using the manufacturer’s protocol.  Briefly, LS180 cells were 
seeded in 96 well plates (See Table 2.1 for seeding density) for 24 hours prior to 
dosage with ligands for another 24 hours. Control wells containing only media were 
also incubated to obtain a value for background luminescence.  The plate was 
equilibrated at room temperature for approximately 30 minutes, following which 
100μl of the CellTiter-Glo® Reagent was added to the opaque 96 well plate.  The 
content were placed on an orbit shaker for 2 minutes to induce cell lysis then a further 
10 minutes incubation at room temperature to stabilize luminescent signal.  
Luminescence was recorded using the FLUO star Omega micro plate reader (BMG 
Lab tech).   
2.11 Growth Inhibition Assay  
 
LNCaP cells were seeded in 96 well plate as described in table X for 24 hours prior to 
dosage with ligand for 144 hours.  In addition to control wells containing media only 
for background luminescence, un-treated cells were included as a negative control.  
Growth inhibition was determined by CellTiter-Glo® Luminescent Cell Viability 
Assay (Promega: G7570) as described in section 2.10. 
2.12 In Silico Analysis  
 
2.12.1 In Silico Screening for putative response elements 
 
The UGT1A loci sequence obtained from NCBI was screened for putative VDRE and 
ARE using the Regulatory Sequence Analysis Tool (RSAT).   The loci was inputted 




sequence were inputted. For VDRE, the search generated DR3, ER6 and IR6-type 
motifs. The ARE identified by Yueh and Tukey (2007) was applied.    
2.13 CloneJet PCR cloning 
 
2.13.1 Ligation formula 
 
Purified and quantified 1632bp long DNA product was ligated with the PJET1.2/blunt 
end-cloning vector Thermo Scientific (Cat: K1232) using the ligation formula adapted 
from NEBcalculator™ v1.10.0  as described below at either 1:1, 1:3 or 1:5 
insert/vector molar ratios. 
 
Required mass insert (g) = desired insert/vector molar ratio x mass 
of vector (g) x ratio of insert to vector lengths 
 
 Q5 High Fidelity DNA polymerase (NEBlabs, UK) with 3’ to 5’ exonuclease activity 
was used to amplify the UGT1A enhancer region and so produced blunt-end DNA 
fragments therefore the blunt end cloning protocol was implemented as described by 
the manufacturer.  In other instances, Taq DNA polymerase was used. This produced 
PCR products with 3’dA overhangs.   
 
Table 2.24: Ligation mixture for cloning  
Component  Volume (μl) 
2X Reaction Buffer 10 
Purified blunt end DNA fragment  1 
pJET1.2/blunt Cloning Vector (50ng/μl) 1 
T4 DNA ligase  1 
Nuclease free Water  Up to 20μl 
 
The ligation mixture was vortexed briefly and centrifuged for 3 – 5 seconds, then 
incubated for either 5 minutes, 30 minutes or overnight at room temperature, at 4°C 
or on ice.  The ligation mixture was used for transformation as described in Section 
2.72.   Identified colonies were inoculated and subjected to colony PCR as described 




2.13.2 Analysis of recombinant clones 
 
Analysis of recombinant clones was carried out by colony PCR (See Table 2.24 and 
2.25 below) followed by analysis on an agarose gel for the presence of the PCR 
product. The expected product size was the addition of the UGT1A insert and 
pJET1.2/blunt vector. 
 
Table 2.25: Colony PCR reaction mixture. 
Component  Volume (μl) 
10X Taq buffer  2 
dNTPs (2mM) 2 
pJET1.2 Forward 
Sequencing Primer (10μM) 
0.4 
pJET1.2 Reverse 
Sequencing Primer (10μM) 
0.4 
Taq DNA polymerase 0.1 
25mM MgCl2 1.2 
Bacterial Broth (Colony)  1 
 
Table 2.26: Colony PCR conditions. 
Step   Conditions 
Initial denaturation 95°C for 3 minutes 
Denaturation  94°C for 30 seconds   
25 
cycles 
Annealing 60°C for 30 seconds  
Extension  72°C for 1minute/kb 






Figure 2.4:PJET1.2/blunt is a blunt- end-cloning vector that is 2934bp long. It 
includes a lethal restriction enzyme gene, eco471R that is disrupted by ligation of a 
DNA insert into the cloning site.  For this reason, only the bacterial cells with 
recombinant plasmids are able to form colonies.  If the vector re-circularizes without 
an insert the expression of the lethal restriction enzyme kills the transformed E.coli 
cell. The vector also carries a T7 promoter for transcription initiation. (Image from 
Thermo Fisher Scientific, 2020).  
2.14 Clustered Regulatory Interspaced short palindromic repeats 
interference (CRISPRi) engineering 
 
2.14.1 Single guide RNA design  
 
Single guide RNA (sgRNA) that target the UGT1A enhancer region containing the 
DR3-type VDRE were designed using CRISPR.MIT.EDU, Zhang lab, (2019) 
previously available online. The generated output is listed in table 2.26.  The UGT1A 
loci sequence was retrieved from the human genome browser (Kent et al., 2002). 
Output sgRNA were chosen based on specificity to target DNA sequence.  Target 





2.14.2 Ribonucleoprotein (RNP) complex formation and lipofection 
 
For cell suspension preparation, LS180 cells were washed in PBS and detached from 
the flask by scrapping and the cell density was determined as described in section 2.1.  
1x105 cells or 4x105 cells (for 24 well plates and 6 well plates respectively) were 
transferred into a 1.5ml microcentrifuge tube and the cells were collected by 
centrifugation at 200xg for 5 minutes.  The supernatant was discarded and the 
supernatant and cells were re-suspended in 500μl of supplemented MEM.  RNP 
complex was formed using the Synthego, USA guidelines as depicted in table 2.29.  
The transfection solution was formed as depicted in table 2.27 and was incubated at 
room temperature for 5 minutes.  The RNP complex was then added to the transfection 
solution, mixed by pipetting and left to incubate for no more than 10 minutes. For 
lipofection, the RNP-transfection solution was added to each well, followed by each 
cell suspension previously prepared, by pipetting.  500μl or 2ml of supplemented 
MEM with each ligands (EtOH or 1,25D) was then added to each well.  Plates were 
incubated at 37°C/5% CO2 for 48 hours prior to analysis.  Samples seeded in 24-well 
plate were subjected luciferase activity assay as described in section 2.74, whereas 
samples prepared in 6-well plate were subjected to RNA extraction and gene 


















Table 2.27: sgRNA sequences for CRISPRi-based approach 
Target On target 
locus 


















































Table 2.28: RNP formation reaction 
Reagent 6-well plate/well 24-well plate/well 
Opti-MEM I reduced 
Serum Medium  
100μl 25μl 
Cas9-Dead-NLS 600pmol 100pmol 
UGT1A sg RNA guide 780pmol 130pmol 
Lipofectamine 
CRISPRMAX Cas9 Plus 
Reagent 
4μl 1μl 
pGL3-UGT1A-290  500ng 

















Table 2.29: CRISPRi transfection mixture 
Reagent Volume (μl) (6-
well plate) 
Volume (μl) (24-well 
plate) 
Opti-MEM I Reduced 









Figure 2.5: CRISPRi transcriptional silencing model. This technique employs a 20bp 
sequence that is complementary to the targetted DNA (sgRNA). SgRNA is fused with 
dCas9, catalytically inactive enzymes that blocks the targeted DNA sequence.  
Altogether, this simaltenously silences the activity of the targeted sequence (e.g 
VDRE), which silences trascriptional activity without genetic modification.  (Image 




























3: Chapter 3 
Induction of UGT1A gene family members by  














Following the discovery that PXR is a pharmacologically distinct CYP3A inducer, the 
concept of PXR mediated drug metabolizing enzymes has been under scrutiny in 
recent years, prompting potential implications in drug-drug interactions in humans 
(Lehmann et al., 1998; Pascussi et al., 2000 and Luo et al., 2002).  Predominantly 
investigated in a hepatic context, PXR is highly homologous to VDR both in its 
mechanistic action and in sequence (Sueyoshi and Negishi, 2001). Consequently, 
scientists have taken an interest in translating these findings to an extrahepatic context, 
where VDR is predominantly expressed (Lee et al., 2018). In addition to phase I 
metabolic genes, UGT1A1, UGT1A6 and UGT1A9 are regulated by liganded PXR 
(Chen et al., 2012; Hanioka et al., 2012).  Multi-drug resistant 1 (MDR1), Multi-drug 
resistance-associated protein 2 (MRP2) and organic anion transporting polypeptide 2 
(OATP2) enzymes that facilitate in the basolateral efflux of metabolites are also 
induced by PXR (Wagner et al., 2005).   
 
Schmeidlin-ren et al., (1997) were the first to identify an increase in CYP3A4 mRNA 
and protein level in Caco-2 cells by 1,25D/VDR signaling. To date, this focus is still 
rudimentary, but what we know so far is that Thompson et al., (2002) identified a 
distal DR3-type (-7719/-7733) and a proximal ER6 (-169/-152) VDRE within the 
CYP3A promoter.  Expanding upon this concept, Maguire et al., (2012) identified that 
CYP3A4 and CYP3A5 are modulated by VDR in LNCaP prostate cell line model.  
Disrupted VDR examined in mice models (VdrΔIEpC) generated by Cheng et al., (2014) 
consequently exacerbated LCA-induced hepatotoxicity.  Evidently, liganded VDR is 
important in regulating CYP3A4, and in this context, the detoxification of bile acid 
induced toxicity in the gastrointestinal tract.   
 
Phase II metabolic enzymes have attracted less attention than CYPs, mainly because 
drug interactions involving these enzymes are relatively rare.  Conversely, emerging 
evidence raises clinical concern.  For example, in 2004, Echchgadda et al., observed 
an increase in phase II metabolic gene SULT2A1 expression by VDR. This finding 
was supported by the identification of a VDRE at the -191 to -168 position of rat and 
mouse Sult2A1 promoter, supporting its direct inducibility by VDR activation 




investigated the regulation of phase II enzymes SULT1 gene family members by 
multiple NR signaling pathways in LS180 cells, amongst these was an observation 
that 1,25D/VDR signaling induced SULT1C2 mRNA, protein and reporter activity, 
the latter by a 5.5-fold increase.  More evidence of this effect by Seo et al, (2013) 
implicated liganded VDR to SULT2B1 induction in mice and prostatic cancer cell line 
models. SULT2B1 is known to convert dehydroepiandosterone (DHEA) to 3β-sulfates, 
thus interfering with intra-prostate androgen synthesis (Seo et al., 2013). These 
findings highlight VDR’s therapeutic role in controlling prostate cancer growth.   
 
The interest of VDR mediated phase II metabolic products has since broadened to 
investigate UGT1A family members as glucuronidation has been identified as an 
important cause of drug-drug interactions (DDI), and as such, a growing clinical 
problem and potential economic loss for the pharmaceutical industry (Ciotti et al., 
1999).  The liver is the primary glucuronidation site; however, extrahepatic 
glucuronidation, mediated by VDR has been shown to hold clinical significance 
(Strassburg et al., 2002).  Evidenced by Kaeding et al., (2008), liganded VDR was 
identified as a negative regulator of UGT2B15 and UGT2B17 in LNCaP and 22Rv1 
cell lines, an effect thought to reduce androgen glucuronidation. This suggests that 
VDR ligands may have profound consequences for androgen homeostasis and activity 
in androgen-sensitive prostate cancer cells, but most importantly corroborates UGT 
regulation by VDR.   
 
Interestingly Kasai et al., (2005), observed a link between UGTs and Vitamin D 
metabolism.  Their laboratory demonstrated that the hexafluorinated analog of the 
active form of 1,25D, 26,26,26,27,27,27-Hexafluoro-1α,25-dihydroxyvitamin D3 
[F6-1α,25(OH)2D3], used as a clinical drug in the treatment of hyperparathyroidism, 
was subjected to CYP24A1 catabolism, but also UGT1A3 mediated glucuronidation, 
forming a F6-1α, 23S,25(OH)3D3 metabolite in the liver.  This was followed by the 
discovery that recombinant UGT1A3/UGT1A4 isozyme generated three 25OHD3 
monoglucuronides (25OHD3-25-glucuronide, 25OHD3-3-glucuronide, and 5,6-trans-
25OHD3-25-glucuronide) in the human liver microsomes and human hepatocytes 




gene products are a critical part in Vitamin D homeostasis, an effect we see in the 
phase I CYP24A1, a potent VDR target gene.   
 
Wang et al., (2014) later emphasized the growing concern in UGT1A isoform 
mediated induction by VDR. Mycophenolic acid (MPA) was found to be a susceptible 
intestinal UGT1A8 and UGT1A10 glucuronidation substrate; an effect that influences 
the drug’s pharmacokinetics in kidney transplant recipients.  Further supporting 
UGT1A induction by VDR was the identification of VDREs following a genome-wide 
study.  Multiple VDRE were identified, including those within the UGT1A locus, upon 
1,25D exposure in LS180 cells (Meyer et al., 2012). Additionally, antiretroviral 
(ARVs) drugs such as Raltegravir and Efavirenz are metabolized by UGTs (Belanger 
et al., 2009 and Cattaneo et al., 2010).   This topic is a major concern where there is 
high prevalence of UGT1A1*28 and UGT1A1*6 polymorphisms and Human 
Immunodeficiency Virus (HIV) cases. Contrariwise, Atazanavir inhibits UGT1A1 
activity. Kanestri et al., (2014) found that homozygous UGT1A1*28 carriers, whose 
UGT1A1 mediated glucuronidation is already decreased (e.g. bilirubin), upon 
administration of this drug were at even higher risk of severe hyperbilirubinemia. 
Additionally, over 50% of known drugs are metabolized by different UGT1A isoforms 
(e.g. Irinotecan- UGT1A1, Tamoxifen- UGT1A4), the need to investigate the 
characteristics of each isoform regulation is of great importance. From the nine 
biologically active isoforms within the UGT1A locus, (Chapter 1; See Figure 1.6) there 
is limited evidence of its intestinal regulation by VDR, however the above-mentioned 
findings highlight the need for its investigation, as it could be as important as hepatic 
glucuronidation and even phase I metabolism.  Although an increase in UGT1A 
expression raises concerns concerning drug metabolism its upregulation is much 
appreciated in diseases were UGT1A expression is compromised.  Hyperbilirubinemia 
is one such case where UGT1A1 up-regulation would be appreciated.  
 
Clinical relevance of UGT1As extend beyond DDI.  Cancer researchers are 
increasingly taking an interest in UGT1A regulation following the discovery of its 
differential expression in normal versus malignant tissue (Strassburg et al., 1997; 
Izumi et al., 2012; Yilmas et al., 2015; Zhou et al., 2015 and Hanioka et al., (2012).  




cells and humanized mice models treated with UVB exposed tryptophan.   This came 
after concerns of inadequate UGT1A1 expression in human neonates, who then present 
with hyperbilirubinemia, or kernicterus if left untreated.  This finding was crucial in 
that, Vitamin D through sunlight exposure can induce UGT1A1, increasing bilirubin 
metabolism, treating neonatal jaundice, while allowing breast-feeding.  As per Arias 
et al., (1964) and more recently Gourley (2002), it is reasonable to speculate that 
breast-fed neonates have high total serum bilirubin due to pregnane−3α,20β-diol 
which is evidenced to inhibit bilirubin glucuronidation in vitro. Contrary to these 
findings, Murphy et al., (1981) barely detected pregnane-3α, 20β-diol in breast milk. 
However, non-esterified fatty acid, β-glucuronidase in the milk were also thought to 
cause high serum bilirubin (Yigit et al., 2001). Zanardo et al., (2007) hypothesized 
that inflammatory signaling caused by an abundance of cytokines in breast milk 
inhibited intestinal UGT1A1 activity. However, this phenomenon is still 
underdeveloped.    Sumida et al., (2013) findings could be a start in eliminating the 
risk of breast-feeding, complications of phototherapy, invasive blood transfusion and 
mother-infant separation.  
 
The identification of UGT1A1 induction by VDR could be a key finding in restoration 
of UGT1A1 activity where UGT1A1 expression is compromised. To date over 50 
mutations are associated with hyperbilirubinemia (Canu et al., 2013).  The most 
common hereditary hyperbilirubinemia conditions are caused by single nucleotide 
polymorphisms (SNPs) UGT1A1*28, UGT1A1*6, UGT1A1*34 and UGT1A1*35. 
UGT1A1*6 being prevalent amongst the Japanese population (Akiyama et al., 2008).  
These conditions include Gilbert’s Syndrome (GS), Crigler –Najjar Syndrome I (CNS 
I) and CNS II which presents with reduced UGT1A1-mediated glucuronidation 
capacity, and the latter complete loss, which is life threatening (Jansen et al., 1969). 
VDR mediated UGT1A1 induction could possibly aid in managing and reducing these 
devastating consequences.  Our findings will be of clinical importance since GS 
prevalence is as high as 9% globally and 1 in 3 patients are unaware of their status 
until they present with drug toxicity due to reduced glucuronidation ability (Fretzayas 
et al., 2012).  Whilst the rest of the symptoms including jaundice (yellowing of the 
skin) are benign, drug toxicity remains a critical clinical concern and as such raising 




Comprehensive examination of UGT1A1 regulation by VDR could potentially lead to 
Vitamin D analogues as treatment for the abovementioned conditions. Nevertheless, 
advancement in this direction are still limited, also because of the lack of animal 
models presenting hyperbilirubinemia.   Progress in this route was conducted by Chen 
et al., (2005) who cross-bred Ugt1+/- with transgenic (Tg)UGT1 mice to generate a 
fully humanized model system (hUGT).  Chen et al., 2012 went on to examine hUGT 
with PXR deficiency. Surprisingly, hyperbilirubinemia was not observed, but rather a 
gradual decline in serum bilirubin, which shortly recovered; an effect implying 
intestinal UGT1A1 bilirubin metabolism.  It was speculated that other signaling 
pathways could be involved, such as nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB). NF-κB plays an important role in UGT1A1 regulation. This 
was proven by Fujiwara et al., (2012) who compared the effects of breast milk to 
formula milk in hUGT1 mice models. Breast milk suppresses intestinal IκB kinase α 
and β.  These enzymes are part of the NF- κB signal transduction cascade.  
 
As shown, VDR plays an important role in the metabolism circuit. In addition to phase 
I and II metabolic gene products, others and we intimate 1,25D also to up-regulate 
phase III transporters, including MDR1 from which EMSA identified multiple DR3 
and DR4-type VDREs within between -7.9/-7.8kp upstream of the TSS (Saeki et al., 
2008).  Knowing that hyperbilirubinemia is also caused by a decrease in phase III 
transporters, perhaps VDR activation could reverse these effects (Keppler, 2014).  
This evidence sees Vitamin D and its cognate VDR as a necessity in phenotypic 
stability, disease protection and efficacy of exogenous compounds, again highlighting 
the importance of understanding this regulation further.  Whilst the above mentioned 
studies have characterized VDR in the involvement of metabolic pathways, data 
linking VDR and UGT1A gene family members has been limited.  In this study we 
aim to fully characterize the entire UGT1A gene family’s responsiveness to activated 
VDR and transcriptional and functional level,  in addition to defining the molecular 
mechanisms involved, including the manipulation of possible binding motifs which 







3.2 Results  
 
3.2.1 Vitamin D regulates the expression of UGT1A gene family 
members 
 
Preliminary endpoint PCR analysis confirmed the expression of UGT1A genes and 
known VDR targets CYP24A1 and CYP3A4 in LS180 cells (Figure 3.1) however, 
through implementing real-time Q-PCR analysis using TaqMan gene expression 
assay, a quantitative measure of gene expression was obtained.  Previous studies have 
investigated individual UGT1A isoform expression, whereas here the entire expression 
profile across this gene family are analyzed, relative to their transcriptional responses 














Figure 3.1: Gene expression in LS180 cells.  To detect NR expression, RNA was 
extracted in LS180 cells exposed to EtOH, 1,25D, EB1089 and tBHQ  for 24 hours. 
RT-PCR was carried followed using 1.5% agarose gel electropherosis.  The PCR 
product was visualized using a UV transluminator and images captured using the 







Figure 3.2 shows differential fold induction (a) and relative mRNA expression levels 
(b) across all UGT1A isoforms in LS180 colonic cancer cells. UGT1A1 is significantly 
enhanced by 1,25D (2.1-fold) and its synthetic analogue EB1089 (3.5-fold), but no 
significant effects are noted for 3kLCA and rifampicin (RIF).  3kLCA is a less potent 
VDR agonist we included in our investigation. Its ability to induce UGT1A gene 
family members would suggest that VDR is also involved in the bioavailability of 
secondaty bile acids which in excess cause colorectal cancer (Ishizawa et al., 2018).  
Enhanced UGT1A gene expression by 3kLCA would confirm VDR to be a crucial in 
chemoprevention.  RIF on the other hand is a PXR agonist.  As already mentioned, 
PXR is a close relative of VDR and has also been identified to enhance UGT1A gene 
family members, we included this ligand in our experiments to compare these known 
effects to that of activated VDR.  UGT1A1 and UGT1A3 show a similar profile in the 
overall levels of mRNA expression in LS180 (colon adenocarcinoma ) cells, although 
here in addition to 1,25D- (2.1-fold) and EB1089- (1.96-fold) mediated, the expression 
of UGT1A3 is increased 1.3-fold by 3kLCA, an effect that is statistically significant.  
UGT1A3 and UGT1A4 share 93% identity in primary amino acid sequences, yet 
Figure 3.1 depicts a different expression profile (Jiang et al., 2015). While UGT1A4 
exhibits a relatively low basal level of mRNA expression (compared to UGT1A1), this 
isoform exhibits the highest sensitivity to treatment with VDR ligand.  Our 
experiments found that 1,25D, EB1089 and 3kLCA significantly enhance the levels 
of UGT1A4 mRNA expression by 9.9-, 14- and 4.8-fold increase respectively with 
rifampicin having no effect.  A similar profile of expression is noted for UGT1A5, 
with 1,25D, EB1089 and 3KLCA increasing its expression by 5.7-, 8.5- and 2.8-fold, 
respectively.  More modest, albeit still significant effects on UGT1A7 are also noted 
with 1,25D and EB1089.  Contrary to previous findings Wang et al., (2014), we find 
no significant change in UGT1A8 and UGT1A10 gene expression to be elicited 
through our selected treatments. Our findings highlight EB1089 to have the most 
potent UGT1A regulatory effects. Similarly Hansen et al., (2000) who identified that 
the synthetic analogue is 50 to 200 times more potent than 1,25D in inducing genes 
with antiproliferative effects in U937 lymphoma cells, MCF-7 breast cancer cells and 
HaCaT cell.  Furthermore, although PXR is a known UGT1A inducer, we observed a 





Figure 3.2: UGT1A expression profile in LS180 cells.  RNA was extracted from 
LS180 cells treated with 1,25D (10-8M), EB1089 (10-8M), 3kLCA (10-5M), RIF(10-5M) 
or vehicle control for 24-hours. ETOH was the vehicle control for 1,25D, EB1089 and 
3kLCA. Methanol (METH) was the vehicle control for RIF.   Represented here are 
fold inductions (ΔΔCT) obtained relative to the vehicle (A) and ΔCT was calculated 
relative to HPRT as a housekeeping gene (B). Data presented in an average of three 
independent experiments were n=3.  Statistical analysis was obtained from Student’s 






In order to confirm the validity of our findings, we investigated the mRNA expression 
levels of known VDR target genes. Figure 3.3 shows CYP24A1 is significantly 
induced by all VDR ligands whereas PXR ligand did not induce this gene.  Our 
findings for CYP3A4 modulation by activated PXR are comparable to that of Hustert 
et al., (2001), as a 2.5-fold increase was observed in LS174T cells, although this was 
still minimal compared to a 155-,222- and 86-fold increase modulated by 1,25D, 
EB1089 and 3kLCA respectively.   Finally, treatment of LS180 cells with 10-8M 1,25D 
and EB1089 resulted in a drastic increase in TRPV6 expression.  3kLCA also enhanced 
TRVP6 expression by 26.7-fold. Our previous unpublished data depicted in Figure 3.4 
shows that UGT1A1 and UGT1A4 are induced in a time-dependent manner.  Both 
1,25D and EB1089 significantly increased UGT1A1 expression after 12 hours by 2- 
and 3-fold respectively.  After 24 hours, EB1089 increased UGT1A1 expression by 
approximately 5-fold, peaks at 8-fold after 48 hrs.  1,25D increased UGT1A1 by 2.5-
fold after 24-hours also peaks after 48-hours at 2.6-fold.  3kLCA induced UGT1A1 
gene expression by a significant 1.7-fold, 1.9-fold and 2.1-fold increase following 12-
, 24- and 48-hours treatment. 1,25D induced UGT1A4 by 8-fold, 15-fold  and 9-fold 
after 12-, 24- and 48-hour treatment respectively, while EB1089 induced the same 
gene significantly, by 15-, 38- and 35-fold after the same time points.  Additionally, 
3kLCA was also inducible in a time dependent manner (2-, 5- and 7-fold).  Rifampicin 
significantly alters UGT1A1 and UGT1A4 expression after 12- and 24-hours 
respectively (1.3-fold and 3-fold). Time-dependent effects similar to VDR ligands 
were not observed in this case.  Our data show a significant difference in the 
expression profile of UGT1A1 and UGT1A4 induced by 1,25D and EB1089.  Clearly, 
both ligands influence these genes in a time-dependent manner, although EB1089 is 













Figure 3.3: mRNA expression of VDR target genes in LS180 cells.   RNA was 
extracted from LS180 cells treated with 1,25D (10-8M), EB1089 (10-8M), 3kLCA (10-
5M), Rif (10-5M) or vehicle control for 24 hours.   ΔCT was calculated relative to 
HPRT as a housekeeping gene. Fold inductions (ΔΔCT) obtained relative to the 
vehicle.  Data shown is an average of three independent experiments were n=3.  
Statistical analysis was obtained from Student’s two-tailed t.test were *P<0.05, 







Figure 3.4: Time-dependent mRNA expression of UGT1A genes by VDR and PXR 
ligands.RNA was extracted from LS180 cells treated with 1,25D (10-8M), EB1089 (10-
8M), 3kLCA (10-5M), Rif (10-5M) or vehicle control for 24 hours.   ΔCT was calculated 
relative to HPRT as a housekeeping gene. Represented here are fold inductions (ΔΔCT 
obtained with ligand relative to the vehicle).  Represented are fold induction of the 
average of three independent experiments were n=3.  Statistical analysis was obtained 
from Student’s two-tailed t.test were *P<0.05, **P<0.01 and ***P<0.001.  
(Unpublished data from our laboratory). 
 
3.3 VDR is an autonomous regulator of the UGT1A1 gene  
 
The significant induction of UGT1A1, UGT1A3, UGT1A4, UGT1A5 and UGT1A7 
(Figure 3.2) gene transcripts following 1,25D, EB1089 and 3kLCA would suggest that 
these genes are directly regulated by VDR.  Seeing that UGT1A1 is the most 
abundantly expressed isoform in our chosen cell model system, we investigated the 
UGT1A1 promoter region more closely using reporter-based luciferase assays as 
described in section 2.7.  For this, we obtained pGL3-UGT1A1-2K, which contains 




distal enhancer sequence. These were kindly gifted by Professor Masahiko Negishi 
(Research Triangle Park, North Carolina) (Figure 3.5).  LS180 cells were transiently 
transfected with the pGL3-UGT1A1-2K (U2K) or pGL3-UGT1A1-290 (U290) and 
also either a VDR expression vector or an empty parent vector, followed by 24-hour 
treatment with 10-8M 1,25D, 10-8M EB1089 or 3kLCA.  Data was obtain from dual 
luciferase glo assay (Promega, UK).   As shown in Figure 3.6 UGT1A1 promoter 
activity effects activated by endogenous VDR were observed following transient 
transfection of LS180 with either the U2K or the U290 reporter vectors.  This data 
suggests that, within both the 2kbp and 290bp fragments, there are putative VDREs 
that are potentially accountable for inducing UGT1A1 promoter activity.  1,25D 
increased UGT1A1 promoter activity by 3.8- and 2.9-fold, EB1089 by 4.8- and 2.8-
fold, and lastly 3kLCA by 3.6 and 9.5-fold for the U2K and U290 reporter plasmids 
respectively. Our findings suggest that U290 is the most responsive reporter construct. 
However, for 3kLCA U2K was the most responsive. After overexpression of VDR in 
LS180 cells, the activities of both the U2K and U290 reporter plasmids became further 
augmented.  Exogenous VDR increased U2K and U290 reporter plasmid activity 
following 1,25D exposure by 13-fold and 10-fold respectively.  For EB1089 treatment, 
a 7.7-fold and a dramatic 21.2-fold increase was observed.  These findings suggest a 
direct correlation between VDR expression and UGT1A1 promoter activity.  It is 
noteworthy that in this instance, VDR protein expression was not analysed.  However 
it is important to support our data measurement of VDR levels upon overexpression 
in order to fuller determine a positive correlation between VDR and UGT1A 













Figure 3.5: The UGT1A1 phenobarbital responsive enhancer module. Binding sites 
for multiple NRs were previously identified to be clustered within the human UGT1A1 
promoter region  (-3.5 to 3.2kbp) termed the phenobarbital responsive enhancer 
module (gtPBREM).  Our laboratory obatined a 2kbp fragment (U2K) and a 290bp 
fragment of this region, both containing a putative  DR3-type motif VDRE.A promoter 
vector containing 2bp mutation of the VDRE was generated and subsequently used to 
























Figure 3.6: VDR regulates UGT1A1 promoter activity.  LS180 cells were co-
transfected with either the pGL3-UGT1A1-290 (U290) or pGL3-UGT1A1-2K (U2K) 
reporter plasmid and either VDR expression construct or parent vector control using 
Invitrogen™ Lipofectamine™ 2000 Transfection Reagent, followed by 24-hour 
treatment with VDR ligands. Reporter activity was measured after 24 hours with Dual-
Luciferase® Reporter Assay System (Promega, UK). Figures represent an average 
percentage (%) relative light units (RLUs) relative to vehicle control from three 
independent experiments where n=3 for each data point. Statistical analysis was 
obtained from Student’s two-tailed t.test were *P<0.05, **P<0.001, ***P<0.0001, 
****P<0.00001. $ represents exogenous VDR statistical significance relative to 




3.4 Direct repeat 3 (DR3) motif within the UGT1A1 proximal gene 
promoter is a functional Vitamin D response element (VDRE) 
 
The 290bp UGT1A1 promoter sequence was screened for putative VDREs using the 
RSAT tool (Figure 3.7).  A DR3-type putative was identified. This led to the 
construction of a pGL3-UGT1A1-290 mutant (U290 MUT) by site directed 
mutagenesis. Sequencing confirmed the engineered 2bp change within  the 3’ half-site 
of the VDRE, where the VDR component of the heterodimer is expected to bind. To 
confirm the functionality of the identified VDRE, transcriptional effects of the pGL3-
UGT1A1-290 mutant (U290 MUT) were compared to those generated by the wild-
type reporter in LS180 cells, following exposure to 1,25D (10-8M) , 3kLCA (10-5M)  
and vehicle control for 24-hours. Renilla luciferase construct was also co-transfected 
and used as a reference for normalisation of transfection efficiency in all our luciferase 
based assays.  As depicted in Figure 3.8, our findings confirm the DR3-type motif 
within the U290 reporter vector is conceivably a functional VDRE.  As expected, when 
compared to the activities elicited by the intact reporter vector, the transcriptional 
responses to 1,25D and 3kLCA for the mutant version of the reporter become, 
significantly diminished by 75% and 41% respectively.  Based upon these 
observations, this DR3-type motif is suggestive to be responsible for direct VDR 
modulated UGT1A1 expression, although it is noted the VDRE mutation does not 
completely abolish the responses to 1,25D and 3kLCA.  This suggests that other motifs 
within the promoter region may also contribute to VDR-mediated effects, or that the 
2bp mutation did not completely abrogate binding of the heterodimer to this element.   
 
We also aimed to characterize the putative DR3-type element in terms of its specificity 
for mediating response to VDR ligands, compared to other nuclear receptors.  This 
was achieved through transfecting LS180 cells with either the wild type or mutant 
versions of the 290bp promoter vector.  Upon co-tranfection with VDR or PXR 
expression vectors, LS180 cells were exposed to 1,25D (10-8M) or Rifampicin for 24-
hours, then luciferase activity was measured by dual luciferase glo assay (Promega, 
UK).  Similar to previous findings, exogenous VDR significantly increased UGT1A1 
promoter activity. Our findings also confirm PXR as a regulator of the phase II 




activity (compared to the wild type construct) by 69% and 33.4% respectively, 
following 24-hour 1,25D and Rifampicin exposure.   
 
To characterize further the potential exclusivity of this DR3 element for VDR-
mediated effects, we compared UGT1A1 luciferase activity in LS180 cells co-
transfected with expression vectors for either LXRα or FXR (both expressed as N-
terminal ‘tagged’ with the V5 epitope). 
 
LXRα has been shown to transcriptionally activate UGT1A both in vitro and in vivo 
studies (Verreault et al., 2006).  Here a similar effect is shown where reporter activity 
is increased by approximately 3.5-fold after 24 hour treatment with TO901317, a 
potent LXR agonist.  We further investigated the consequence of exposing LS180 cells 
to FXR agonist GW474066 prior to transfection with either DR3-type motif wild type 
or mutant.  Similar to the above-mentioned outcome, FXR activation increased 
UGT1A1 promoter activity by approximately 8-fold ( Figure 3.10). Our data here show 
that both FXR and LXR are unaffected by the putative VDRE mutation.  This confirms 
that specificity of the DR3-type motif and its functionality, in addition to the fact that 












































Figure 3.7: UGT1A sequence. Grey represents TF rich sites identified from the 






Figure 3.8: Identification of a functional VDRE within the UGT1A1 promoter 
region. LS180 cells were co-transfected with either the wild-type U290 (U290 WT) or 
(U290 MUT) reporter VDR expression vector using Invitrogen™ Lipofectamine™ 
2000 Transfection Reagent, followed by 24 hour treatment with VDR ligands. 
Reporter activity was measured after 24 hours with Dual-Luciferase® Reporter Assay 
System (Promega, UK). Figures represent an average percentage (%) relative light 
units (RLUs) relative to vehicle control from three independent experiments where 
n=3 for each data point. Statistical analysis was obtained from Student’s two-tailed 
t.test were *P<0.05, **P<0.001, ***P<0.0001, ****P<0.00001. $ represent U290 













Figure 3.9: VDR and PXR share the same DR3-type binding motif within the 
UGT1A1 promoter region. LS180 cells were co-transfected with either the wild-type 
U290 (U290 WT) or (U290 MUT) reporter VDR,  PXR or control expression vector 
using Invitrogen™ Lipofectamine™ 2000 Transfection Reagent, followed by 24 hour 
treatment with VDR or PXR prototypical ligands.  Reporter activity was measured 
after 24 hours with Dual-Luciferase® Reporter Assay System (Promega, UK). Figures 
represent an average percentage (%) relative light units (RLUs) relative to vehicle 
control. Fold induction was calculated relative to vehicle control from three 
independent experiments where n=3 for each data point.  Statistical analysis was 




****P<0.00001. $ represent U290 MUT statistically significance decrease relative to 
U290 WT. ($ P<0.05, $$P<0.001 and $$$ P<0.0001 
 
Figure 3.10: Defining the DR3-type motif specificity within the UGT1A1 promoter 
region  LS180 cells were co-transfected with either the wild-type U290 (U290 WT) or 
(U290 MUT) reporter LXR (A) or FXR (B) expression vector using Invitrogen™ 
Lipofectamine™ 2000 Transfection Reagent, followed by 24 hour treatment with LXR 
or FXR prototypical ligands.  Reporter activity was measured after 24 hours with 
Dual-Luciferase® Reporter Assay System (Promega, UK). Figures represent an 
average percentage (%) relative light units (RLUs) relative to vehicle control. Fold 
induction was calculated relative to vehicle control from three independent 
experiments where n=3 for each data point.  Statistical analysis was obtained from 







3.5 Vitamin D enhances UGT1A protein expression in LS180 cells  
 
Since mRNA expressions of UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A7 all 
appear as modulated through VDR signaling, we then wished to determine if these 
changes were also manifest at a protein level in the same colonic cell line. However, 
the UGT1A gene family members share a very high level of sequence identity (70-
95%); obtaining isoform specific antibodies has been a challenge (Ikushiro et al., 
2006).  The work of Ikoshiro et al., (2006) successfully used a peptide specific 
antibody strategy against each UGT1A gene, whose findings demonstrated the 
independence of each isoform in its induction by various substances.  
 
We then wished to examine the effects of nuclear receptor ligands upon the detectable 
levels of  UGT1A protein expression in LS180 cells. Initially we compared the effects 
after 24 hours exposure to ligands for VDR, (1,25D, 3kLCA), FXR (GW474066) or 
LXR (TO901317) at concentrations defined in Table 2.2.  Whole cell lysates were 
derived from treated cells and then probed through western blot analysis as described 
in section 2.5.3.  Commercially, antibodies for the individual isoforms are still 
unobtainable, and so this study incorporated an anti-UGT1A antibody (that likely 
recognizes all 10 functional isoforms.  This antibody is raised against amino acids 234-
533 located at the C-terminus of the human UGT1A (Santa Cruz Biotechnology, 
2020).   
 
Analysis of the protein expression data shows that 1,25D and 3kLCA enhanced the 
detectable levels of UGT1A protein, the former, more robustly (Figure 3.11). There 
was a slight Rifampicin effect relative to methanol.  Interestingly DMSO, known for 
its ability to stabilize protein even at as low concentrations as 4% (v/v) (Yedavalli and 
Rao, 2013), also slightly raises the detection of UGT1A protein in relation to the 
ethanol vehicle control.  Both LXR and FXR agonists (TO901317 and GW474066, 
respectively) also cause a modest increase in UGT1A protein.  Interestingly, 1,25D 
remains the strongest inducer (Figure 3.11).  Our data also confirms that EB1089, 
similar to 1,25D increases UGT1A protein expression. (Figure 3.12).  
 
 We then examined the effects of exogenous VDR and PXR expression on UGT1A 




PXR agonists (1,25D 10-8M and Rifampicin 10-5M). Our findings conclude that, while 
over expressing PXR did not affect UGT1A protein expression, exogenous VDR on 
the other hand further enhanced UGT1A protein levels as demonstrated by the 
significantly intensified band (See Figure 3.1).  Our protein expression data also show 
that VDR expression modestly increases UGT1A expression in the absence of ligand 
(1,25D).  Our findings are consistent with our gene expression and reporter based data.  
A possible reason for VDR as the most relevant UGT1A regulator due to the NR’s 
expression levels relative to the PXR, FXR and LXR in LS180 cells. Our endpoint 
PCR data show negligible FXR expression in colonic cancer cell lines LS180, Caco-
2 and LNCaP prostatic cancer cell line (Figure 3.13).  Other NRs were expressed in 






























Figure 3.11: Western Blot analysis showing UGT1A protein expression in LS180 
cells. LS180 cells were exposed to VDR (1,25D and 3kLCA), PXR (RIF), LXR 
(TO901317) or FXR (GW474066) prototypical ligands (A) followed by protein 
extraction (endogenous NR expression). B represents LS180 co-transfected with either 
PXR, VDR (exogenous) or control empty vector (endogenous) followed by 1,25D or 
Rifampicin treatment for 24 hours.  UGT1A protein was then detected.  β-actin and 
HPRT were used as loading controls respectively.  Figures show a representation of 

















Figure 3.12: UGT1A protein expression in LS180 cells by VDR and PXR ligands. 
LS180 cells were exposed to VDR and PXR ligands for 24-hours followed by protein 
extraction. UGT1A protein was then detected.  β-Actin was utilized as a loading contr 













Figure 3.13: Nuclear receptor expression in various cancer cell lines. To detect NR 
expression, RNA was extracted in LS180, LNCaP and CaCo-2 cells exposed to ethanol 
for 24 hours. RT-PCR was carried followed using 1.5% agarose gel electropherosis.  
The PCR product was visualized using a UV transluminator and images captured 








3.6 Vitamin D increases glucuronidation activity in LS180 cells  
 
After demonstrating, the regulation of UGT1A isoform expression by 1,25D at both 
mRNA and protein level, with identification of a DR3-type motif within the UGT1A 
promoter region as a functional VDRE, we next addressed the question as to whether 
this regulation had relevance for detectable changes in functional enzymatic activity.  
For this purpose, we examined glucuronidation activity through the UGT-Glo assay 
within microsomal fractions extracted from cells treated with 1,25D, EB1089 or 
vehicle control for 24 hours. The treated microsomal fractions were exposed to a 
multi-enzyme substrate susceptible for glucuronidation.  The addition of Luciferin and 
D-cysteine converted the substrate to luciferin which in turn emitted light.  
Glucuronidation reduces the amount of substrate available for luciferin conversion and 
therefore this enzyme activity is noted as a reduction in the level of emitted light 
Therefore the glucuronidation activity measured was inversely proportional to the 
luciferin/emitted light.   Using this approach, we note UGT1A enzyme activity to be 
significantly increased in response to 1,25D by a modest 1.5-fold.  In addition, EB1089 
also enhanced this activity by 1.62-fold although we could not obtain statistical 
significance for this experiment (Figure 3.14).  Upon investigating glucuronidation in 
human liver microsomes (HLM) which were used as a positive control due to high 
UGT1A concentrations, our findings showed drastically high endogenous levels of 
glucuronidation activity, compared to effects obtained in LS180 extracts perhaps 
leading to questioning the sensitivity of using cell culture based system in our chosen 

















Figure 3.14: VDR ligands enhance glucuronidation activity in LS180 cells 
Glucuronidation activity was analysed using the UGT-glo Assay using 50ug of LS180 
microsomal fractions treated with 1,25D, EB1089 and EtOH as the vehicle control for 
24 hours. Human Liver Microsomes (50μg) were used as a positive control.  Figure 




















3.7 Discussion  
 
The generation of a humanized mouse model, that expresses the entire UGT1A loci 
with a Ugt1-null background has contributed towards advancing knowledge in UGT1A 
regulatory mechanisms, particularly with emerging evidence of its clinical 
significance ranging from disease prevention to drug clearance (Cai et al., 2010).  
Scientists have to date demonstrated that UGT1As are highly regulated in response to 
various compounds that act as NRs agonists including dietary substances, 
environmental toxins clinical drugs and endogenous substances  (Walle et al., 2000; 
Malfatti et al., 2005; Wang et al., 2014 and Duguay et al., 2004).  Most in vivo UGT1A 
regulatory investigations have been limited to a hepatic context.  Although all UGT1A 
family members are highly homologous, they exhibit differential expression, and are 
modulated by different NR agonists (Ikushiro et al., 2006; Sugatani et al., 2005).   
 
 VDR on the other hand has emerged as a crucial TF in regulating a number of genes 
related to metabolism.  By probing a Chip-seq data set derived from Pike’s Laboratory 
(University of Wisconsin-Madison), multiple peaks representing enrichment of 
VDR/RXR binding within the UGT1A locus were identified. In expanding upon this 
knowledge, this study demonstrates for the first time a profile of UGT1A expression 
modulated by VDR in an extrahepatic context. LS180 cells were primarily used due 
to their ability to recapitulate transcriptional regulatory mechanisms of 1,25D in the 
intestine and colon (Yamaura et al., 2016).  Wang et al., (2014) were the first to 
investigate VDR mediated UGT1A8 and UGT1A10 VDR mediated transactivation in 
LS180, HCT-116 and CaCo-2 cells.  However, we, examine the entire UGT1A family 
in this regulation.  Interestingly, in this study, VDR agonists did not modulate  
UGT1A8 and UGT1A10 possibly due to the low mRNA expression levels observed in 
this cell line.  Notably UGT1A1 was significantly induced by 1,25D and more strongly 
by EB1089 (See Figure 3.2). As depicted in Figure 3.4, we observe a time-dependant 
and dose-dependent induction of UGT1A1 and UGT1A4 gene family members.  These 
findings imply VDR is directly involved in the transcription of these genes.  PXR 
agonist rifampicin also increases UGT1A1 and UGT1A4 but significantly less so when 
compared to VDR ligands. This may be caused by low levels of PXR expression 
compared to VDR in our cell line model.  Since both PXR and VDR share the same 




ligands suggest that VDR regulation of UGT1A genes is the most physiologically 
relevant in an extrahepatic setting, whereas PXR, predominantly regulates hepatic 
metabolism.    
 
In consideration of the overlap in substrate glucuronidation, UGT1A1 is the sole 
enzyme responsible for bilirubin conjugation, with no other alternative pathway 
existing for its clearance (Kadakol et al., 2000).  Conditions such as Gilbert’s 
Syndrome (GS), characterized by intermittent unconjugated bilirubin is a result of 
reduced UGT1A1 activity by up to 30% (Fretzayas et al., 2011).  GS is benign and as 
such, symptoms manifest as intermittent mild jaundice in adolescence (Singh and 
Jialal, 2019).   However, combination of Glucose 6-phosphate dehydrogenase (G6PD) 
deficiency, spherocytosis, thalassemia and GS cause severe hyperbilirubinemia 
(Fretzayas et al., 2011).  GS is a pharmacogenetic risk factor for drug toxicity 
including irinotecan. Its active metabolite (irinotecan), 7-ethyl-10-
hydroxycamptothecin (SN-38) is metabolized by UGT1A1; therefore reduced 
clearance capacity results in irinotecan toxicity in GS patients (Lankisch et al., 2008). 
Since the condition can only be managed and not cured, GS genotyping should be 
carried out prior to drug administration and much attention should be drawn to 
homozygous UGT1A1*28 polymophism carriers.  Other hereditary 
hyperbilirubinemia conditions that result from UGT1A1 gene mutations are Crigler-
Najjar Syndrome Type (CNS) type I and CNS II. The former is a much more serious 
condition characterized by complete loss of UGT1A1 activity (Liaqat et al., 2018).  
Serum bilirubin levels reach 20-50mg/dL and patients usual develop fatal 
encephalopathy (Liaqat et al., 2018).   
 
 Efforts into restoring UGT1A1 expression to combat this condition have been carried 
out by numerous scientists including Fujiwara et al., (2014) who previously identified 
that glucose increased extrahepatic UGT1A1 expression in Caco-2 cells.  In the same 
study, glucose enhanced intestinal UGT1A1 in hUGT1 mice, and upon measurement, 
serum bilirubin was significantly reduced. In addition, Medley et al., (1995) 
transplanted small intestinal tissue from Wistar rats to homozygous Gunn rats 
deficient in UGT1A expression and this allayed hyperbilirubinemia.  Their work and 




potential for enhanced intestinal UGT1A1 as an alternative treatment where UGT1A1 
expression is reduced.  It is also noteworthy that vitamin D administration could revive 
UGT1A1 expression in neonates for better and less invasive management of neonatal 
jaundice, to counteract the effects of breast-feeding, and most importantly to prevent 
kernicterus.  Moreover, since UGT1A play a role in the metabolism of endogenous and 
exogenous carcinogenic compounds, numerous case studies as discussed by Hu et al., 
(2016) have characterized UGT1A polymorphisms as a genetic risk factor for a wide 
range of cancers including, colorectal, prostate, oesophageal and breast cancer.  Our 
findings on UGT1A regulation intimate vitamin D as a chemo-preventative or 
chemotherapeutic measure.   
 
UGT1A3 together with UGT1A4 are expressed both in a hepatic and extrahepatic 
context and possess very similar sequence homology (Jiang et al., 2015).  However, 
our findings reveal higher UGT1A3 mRNA expression levels in LS180 cells compared 
to UGT1A4, but UGT1A4 as the most sensitive isoform to VDR ligands.  ( Figure 3.2). 
UGT1A3 plays a role in bile acids, catechol oestrogens, androgen glucuronide 
formation, in addition to drug clearance including, anti-retroviral (ARVs) drugs (e.g.  
Dolutegravir, Raltegravir), L-Thyroxine (T4) (thyroid cancer drug) Cyproheptadine 
and Clozapine glucuronidation (Ramsey et al., 2014; Santoro et al., 2014; 
Mallayasamy and Penzak, 2019). UGT1A4 on the other hand conjugates pregnanediol, 
steroids, dietary carcinogen and numerous drugs including antihistamines, 
antipsychotics (e.g. clozapine), antidepressants such as imipramine and tamoxifen 
(Sutiman et al., 2016; Suzuki et al., 2019 and Benoit-Bianamano et al., 2009). Our 
results could imply that a VDR agonist could alter the glucuronidation rate of the 
above-mentioned substances. 1,25D or its analogues could contribute towards the 
prevention or treatment of diseases where high oestrogen (UGT1A3) or perhaps 
dietary carcinogens (UGT1A4) for example, lead to ovarian cancer, breast cancer, 
blood clots or colon cancer. Conversely, VDR mediated UGT1A3 and UGT1A4 
implicate drug clearance, especially with emerging evidence of intestinal tissue as a 
major glucuronidation site (Wang et al., 2014 and Mizuma et al., 2009).  Therefore, 
our findings imply that VDR agonists or vitamin D status may be a consideration when 





Interestingly, UGT1A3 conjugates the 23-hydroxylated metabolite of the analogue 
26,27-F6-1α,25-(OH)2D3 Kasai et al., (2005) and Hashizume et al., (2008) found that 
UGT1A4 metabolizes glucuronidation of 1,25D itself.  Research on 1,25D 
glucuronidation is in itself rudimentary, however closely related is the use of 
recombinant UGT1A3/UGT1A4 isozyme by Wang et al., (2014) who detected 25-
(OH)D3 monoglucuronides (25-(OH)D3-25-glucuronide, 25-(OH)D3-3-glucuronide, 
and 5,6-trans-25(OH)D3-25-glucuronide) in the human liver microsomes and human 
hepatocytes. Also in the same study, 25OHD3-3-glucuronides were identified in the 
plasma and bile.  These findings point to an alternative catabolic pathway of 25-
(OH)D3 elimination, affecting the regulation of 1,25D regulation.  Additionally, 
25OHD3-3-glucuronides in the bile may indicate an initial step in the paracrine 
signaling loop, which regulates intestinal VDR target genes such as TRPV6 and 
CYP3A4 (Wang et al., 2014).  At physiological level, the induction of UGT1A3 and 
UGT1A4 could contribute calcium absorption and influence metabolism.  These 
findings point to a possibility that UGT1A3 and UGT1A4 may play a role in vitamin 
D homeostasis.   
 
Upon characterization, UGT1A7 transcripts were identified in the stomach esophagus 
and orolaryngeal tissue (Zheng et al., 2001).  Our findings reveal a modest elevation 
in their expression through 1,25D and EB1089 but not 3kLCA (Figure 3.2).  
Interestingly, Fang et al., (2013), characterized azidothymidine and estradiol 
glucuronidation in primary hepatocytes from C57BL/6NCr mice following the 
addition of taurolithocholic acid (TLCA; a taurine conjugated form of lithocholic acid) 
and recombinant UGT1A isoforms.  Findings differed for each UGT1A isoform; 
however, TLCA (100μM) inhibited UGT1A7 activity by 90%.  Lithocholic acid 
derivatives (e.g. LCA acetate) can act as VDR agonists (Adachi et al., 2006).  In this 
study, we include 3kLCA, another LCA as one of the VDR agonists to examine.  
Taking into account Fang et al., (2013) and this study, 3kLCA could also be inhibiting 
UGT1A7 modulation, although the molecular mechanisms at this stage were not 
explored further.  UGT1A3, UGT1A4, UGT1A5 expression was significantly enhanced 
by 3kLCA, implicating VDR activation with extrahepatic circulation of bile acids as 
well as enhancing its glucuronidation as a preventative measure against colonic 




increase the clearance of tobacco carcinogens associated with orolaryngeal cancer 
(Zheng et al., 2001).   
 
UGT1A5 is the least studied isoform amongst the phase II metabolic genes.  Recent 
work by Finel et al., (2005) detected its low basal levels in human hepatocytes and 
protein detection in human liver is limited unless exposed to rifampicin. This suggests 
that UGT1A5 is expressed only in response to its transcription factor agonist. 
Contrariwise, our findings reveal that rifampicin did not enhance UGT1A5 mRNA 
expression and similarly to UGT1A4, mRNA expression levels were substantially low 
compared to UGT1A1 and UGT1A3.  So far, its clinical relevance has been linked to 
1-hydroxypyrene, 4-methylumbelliferone and scopletin glucuronidation (Finel et al., 
2015).  Although this study identified a similar expression profile to UGT1A4, its 
catalytic activity differs, for example, UGT1A5 glucuronidation of 4-aminobiphenyl 
was absent. This is a good UGT1A4 substrate (Al-Zhoughool and Takaska, 2006).   
 
Both UGT1A4 followed by UGT1A5 were markedly the most sensitive of the tested 
isoforms to all VDR agonists tested, EB1089 being the most potent ( Figure 3.2).  Our 
findings implicate this finding to the possible involvement of multiple VDRE binding 
sites within the promoter region.  ChIP-seq data from the Pike laboratory reveal 
multiple binding sites at potential 1,25D dependant major cis-regulatory module 
upstream of UGT1A1, which could affect UGT1A isoform expression near this loci, 
including UGT1A4 and UGT1A5.  Furthermore, using the GeneHancer database, 
which reveals clustered interactions of specific gene enhancers, mapped the UGT1A4 
enhancers clustered within the identified cis-regulatory module (Kent et al., 2002).  
With this evidence, there is more reason to speculate that the involvement of multiple 
enhancer modules synergistically enhance gene transactivation. The DR3-type motif 
identified as a functional VDRE was mutated and although significantly reduced 
promoter activity was recorded after both VDR and PXR agonist exposure, it was not 
completely abolished; implying the involvement of other response elements in the 
promoter vector (Figure 3.8).  Moreover, this study along with those previously 
mentioned demonstrate cell-type specific and complex UGT1A gene regulation. 





As previously established, numerous exogenous and endogenous substrates for 
UGT1A are biologically active molecules that activate specific NRs.  As such, their 
glucuronidation forms part of a feedforward or feedback mechanism by which the 
substrates mediate their own NR-mediated metabolism.   
 
Up to now, studies such as those by Fisher et al., (2000) have correlated UGT1A1 and 
UGT1A6 expression to estradiol-3- and acetaminophen-O-glucuronidation 
respectively.  NR mediated glucuronidation was reported by Chen et al., (2005) whose 
findings showed an enhanced SN-38 glucuronidation correlated with UGT1A1, 
UGT1A9 and UGT1A10 mRNA induction in PXR-expressing cells.    Closely related 
to our study was Wang and colleagues’ work (2014) who reported altered 
mycophenolic acid (MPA) drug pharmacokinetics following inter-individual 
variability in kidney transplant patients who often co-administer Vitamin D 
supplements.  Our study did not examine specific substrate glucuronidation (e.g. 
measurement of bilirubin glucuronides upon 1,25D exposure by LC-MS/MS), but for 
the first time, we report UGT1A protein expression dramatically enhanced by 1,25D, 
and this also correlates with exogenous VDR expression (Figure 3.11).  We 
investigated this expression with PXR, FXR and LXR prototypical agonist whose 
effects were modest (Figure 3.11) Finally, the multi-enzyme glucuronidation assay 
reveals 1,25D significantly increases enzymatic activity. The limitation to this assay 
was very low sensitivity relative to HLM, which have concentrated amounts of UGTs 
(Figure 3.14).   
 
The study highlights yet another important role of VDR and possibly how extensively 
it is involved in maintaining overall cellular health.  The ability for VDR-mediated 
intestinal UGT1A induction means that Vitamin D supplementation could be used as 
treatment where the UGT1A gene expression is compromised (e.g. GS and CNS). 
Similar to Aoshima’s  et al., (2014) work Vitamin D can be used to combat neonatal 
jaundice.  Since GS prevalence is as high as 16% in other populations, genotyping and 
Vitamin D co-administration could revive UGT1A1 enzymatic activity.  1,25D could 
be classed as a chemo-preventative measure due to enhanced carcinogen 
glucuronidation. Breast-feeding could be continued along with vitamin D 




other hand, since enhanced UGT1A expression and activity increase drug clearance, it 
is important to avoid co-administration for optimum drug efficacy.  Further in vivo 
functionality experiments are needed to confirm these clinically significant effects.   
The use of UGT1A transgenic mice models with a Ugt1-null background will be ideal 
to investigate the physiological relevance as well as functionality of UGT1A 
regulation.  Upon Vitamin D administration, examination of metabolites such as that 
of total serum bilirubin can then be measured in order to determine whether 
extrahepatic UGT1A regulation by VDR is relevant in hyperbilirubinemia treatment.    
Additionally, a limitation to this study was the use of one intestinal cell line model.  
As previously mentioned, the chosen cell line (LS180 cells) imitates the biology of 
vitamin D in an intestinal context (Meyer et al., 2012), however the investigation of 
UGT1A regulation in other VDR expressing cell lines (e.g. kidney, skin, breast and 
other colon cell lines) will further strengthen our findings.  Optimization of the 
functionality assay or use of LC-MS/MS to measure substrate metabolites upon 
exposure to VDR ligands will also strengthen evidence of VDR activity’s relevance 
in UGT1A biology.  It is also noteworthy that VDR protein levels should be analysed 
upon over-expression to further streghthen our findings on VDR mediated UGT1A 
regulation.   
 
Altogether, findings also highlight the need to fully understand the molecular 
pathways involved in UGT1A regulation and the role of 1,25D as a ‘guardian for 























3.8 Summary of key findings  
 
• UGT1A1, UGT1A3, UGT1A4, UGT1A5 and UGT1A7 are significantly 
enhanced by activated VDR 
• UGT1A4 is the most sensitive isoform to VDR activation 
• UGT1A1 is the most abundantly expressed isoform in LS180 cells.   
• UGT1A protein is enhanced by VDR ligands (1,25D, 3kLCA and EB1089).   
• VDR expression positively correlates with UGT1A protein expression and 
promoter activity.   
• VDR is more potent at enhancing UGT1A expression compared to PXR in 
LS180 cells. 
• The DR3-type motif within the UGT1A1 promoter region is a functional 
VDRE and is only specific to VDR and not other nuclear receptors (e.g. 

















4: Chapter 4 
 
Examining the cross-talk between Vitamin D 
Receptor and Nuclear Factor Erythroid 2-Related 














4.1 Introduction  
 
Upon activation, Vitamin D Receptor (VDR) forms a heterodimer with retinoid X 
receptor (RXR) and the complex binds to vitamin D response elements (VDRE).  This 
transcriptional activity initiates the expression of numerous genes, that in turn lead to 
several functional processes including mineral homeostasis, cell growth, anti-aging 
and detoxification processes.  Many of these processes depend on the ability of VDR 
to increase the expression of UGT1A gene family members and Nuclear factor 
erythroid 2-related factor 2 (NRF2), a key transcriptional factor involved in the 
neutralization of a plethora of cellular oxidative stress inducers (Ahmed et al., 2017).  
NRF2 in-turn enhances a number of its target genes (Discussed in chapter 1) including 
Glutamate-Cysteine Ligase Catalytic Subunit (GCLC), NAD (P) H dehydrogenase 
quione 1 (NQO1), Glutamate-Cysteine Ligase Modifier Subunit (GCLM) and UGT1A 
genes itself (Tonelli et al., 2018). Berridge et al., (2015) identified that a dysregulation 
VDR signalling resulted in the elevation of oxidative stress, augmented cellular aging  
and increased neural calcium levels in Alzheimer’s disease transgenic mice.  This 
dysregulation was reversed by the administration of Vitamin D which also led to 
increased NRF2 expression.    This evidence raises questions as to whether VDR 
signalling is a major component particularly in the neutralization of oxidative stress.  
Knowing that NRF2 also enhances UGT1A gene family members (Tonelli et al., 
2018), and linking that to our findings of VDR mediated UGT1A gene expression, we 
sort to investigate whether VDR ultimately plays a key role in enhances NRF2 
mediated responses and more importantly, whether there is an interplay between VDR 
and NRF2 in further enhancing UGT1A gene expression.   
 
 Under normal conditions, NRF2 is bound to Keap1 that presents it to the E3 ligase 
complex by Cullin-3 (Cul3), leading to constant degradation by the ubiquitin 
proteasome system (Zhang et al., 2004).  Upon insults, NRF2 translocates into the 
nucleus, where it forms a heterodimer with small Maf (sMaf) proteins (Zhang et al., 
2004). The complex binds to anti-oxidant response element (ARE) motifs within the 
promoter region of target genes; co-regulatory complexes are then recruited, leading 





NRF2 activation interplays with other molecular pathways including innate immune 
responses (Thimmulappa et al., 2006). Scratch injury to culture primary astrocytes 
elevates tumour necrosis factor-alpha (TNF-α), interleukin -1β (IL-1β), IL-6 and 
matrix metallopeptidase 9 (MMP9) more prominently in NRF2 knockout (KO) than 
wild-type counterparts (Pan et al., (2012).  The elevation of pro-inflammatory 
cytokines suggests that NRF2 controls inflammation responses through the control of 
nuclear factor kappa-light-chain enhancer of activated B cells (NF- κB) and its 
downstream targets (Wardyn et al., 2015).  NF-κB modulates immune, inflammatory 
responses, cellular development and differentiation (Liu et al., 2008). The NF-κB p65 
subunit also antagonizes NRF2 signaling through the recruitment of co-repressors and 
histone deacetylases (HDACs) (Liu et al., 2008).  Heme Oxygenase 1 (HMOX1) is a 
key NRF2 target gene involved in haem metabolism, ultimately producing serum 
bilirubin (Loboda et al., 2016).  Seldon et al., (2007) observed that in endothelial cells, 
HMOX1 inhibited E-Selectin and vascular cell adhesion molecule 1 (VCAM-1), both 
mediated by NF-κB.   
 
Furthermore, NRF2 interplay evidenced through extrahepatic UGT1A8 and UGT1A10 
induction was co-ordinated by cross-talk with Aryl hydrocarbon Receptor (AhR) 
(Kalthof et al., (2010).    NRF2 also directly enhances heat shock factor 1 (HSF1) gene 
expression in MCF7 breast cancer cells exposed to OS (Paul et al., 2018).  
Furthermore, NRF2 signalling is a well-characterized pathway in various pathologies 
including diabetes, cardiovascular diseases, and neurodegenerative disorders 
(Berridge, 2015).   
 
Based on the abovementioned evidence and that activated VDR enhances NRF2 
expression, we speculate its potential interplay with VDR to further enhance 
antioxidant responses.  Evidence by Nakai et al., (2013) observed that systemic and 
intra-renal OS was diminished by 1,25D treatment in Type 2 diabetes rats that 
presented with nephropathy.  Additionally, NRF2 expression was restored in the rats 
exposed to 1,25D (Nakai et al., 2013).  This evidence is enough to speculate that 1,25D 
could enhance cyto-protection through NRF2 crosstalk, thereby enhancing 
detoxification and expression of OS neutralizing enzymes.  Lee et al., (2015) observed 




where Caco-2 cells were exposed to both VDR and NRF2 ligands (1,25D and 
Sulphorafane (SFN) respectively). The Wnt-pathway controls cell growth, 
differentiation and survival; however, alteration in genes involved in this pathway also 
lead to malignancies such as colorectal cancer where ~ 90% of cases present with 
aberrant Wnt-pathway signalling (Duchatre et al., 2016). Moreover, numerous studies 
have demonstrated that NRF2 itself increases UGT1A expression, both in in vitro and 
transgenic mice models (Yueh and Tukey, 2007).  Kalthoff et al., (2010) later 
identified that coffee, a known NRF2 ligand enhances UGT1A isoforms by up to 6.1-
fold.  From these findings, we speculate that NRF2 pathway is altered by 1,25D/VDR 
signalling, thus leading to a greater UGT1A response, contributing towards its role as 
a ‘custodian for phenotypic stability, as Berridge’s (2015) hypothesised.   
 
We hypothesize that VDR signalling, together with NRF2 signalling, enhance the 
expression of UGT1A responses to further amplify the scavenging of toxic insults and 
the neutralization of OS.  Moreover, their interplay results in enhanced chemo 
protection and control of tumorigenesis through anti-proliferative and apoptotic 
properties.  We hypothesize that diminished functionality of either transcription factor 
leads to impaired signalling of the other. To test this hypothesis, we exposed LS180 
cells to SFN (synthesized from glucoraphanin through hydrolysis by myrosinase 
enzyme were cruciferous vegetables, including broccoli are mechanically damaged or 
digested) and tert-butylhydroquione (tBHQ) (common food additive), the most 
common NRF2 activators.  LS180 cells were also exposed to 1,25D and 3kLCA as 
vitamin D receptor (VDR) prototypical ligands derived from endocrine and bile acid 
pathways, respectively (Abbaoui et al., 2018 and Zargorski et al., 2013).  Comparative 
analysis was also performed on androgen-sensitive LNCaP human prostate 
adenocarcinoma cells derived from the left supraclavicular lymph node metastasis due 
to the evidence of functional NRF2 activity and correlation between OS to the 
initiation and progression of prostate cancer (PCa) (Bellezza et al., 2017).  In addition, 
since SFN increases the efficacy of anti-androgens, its interplay with 1,25D was 
examined (Khurana et al., 2016).   





4.2.1 Cell Viability Assay  
 
In this study, we sought to address whether NRF2 and VDR signalling pathways 
interact to neutralize oxidative stress by enhancing UGT1A gene expression.  As a 
model system, we used LS180 and HEK293 cell lines to compare this interaction.  
Firstly, to determine ideal concentrations for the chosen NRF2 ligands SFN and tBHQ, 
LS180 cells were treated with different concentrations of SFN (0, 5, 10, 30, 40, 50 and 
100µM) and tBHQ (20, 40, 60, 80, 100, and 500µM) for 24 hours (Figure 4.1). 
Afterwards, cell viability, which quantifies ATP presence, correlating to metabolically 
active cells was, assessed (Kumar et al., 2018). Of note, both SFN and tBHQ inhibited 
viability in a dose dependant manner, although not to the level that would determine 
an IC50.  SFN significantly reduced cell viability at 20μM up to 100μM, suggesting 
that lower concentrations are ideal for investigating NRF2 responses in LS180 cells. 
In comparison, LS180 cells were less sensitive to the synthetic aromatic organic NRF2 
inducer, tBHQ.  Concentrations up to 80μM were not toxic to cells, but an approximate  
30% and 50% decrease in cell viability was observed following exposure to100μM 
and 500μM of tBHQ, respectively.   
 
 
Figure 4.1: Cell Viability of NRF2 ligands in LS180 cells.  LS180 cells were seeded 
in 96-well plate for 24-hours, followed by dosage with increasing concentrations of 
SFN (0-, 5-, 10-,20-, 30-, 40-, 50- and 100μM) or tBHQ (20-, 40-, 60-, 80-, 100-, 
500μM) for another 24 hours.  Cell Viability was obtain using the Cell-titre-glo assay 
(Promega, UK). Data represents 3 independent experiments where n=3, shown in 
percentage (%) viability. Statistical analysis was obtained from Student’s two-tailed 





4.2.2 NRF2 and VDR ligands alter ARE signalling in LS180 cells 
 
Both SFN and tBHQ are known to promote NRF2/ARE association (Kubo et al., 2017 
and Kalthof et al., 2010). We therefore examined ARE minimal promoter driven 
functionality by transiently transfecting pGL4.37[luc2P/ARE/Hygro] which contains 
four copies of the ARE. LS180 cells were treated with varied concentrations of each 
NRF2 agonist (SFN: 5-, 10-, 20-, 30-, 40-, 50- and 100μM and tBHQ: 20-, 40-,60-, 
80-, 100-, 500μM) for 24-hours.  Luciferase activity, testing the responsiveness of the 
endogenous NRF2 system was also measured by Dual Luciferase Reporter Assay 
system (Promega, UK).  Reporter activity showed a gradual concentration-dependent 
response to tBHQ (7.3-, 9.9-, 51.9-, 68.5- and 70-fold, relative to the above mentioned 
concentrations) with a diminished response at 500µM ( Figure 4.2 A and B) correlating 
with a decline on cell viability (Figure 4.1). Of note SFN also significantly enhanced 
ARE promoter activity by 38.4-, 78.3-, 45.9-, 21.8-, 3.1-, 4.3 and 9.1-fold increase 
relative to the concentrations mention previously.  SFN was the most effective NRF2 
agonist with the maximum response at 10μM (78.3-fold increase).  It is also 
noteworthy that the SFN and tBHQ profile are different.  SFN induced ARE activity 
peaks at 10μM, a much lower concentration compared to tBHQ (100μM).  This may 
be attributed by the fact that SFN is a natural compound that requires low 
physiological concentrations to exert an intact ARE response. TBHQ on the other hand 
is synthetic food preservative, which, at low concentrations initiates cyto-protection, 
and only at higher concentrations, cytotoxic properties are triggered.   
 
The ARE activity profile observed is similar to our cell viability assay in Figure 
4.1.This data confirms functionality of ARE and the responsiveness of the two NRF2 
prototypical ligands.  For future experiments, we chose 40µM for tBHQ, 6µM for SFN 
as these do not elicit significant reductions in cell viability, and produce significant 
transcriptional responses.  
 
In view of the fact that NRF2 signalling is mediated via ARE promoter activity, and 
1,25D has been reported to upregulate NRF2 mRNA expression (Chen et al., 2019), 
we examined whether co-operative ARE reporter activation could be observed in 




impacted through addition of exogenous VDR to the cell system (Figure 4.2 C and D).  
In LS180 cells expressing endogenous VDR, 24-hour treatment with 1,25D 
significantly enhanced ARE activity by 1.81-, 1.42- and 1.17- fold respectively. 
Exogenous VDR altered this activity as a 1.6-, 1.6- and 1.29-fold increase was 
observed respectively, however our statistical analysis did not show any significance.  
We conducted the same experiment in HEK293 cells, where endogenous VDR 
expression is negligible.  We found that 1,25D enhanced ARE activity by 2.62-, 2.55- 
and 2.61-fold at the concentrations applied, respectively. VDR over-expression further 
increased ARE activity by 1.03-, 0.59- and 0.18-fold. Similar to LS180 cells, the 
effects of over-expressing VDR were not statistically significant. This data show that 
1,25D augments ARE activity, although this response is not concentration dependent. 
Compared to endogenous VDR, ARE activity following overexpression of VDR was 
notably greater, particularly in HEK293 cells.  Our data also show that 1,25D has 
significantly less influence on ARE activation compared to SFN and tBHQ.   
 
Figure 4.2: Titration curve of ARE activation in LS180 and HEK293 cells. The 
titration curve shown was obtained from the titration of SFN (A), tBHQ (B) and 1,25D 
(C) in LS180 cells and 1,25D in HEK293 cells (D). C and D also depicts ARE 




activated. Luciferase activity was measured using the Dual-Glo Assay (Promega, 
UK). Data represents 3 independent experiments were n=3 shown as % Relative Light 
Units (RLUs).  Statistical analysis was obtained from Student’s two-tailed t.test were 
* P<0.05, **P<0.005, ***P<0.0005).  
 4.2.3. ARE-signalling in Vitamin D pre-treated LS180 cells 
Given that there is considerable evidence to suggest that NRF2/ARE signalling 
alterations may contribute to numerous diseases linked to Vitamin D deficiency, and 
that 1,25D treatment resulted in a modest increase in ARE basal activity (Figure 4.2), 
we sought to investigate whether  prolonged 1,25D exposure has an impact on further 
augmenting ARE activation when NRF2 is activated.  Furthermore, since 1,25D 
slightly increases ARE activity, it is worth investigating an additive effect of this kind.  
 
Cells were exposed to either EtOH or 1,25D for 24-hours, before then dosed with SFN 
(3, 6 or 9µM) or tBHQ (30, 50 or 70µM) for further 24-hours, followed by 
measurement of reporter activity.   ARE reporter activity was significantly increased 
by both NRF2 prototypical ligands, as expected. SFN evidently altered ARE activation 
in a dose-dependent manner where a gradual increase in ARE activation is observed 
by approximately 5-fold, 15-fold and 30-fold respectively (Figure 4.3A). On the other 
hand, tBHQ dose-dependent response while less impressive, nonetheless, significantly 
increased ARE activity by approximately 17-fold to 25-fold (Figure 4.3B). 1,25D has 
no apparent effect on ‘priming’ any further enhancement of ARE activity.  Although 
there is a trend in that 1,25D pre-treated cells result in greater reporter activity, the 


















Figure 4.3: ARE activation by NRF2 ligands following pre-treatment in LS180 cells.  
ARE activation by NRF2 and VDR ligands.  LS180 cells were transfected with ARE-
luc reporter construct (650ng/well).  The cells were subsequently pre-treated with 
ETOH or 1,25D for 24 hours, followed by SFN (3-, 6-, and 9µM) (A) and  tBHQ (30-
, 50-and 40µM) (B) for 24 hours. Relative Light units were then measured by Dual 





vehicle control were n=3. Statistical analysis was obtained from Student’s two-tailed 
t.test were p<0.05=* , p<0.005=** 
 
4.2.4 ARE minimal promoter activity is modulated by NRF2 and 
VDR ligands  
 
We then examined whether ARE activity could be influenced by another VDR ligand, 
3kLCA in comparison to 1,25D. LS180 cells were transiently transfected with 
pGL4.37[luc2P/ARE/Hygro] then subsequently treated with VDR ligands (1,25D or 
3kLCA) ( Figure 4.4.A) or NRF2 ligands (SFN and tBHQ) (Figure 4.4 B) for 24 hours. 
Similar to preliminary findings of 1,25D inducing ARE activation, there was a notable 
1.35-fold increase in transcriptional activity by 1,25D (Figure 4.4C). Surprisingly, the 
3kLCA had a more significant effect and increased ARE activity by a 4.03-fold.  This 
result is indicative of the fact that ARE/NRF2 signalling may be the first line of 
defence against secondary bile acid toxicity in the intestine. It is therefore reasonable 
to speculate that ARE promoter activity increase suggests a more rapid and efficient 
clearance of 3kLCA through neutralization of oxidative stress, leaving the intestinal 
tract less susceptible to injury that they might be. 3kLCA responses were observed 
with endogenous VDR in our chosen cell line, however to test whether this is a VDR 
dependant response, silencing the VDR silencing using Small interfering RNA 
(SiRNA) can be used to confirm this mechanism in the future. 
 
SFN and tBHQ induce nuclear accumulation of NRF2 and NRF2-dependant 
regulation of ARE mediated gene expression, therefore it was not surprising that in 






Figure 4.4: ARE minimal promoter activity is mediated by NRF2 and VDR ligands.  
LS180 cells were transfected with ARE-luc reporter construct (650ng/well).  The cells 
were subsequently treated with SFN (6μM), tBHQ (40μM) (A), 1,25D (10-8M) or 
3kLCA (10-4M) (B) for 24 hours. Luciferase activity was obtained using Dual-Glo 
Luciferase Assay (Promega, UK). Data represents 3 independent experiments were 
n=3. %RLU are relative to vehicle control. Statistical analysis was obtained from 
Student’s two-tailed t.test were *P<0.05, **P<0.005, ***P<0.0005, ****P<0.0001 
 
4.2.5 The effects of NRF2 and VDR ligands co-treatment in LS180 
cells 
 
Next, we wanted to verify whether co-treating LS180 cells with both VDR and NRF2 
ligands (simultaneously, rather than pre-treatments) would enhance ARE activity.  The 
previous sets of experiments indicate that each of our tested ligands has some noted 




activity. This was confirmed in the above experiments, where individually we see a 
significant modulations of ARE promoter activity (SFN 43-, tBHQ 32- 1,25D 5.5- and 
EB1089 13-fold increase).  We questioned whether simultenously treating cells with 
a combination of VDR and NRF2 ligands would additively increase ARE activity, 
particularly because two signalling pathways are involved.   
 
 Surprisingly, co-treatment of 1,25D and SFN reduced ARE activity by 20.5% 
compared to SFN alone.  1,25D and tBHQ combinatorial treatment also reduced ARE 
activity by a dramatic 63.7% compared to tBHQ treatment alone.  Also shown in 
Figure 4.5B, co-treatment of LS180 cells with the EB1089 (the synthetic 1,25D 
analogue) and SFN reduced ARE activity by 50% compared to SFN treatment alone. 
Additionally, tBHQ and EB1089 co-treatment suppressed ARE activation by 57.8% 
compared to tBHQ treatment alone.   
 
Overall, co-treatment with either 1,25D or EB1089 did not cause any synergistic or 
additive effects when applied in combination with NRF2 ligands, but instead elicited 
a profound repression of the NRF2 mediated effect. Taking into consideration the 
above-mentioned results, this may suggest the presence of inhibitory interaction 
between the receptors, although unclear, it will be worth investigating further by 
competitive binding assay in which NRF2 ligands may compete for radiolabelled 

















Figure 4.5: VDR and NRF2 ligands co-treatment in LS180 cells.  LS180 cells were 
transfected with ARE-luc reporter construct (650ng/well).  The cells were 
subsequently treated with SFN (6μM), tBHQ (40μM), 1,25D (10-8M) (A), EB1089 (B) 
or combination (1,25D+SFN/tBHQ or EB1089+SFN/tBHQ) for 24 hours. Luciferase 
activity was obtained using Dual-Glo Luciferase Assay (Promega, UK). Data 
represents 3 independent experiments were n=3. % RLU are relative to vehicle control. 
Statistical analysis was obtained from Student’s two-tailed t.test were *P<0.05, 
***P<0.0005, ****P<0.000. $ represents significant relative to SFN or tBHQ 





4.2.6 Establishing interactions between VDR and NRF2 in 
regulation of UGT1A expression. 
 
290bp of UGT1A1 promoter plasmid containing the mutagenized VDRE or ARE was 
transfected into LS180 cells that were subsequently treated with either 1,25D, 3kLCA, 
SFN or tBHQ for 24 hours.  The use of the alternate mutant reporter vector was 
intended to further examine possible interactions between the VDR and NRF2 
mediated pathways in regulation of UGT1A genes. Mutagenesis of the respective 
response element is expected to diminish responses to VDR and NRF2 ligands, but a 
question to peruse was if these effects of mutated response element on ligand 
responses were mutually exclusive or exhibited co-dependency?  
 As expected, both VDR ligands enhanced significant UGT1A1 promoter activity. 
1,25D by 6-fold and 3kLCA by a less prominent 2.5-fold increase. The introduction 
of the VDRE mutation significantly lessened these effects by 45% and 62.9% 
respectively.  The 2bp mutation of an identified and well-established ARE within the 
UGT1A1-290bp promoter resulted in simultaneous decrease of the responsiveness of 
the UGT1A1 reporter to VDR ligands. The mutation resulted in a 42% and 58% fold 
decreased responsiveness to 1,25D and 3kLCA respectively (Figure 4.6.A).  On the 
other hand, SFN (~3-fold) and tBHQ (~3-fold) also increased UGT1A1 promoter 
activity, confirming that NRF2 signaling trans-activates UGT1A isoforms, which are 
key in the detoxification of endogenous and exogenous toxins (Figure 4.6B) (Kalthof 
et al., 2010). VDRE mutagenesis did not affect NRF2 mediated UGT1A1 mediated 
activity whereas, ARE mutagenesis dramatically diminished UGT1A1 promoter 
activity by 61% (SFN) and 50% (tBHQ). Our data show that while mutagenesis had 
effect on the respective signals, UGT1A1 promoter activity was not completely 
abrogated, suggesting that there are other response elements involved in this 
regulation. Our laboratory and others have identified multiple putative VDREs within 
the UGT1A promoter region, which may further contribute to the VDR effects in 
UGT1A regulation (Wang et al., 2016 and Meyer et al., 2012).  Additionally, Yueh 
and Tukey (2007) identified three AREs within a 60-nucleotide sequence spanning -
3712/-2068 of the UGT1A1 promoter region that contributed towards tBHQ mediated 
UGT1A1 promoter activity.  Similar to the VDR effects, NRF2 responses were not 
completely abrogated due to the other binding motifs that contribute towards ARE 





Surprisingly, our findings also suggest a degree of dependency of VDR signaling upon 
an intact NRF2 pathway, at least for UGT1A1 promoter activity.    
 
Figure 4.6. VDR and NRF2 co-dependency in UGT1A1 induction. LS180 cells were 
transfected with U290 WT promoter vector (U290 WT), U290bp promoter vector 
containing VDRE mutation (U290 VDRE MUT) or U290 promoter vector containing 
an ARE mutation (ARE MUT).  Cells were treated 1,25D (10-8M), 3kLCA (10-4M) (A), 
SFN (6μM) or tBHQ (40μM) for 24 hours followed by luciferase activity measurement 
by Dual Glo Luciferase Assay (Promega, UK). Data represented as Light Units 
relative to vehicle control were n=3. Statistical analysis was obtained from Student’s 
two-tailed t.test were **P<0.005, p<0.05=*, ***P<0.005, ****P<0.0001. $ 







4.2.7. Effects of VDR and NRF2 ligands in combinatorial treatments 
 
Since the previous experiments intimate an element of co-dependency/interaction 
between the VDR and NRF2 signaling pathways, at least in the amplification of 
UGT1A1 promoter activity, the next experiments investigated whether combinatorial 
treatments would impact upon the expression on endogenous target genes.  Figure 
4.7A and B show qRT-PCR analysis of the expressions of the vitamin D target genes 
CYP3A4 and CYP24A1 (relative to HPRT housekeeping gene).  Both genes show a 
significant 650- and ~500-fold induction respectively where LS180 cells were treated 
with 1,25D alone. SFN exposure to LS180 cells had no effect on the expression of 
these genes. However, combinatorial treatment of 1,25D with the more prominent 
NRF2 ligand, SFN, there was a dramatic decline in gene expression to approximately 
85% and 90% respectively, relative to 1,25D treatment alone.  
 
A similar approach was used to examine UGT1A1 and the VDR sensitive UGT1A4 
gene expression levels.  1,25D alone enhanced gene expression by 4.5-fold and 25-
fold respectively.  Treatment with SFN for 24 hours increased UGT1A1 expression by 
significant 2-fold and UGT1A4 by 2.5-fold.  However, upon combination  of 1,25D 
with SFN, UGT1A1 expression increased by a further 2.5-fold, whereas UGT1A4 
expression dramatically decreased by 51% (Figure 4.7 C and D).  This was expected 
as previously established that both the VDRE and ARE motifs are present within the 
UGT1A1 promoter region.  Our findings suggest that SFN had no significant effect on 
UGT1A4 gene, similar to CYP24A1 and CYP3A4 suggesting that it is not regulated 













Figure 4.7: Effects of VDR and NRF2 target genes in combinatorial treatments. For 
gene expression analysis, cells, RNA was extracted in LS180 cells treated with 1,25D 
(10-8M), SFN (6μM) or a combination of both for 24 hours, followed by Real Time Q-
PCR. ΔCT was calculated with HPRT as a house-keeping gene. Fold induction 
represented are relative to each vehicle control.    Statistical analysis was obtained 
from Student’s two-tailed t.test where is *P<0.05.   
 
In addition, protein was extracted from LS180 whole cell lysates previously exposed 
to 1,25D (10-8M), SFN (6μM) or combined treatment of the two ligands for 24-hour 
treatment. Western blot analysis was perform using the UGT1A antibody.  As shown, 
lane 2 and lane 4 confirm that both 1,25D and SFN increase the levels of detection on 
the 64kDa UGT1A protein. When given in combination, the intensity of the band 
corresponding to the UGT1A protein is enhanced (lane 6). (See Figure 4.8A).  
Furthermore, VDR protein (approximately 48kDa) was detected as present across all 
treatments.  There was a slight increase in VDR protein upon exposure to 1,25D, 
relative to EtOH (See Figure 4.8B). DMSO surprisingly caused a greater VDR protein 
signal than SFN treatment, possibly attributed to its ability to stabilize protein. From 




et al., (2008) observed that SFN amplified VDR expression, although this was in 
Caco-2 cell line.   What this data implies is that SFN decreases the expression of VDR 
protein. Nonetheless, combinatorial treatment did abrogate VDR protein expression.   
 
 
Figure 4.8: Effects of VDR and NRF2 target genes in combinatorial treatments. For 
western blot analysis, LS180 whole cell lysates were obtained following 24-hour 
treatment with 1 25D (10-8M), SFN (6μM) or a combination of both for 24 hours.  This 
was followed by signal detection of UGT1A (A) and VDR (B) protein were β-actin was 
used as loading control.   
 
4.2.8 VDRE minimal promoter activity is suppressed by 
sulphorafane (SFN)  
 
Following the investigation of ARE responses to VDR and NRF2 ligands, the activity 
of VDRE was investigated in the same manner.  The use of a VDRE minimal 
promoter-driven firefly luciferase vector system, which consists of  three copies of  
VDRE, facilitated in the examination of specific and defined protein interactions to 
achieve accurate transactivation, was implemented.  In view of the fact that PXR and 






(2006), identified that SFN inhibits PXR-mediated responses, it was of interest to 
examine the comparative effects for how NRF2 ligands upon PXR and VDR responses 
driven off a VDRE (DR3)-based reporter.  As highlighted in Figure 4.8A, SFN causes 
a dose-dependent reduction in the luciferase signal elicited from the VDRE-reporter 
by rifampicin (PXR ligand) over a concentration range 6-, 10- and 20μM in LS180 
cells.   SFN was able to significantly inhibit the responses elicited by rifampicin by 
45%, 60% and 74% respectively. VDRE activity remained significantly enhanced in 
LS180 cells treated with rifampicin in combination with 6μM and 10μM of SFN.  
However, a similar effect was not observed after 24-hours exposure with rifampicin 
and 20μM SFN treatment.  (See Figure 4.9A).   These results were not different from 
experiments in which LS180 cells were also transfected with the VDRE minimal 
promoter and subsequently exposed to VDR ligands 1,25D or 3kLCA, also in 
combination with increasing doses of SFN (6μM, 10μM and 20μM) (See Figure 4.9B).  
As expected, 1,25D treatment significantly enhances VDRE signalling. The addition 
of SFN does not affect this significance, although inhibition of 22% and 43.75% of 
the 1,25D signal generated by VDRE reporter is observed, following co-treatment 
with SFN (10μM and 20μM respectively).  3kLCA on the other hand, appears to be 
even more sensitive to inhibited by SFN also in a dose-dependent manner. LS180 
exposure to 10-4M of 3kLCA significantly enhances VDRE signalling by 31-fold. The 
addition of SFN increments (6μM, 10μM and 20μM) dramatically abrogated this 
effect by 62%, 93.75% and 92.2% respectively (relative to 3kLCA treatment alone).  
Lastly, SFN alone as a single agent evidently enhances VDRE reporter activity by 1.6-
, 1.4- and 1.2-fold increase respectively. However compared to 1,25D (32-fold 
increase), rifampicin (4.5-fold increase) and 3kLCA (31-fold increase), the changes 





Figure 4.9: VDRE signalling in LS180 cells.  LS180 cells seeded in 24-well plates 
were transfected with VDRE minimal promoter vector (650ng) and subsequently 
treated with rifampicin (RIF; 10-5M) only or RIF combined with SFN (6-,10- or 20μM) 
(A). B represents LS180 cells exposed to 1,25D (10-5M) only, 3kLCA only or combined 
with SFN (6-,10- or 20μM).  Luciferase activity was measured using Dual-glo 
Luciferase Assay (Promega, UK). Data presented as %RLU relative to vehicle control. 
Data represents 3 independent experiments where n=3. Statistical analysis was 
obtained from Student’s two-tailed t.test where *P<0.05, **P<0.005, ***P<0.0005. 
$ represents significance relative to RIF, 1,25D or 3kLCA alone.   
 
4.2.9 Vitamin D pre-treatment enhances NRF2-mediated UGT1A1 
activity 
  
So far, our data does show that VDR and NRF2 ligands modulate ARE-driven activity 
to varying degrees, however VDRE signalling, based on a DR3 motif, is specific to 
VDR (and PXR) prototypical ligands.  The addition of SFN appears to antagonize 




ligand binding, inhibition of co-activator recruitment, or diminished expression of 
VDR (and PXR) protein (Figure 4.8B).  Gene expression analysis is in agreement with 
the antagonistic effects of SFN, as VDR-specific target genes are repressed following 
combinatorial treatment. However, for UGT1A1, which contains both the ARE and 
VDRE binding motifs, the response to 1,25D and other VDR ligands is relatively 
unaffected.  
 
For this reason, we decided to further investigate the interplay between these two 
pathways by use of the 290bp long UGT1A1 promoter vector (-3499/-3210) (Sugatani 
et al., 2005). At least one functional VDRE and ARE are known to be present within 
this region (Sugatani et al., 2005). LS180 cells were transiently transfected with this 
promoter vector prior to pre-treatment with either EtOH or 1,25D to evaluate the 
ability of VDR activation in priming the activity of NRF2.  Cells were subsequently 
treated with increments of either SFN (3μM, 6μM, 9μM) or tBHQ (30μM, 50μM, 
70μM).  Here we show that SFN as a single agent, modestly but significantly increases 
the activity of the UGT1A1 based reporter by 1.5- to 2-fold. (Figure 4.10A) The 
addition of 1,25D pre-treatment further enhances this effect with a dose-dependent 
response to SFN becoming more obvious (4-, 5- and 6-fold increases respectively).  
Furthermore, tBHQ doses of 30μM, 50μM and 70μM also increase luciferase activity 
albeit more modestly than those achieved with SFN (1.76-, 2.45- and 2.51-fold 
increase). 1,25D pre-exposed cells caused an even greater response (3.1-, 3.7 and 4.2-
fold increase respectively) (Figure 4.10B). These results confirmed that 1,25D primes 






Figure 4.10: UGT1A1 induction in LS180 cells pre-treated with 1,25D.  LS180 cells 
seeded in 24-well plates were transfected with UGT1A1-290bp promoter vector 
containing a VDRE and an ARE, following which, cells were subjected to 1,25D or 
EtOH pre-treatment for 24-hours, then SFN (3-, 6-, or 9μM) or tBHQ (30-, 50- or 
70μM)  for another 24-hours.  Luciferase activity was measured using Dual-glo 
Luciferase Assay (Promega, UK). Data presented as %RLU relative to vehicle control. 
Data represents 3 independent experiments where n=3. Statistical analysis was 
obtained from Student’s two-tailed t.test where *P<0.05, **P<0.005, ***P<0.0005. 
$ represents 1,25D pre-treated induction relative to corresponding EtOH pre-






4.2.10 Modulation of detoxification products in pre-treated LS180 
cells  
In order to test whether 1,25D enhances the regulation of other  NRF2 target genes 
concerned with control of  oxidative stress, LS180 cells were again pre-treated with 
1,25D or EtOH for 24-hours. Since we hypothesized that VDR does enhance NRF2 
responses, our pre-treatment experiments investigate whether prolonged exposure 
does contribute towards a more prominent NRF2 responses. Clinically, this could 
mean that individuals should maintain optimum levels of Vitamin D in order to 
heighten detoxification responses.  The cells were then further exposed to increasing 
amounts of SFN (3μM, 6μM and 9μM) for another 24-hours, followed by analysis 
through real-time qPCR.  In EtOH pre-treated cells, SFN significantly reduced 
CYP3A4 expression by 30%, 36% and 38% respectively (relative to DMSO 
treatment). However, pre-exposure to 1,25D augmented CYP3A4 expression by a 
58.7-, 53.03- and 81.4-fold, relative to its EtOH pre-treated cells in cells exposed to 
3μM, 6μM and 9μM of SFN   ( Figure 4.11A). 
  In EtOH pre-treated cells, SFN did not alter CYP24A1 expression; however, the 
prolonged exposure to 1,25D induced a dramatic 2278.1-, 1465.56- and 1289.9-fold 
increase relative to EtOH pre-treated cells after a further 24-hour exposure to 3μM, 
6μM and 9μM of SFN (Figure 4.11B).  Our CYP3A4 and CYP24A1 data suggests of 
inhibitory interactions caused by SFN, which we previously observed in Figure 4.7A 
and B.   The increased CYP3A4 and CYP24A1 gene expression were attributed to 
1,25D exposure.  
Surprisingly SFN significantly down-regulated UGT1A4 expression by 7%, 50% and 
59.3%, (relative to DMSO) upon EtOH pre-treated cells and 24-hour SFN exposure 
(3μM, 6μM and 9μM). The effects of 1,25D pre-treatment altered gene expression by 
a 2.6-, 4.3- and 5.2-fold increase regardless of 24-hour treatment with SFN treatment 




SFN alone, in EtOH pre-exposed cells slightly but not significantly inhibits VDR gene 
expression by 2%, 3% and a modest 1.12-fold increase upon 3μM, 6μM and 9μM of 
SFN treatment respectively (relative to DMSO).  1,25D pre-treatment further reduced 
VDR expression by 28%, 14% and 18% (relative to EtOH pre-treatment) upon 3μM, 
6μM and 9μM SFN treatment.   
 























Figure 4.11: Effects of VDR and NRF2 target genes in 1,25D pre-treated LS180 
cells. For gene expression analysis, cells, RNA was extracted in LS180 cells pre-
treated with 1,25D or EtOH as vehicle control for 24 hours, followed by SFN (3-
, 6- or 9μM) dosage for another 24-hours.  Real Time Q-PCR was performed and 
ΔCT was calculated with HPRT as a house-keeping gene. Fold induction 
represented are relative to each vehicle control.  For western blot analysis, LS180 
whole cell lysates were obtained following 24-hour pre- treatment with 1 25D (10-
8M) or EtOH followed by SFN (3-,6- and 9μM) for 24 hours.  This was followed 
by signal detection of protein were β-actin was used as house-keeping gene. 
Statistical analysis was obtained from Student’s two-tailed t.test where is *<P 





Considering our abovementioned luciferase assay findings (Figure 4.9) and VDR 
protein expression analysis (See Figure 4.8B) this data points to the fact that SFN itself 
may interact with VDR ligands or VDR itself,  thus suppressing its activities (VDR), 
the expression itself or VDR specific genes (See Figure 4.11D).  
Next, expression of NRF2-specific genes was assessed in 1,25D pre-treated cells. 
NQO1 gene is involved in the removal of quinines as a detoxification measure against 
ROS and as such, it is a common NRF2 target gene (Shen et al., 2017). As expected 
NQO1 expression is altered by SFN in a dose-dependent manner (4.5-, 3.2- and 3.1-
fold increase respectively).   1,25D pre-treatment down-regulates this expression, 
though not significantly. Surprisingly the effects of 1,25D alone were noted to 
decrease the basal expression of NQO1 by 49% (Figure 4.11E).  GCLC expression 
was significantly enhanced by SFN alone, by a 3.8-fold increase (EtOH pre-treated 
cells) and this effect was not significantly altered by 1,25D pre-treatment (3-fold 
increase) suggesting that 1,25D does not affect GCLC expression (Figure 4.11F). 
HMOX1 gene, which mediates haem catabolism to form biliverdin, is also an NRF2 
target gene (Jiraskova et al., 2017).  Expectedly, HMOX1 induction was influenced in 
an SFN dose-dependent manner (1.8-, 2.8- and 4.1-fold increase respectively).  
However, there was no significance observed cells we also exposed to 1,25D (Figure 
4.11G).  The NRF2 gene itself was also significantly responsive to SFN, (2.5-, 2.64- 
and 2.8-fold increase) however, 1,25D does not influence this expression as previously 
identified (Nakai et al., 2010), and this is possibly due to low level of expression of 




To further understand the interplay between VDR and NRF2, we evaluated genes that 
have been previously reported to be influenced by both signalling pathways. Campos 
et al., (2013) observed that aldo-keto reductase family 1 member C1 (AKR1C1), an 
NAD (P) H-dependent oxidoreductase that catalyzes aldehydes and ketones for easy 
excretion from the body was enhanced by 1,25D treated breast carcinoma associated 
fibroblasts following microarray analysis.  Furthermore, functional ARE motifs were 
localized within the distal promoter of AKR1C1 confirming that it is also influenced 
by NRF2 signalling (Lou et al., 2006).  Firstly, AKR1C1 is highly expressed in LS180 
cells and the gene is significantly increased by SFN in a dose-dependent manner (28.6-
, 59.7- and 71.5-fold increase respectively) (Figure 4.11I).  This data however suggests 
that 1,25D has no influence on AKR1C1 gene expression as it remained enhanced (27-
, 76- and 84-fold increase), although not significantly different compared to SFN 
treatment alone.   Examination of SFN altered UGT1A1 expression also in a dose-
dependent manner, suggestive of its direct regulation through the ARE/NRF2 
signaling (3.2-, 4.0- and 3.2-fold increase respectively).  As we previously observed, 
pre-treatment with 1,25D further increased these expressions in SFN treated cells (3-, 
4.08- and 4.11-fold increase) also suggesting that the involvement of multiple motifs 
further enhanced UGT1A1 expression (Figure 4.11J).  Figure 4.11K depicts that our 
UGT1A1 gene expression data correlates with protein expression analysis. Although 
the antibody detects the entire UGT1A family members, there is a clear distinction of 
LS180 whole cell lysates pre-treated with EtOH and those pre-exposed to 1,25D.  The 
bands intensify as SFN dosage increases, similar to the above-mentioned UGT1A1 
expression (Figure 4.7D).  
 
4.2.11 Anti-tumoural actions of VDR and NRF2 signalling pathways 
 
Given that our results indicate that the nature of VDR and NRF2 signaling cross-talk 
appears to be gene specific, it was of interest to evaluate  impact in another cellular  
signaling pathway, which is the Wnt-signalling pathway involved in cellular fate 
determination, for which 1,25D has been reported to alter its expression.  We evaluated 
Survivin (BIRC5) that identifies as an apoptosis inhibitor; known to be inhibited by 
1,25D (Li et al., 2005). We evaluated the effects of our pre-treatment experimental 
condition on these genes. As shown in Figure 4.11 the levels of BIRC5 expression 




and 17% reduction respectively, relative to DMSO treatment).  The addition of 1,25D 
had no overall effect on the levels of SFN mediated repression, with 1,25D applied as 
a single agent also achieving a 16% reduction in the expression of this gene (See 
Figure 4.12A).   
We then investigated whether the NRF2 and VDR have overlapping properties in 
enhancing E-cadherin (CDH1) gene expression.  CDH1 is an epithelial cellular 
adhesion gene implicated with cancer progression and metastasis.  It is a strictly 
modulated gene, known to be transcriptionally activated by VDR (Pena et al., 2005).  
LS180 cells were exposed to SFN 3μM, 6μM and 9μM for a 24-hour prior to real-time 
qPCR.  An insignificant 1.5-, 1.2- and 1.4 fold increase was observed (relative to 
DMSO).  This data shows that, although ARE/NRF2 signaling is involved in cancer 
prevention activities, it is not implicated with CDH1 gene transcription. Our data 
however, confirm a significant increase in CDH1 expression following 1,25D 
exposure alone (2-fold increase). This is in agreement with previous findings by Lopes 
et al., (2012) who also observed an increase in CDH1 expression in 1,25D exposed 









Figure 4.12: Effects of VDR and NRF2  ligands on anti-tumoural genes. For gene 
expression analysis, cells, RNA was extracted in LS180 cells pre-treated with 1,25D 
or ETOH for 24 hours, then subsequently exposed to SFN (3-, 6- and 9µM) (A) or B, 
cells exposed to  SFN (3-, 6- or 9μM) dosage for 24-hours and C, cells treated with 
1,25D (10-8M) for 24 hours.  Real Time qPCR was performed and ΔCT was calculated 




vehicle control. Statistical analysis was obtained from Student’s two-tailed t.test 
where is *P<0.05. 
 
4.3.1 NRF2 and VDR interplay in LNCaP cells 
 
Next, we tested our hypothesis within a prostatic cellular context, using LNCaP cells.  
OS is linked to initiation and progression of PCa and NRF2 activation appears to 
inhibits prostate cancer (PCa) cell growth through various mechanisms, such as 
ferroportin (a protein involved in iron metabolism) (Xue et al., 2016). SFN also 
suppresses PCa cells by causing apoptosis and in a different context increasing the 
efficacy of anti-androgens (Xue et al., 2016, Singh et al., 2005). Taking this into 
consideration and our knowledge on 1,25D/VDR in LNCaP cells, a targeted 
combinatorial approach could be applied to combat PCa. 
 
Depicted in Figure 4.13 we first examined the presence of functional ARE signalling 
responses in LNCaP cells by transfecting cells with the pGL4.37[luc2P/ARE/Hygro] 
(ARE minimal promoter subsequently followed by SFN (6μM), 1,25D (10-8M) and 
their respective controls for 24 hours.  Luciferase activity represented in % RLUs 
shows a significant 5.5-fold increase in response to SFN.  Similar to LS180 cells, 
1,25D significantly, activated ARE signalling by approximately 2-fold (See Figure 
4.13A).   
 
Next, we evaluated whether prolonged 1,25D exposure primes LNCaP cells to further 
enhance NRF2 target gene expression.  Cells were exposed to either EtOH or 1,25D 
for 24-hours, followed by a SFN (6μM) treatment for another 24-hour period followed 
by gene expression analysis by real time q-PCR.  As shown in Figure 4.14, our gene 
expression data show that SFN significantly increased GCLC by ~ 2.5-fold increase 
(A) with 1,25D pre-treatment having no further effect on this regulation.  NQO1 
expression was significantly altered by 1,25D pre-treatment alone with a 1.69-fold 
increase (B). As expected SFN significantly altered NQO1 gene expression by 9.8-
fold increase.  Unpredictably there was an 8% decreased where both SFN and 1,25D 
pre-treatment was present.  HMOX1 gene expression was similar to that of GCLC, in 




exposure show a 2.6-fold increase (C). Again, HMOX1 gene induction is slightly 
reduced but not significantly, where LNCaP cells were exposed to both ligands.   
 
We further investigated the levels of NRF2 under the same experimental conditions. 
Although NRF2 expression levels were modest in LNCaP cells, we observed a 
significant 1.2-fold and 1.59-fold increase by 1,25D and SFN alone respectively. Pre-
treatment with 1,25D and further SFN exposure did not significantly affect NRF2 
expression. A 1.21-fold increase was observed (relative to SFN treatment alone); an 
effect likely attributed by SFN.  (See Figure 4.13B).   
 
 We evaluated similar effects with the AKR1C1 gene, which we found to be highly 
expressed in LNCaP cells.  Our data show that 1,25D on its own does not alter its 
expression, however SFN significantly increases it by 23-fold.  There was no 
significant difference in AKR1C1 gene expression in EtOH (SFN alone) versus 1,25D 
pre-treated cells and although AKR1C1 expression was still significantly increased for 
the latter (13-fold), it is an effect likely attributed to SFN exposure (See Figure 4.13A).  
We found that UGT1A1 was surprisingly not responsive to 1,25D in LNCaP cells, 
whereas dosage with SFN increased its expression (12-fold) (Figure 4.14B). 
Interestingly, pre-treatment with 1,25D appeared to reduce this effect by 20.7%.   
 
 UGT1A4, the most sensitive isoform to 1,25D was not responsive in LNCaP cells 
(See Figure 4.14C).  The UGT1A gene expression patterns in this cell line suggest that 
the genes may not be highly expressed and hold less clinical relevance in this context 
compared to the colonic tissue.  Finally, Figure 4.14E confirms the regulatory effects 
of 1,25D upon CYP3A4 gene in LNCaP cells following 24-hour exposure (4.6-fold 
increase). The addition of SFN did not alter the regulatory effects of 1,25D.  Similar 
to LS180 cells, SFN does not influence the CYP3A4 gene. Collectively, these results 
show that cross-talk between VDR and NRF2 signalling is gene and cellular specific. 
Additionally, the inhibitory trends observed upon co-administration suggest much 
more complex molecular mechanisms that cannot be explained by gene expression 






 Figure 4.13: ARE signalling in LNCaP cells.  LNCaP cells seeded in 24-well plates 
were transfected with ARE-luc promoter vector following which, cells were subjected 
to 1,25D or SFN ( 6μM) for another 24-hours.  Luciferase activity was measured using 
Dual-glo Luciferase Assay (Promega, UK). Data presented as %RLU relative to 
vehicle control. Data represents 3 independent experiments where n=3. Statistical 


























Figure 4.14: NRF2 target gene regulation in LNCaP cells pre-treated with 1,25D. 
For gene expression analysis, cells, RNA was extracted in LNCaP cells pre-treated 
with 1,25D or EtOH as vehicle control for 24 hours, followed by SFN (6μM) dosage 
for other 24-hours.  Real Time Q-PCR was performed and ΔCT was calculated with 
HPRT as a house-keeping gene. Fold induction represented are relative to each 
vehicle control. Statistical analysis was obtained from Student’s two-tailed t.test 
where is *P<0.05, ****P<0.00001. $ represents 1,25D pre-treatment significance 







Figure 4.15: VDR target gene regulation in LNCaP cells pre-treated with 1,25D. 
For gene expression analysis, cells, RNA was extracted in LNCaP cells pre-treated 
with 1,25D or EtOH as vehicle control for 24 hours, followed by SFN (6μM) dosage 
for another 24-hours.  Real Time Q-PCR was performed and ΔCT was calculated with 
HPRT as a house-keeping gene. Fold induction represented are relative to each 




where is *P<0.05, ****P<0.00001. $ represents 1,25D pre-treatment significance 
relative to EtOH.   
 
4.3.2 VDR and NRF2 ligands inhibit LNCaP and LS180 cell growth 
 
Data from growth inhibition assay of LNCaP cells exposed to 1,25D (10-8M), SFN 
(6μM) or combination of the two ligands for 144-hours is shown in Figure 4.15A. For 
cells exposed to 1,25D, there was a significant 40% growth inhibition relative to 
vehicle control.  In LNCaP cells exposed to SFN growth was inhibited by 80%, 
relative to DMSO.  Co-treatment of LNCaP with 1,25D and SFN for 144-hours 
inhibited growth by 66.8%, although significant collaborative effects were not 
observed.  In LS180 cells, 1,25D significantly inhibited growth by 26%, whereas SFN 
inhibited growth by 50%.  Co-treatment with both ligands inhibited LS180 cell growth 
by a significant 66.7%.  In the previously conducted cell viability assay ( Figure 4.1), 
6μM did not cause growth inhibition as observed in this experiment.  The differences 
is results are likely due to differences in SFN incubation time.  For our cell viability 
experiments, cells were exposed to SFN for 24-hours.  Similar to our LNCaP findings, 
there were no distinct antiproliferative effects between both VDR and NRF2 ligands.  
Our data strongly suggest that VDR and NRF2 signalling pathways work 







Figure 4.16: Growth inhibition assay in LNCaP and LS180 cells. SFN (6μM) and 
1,25D (10-8M) responses to growth in LNCaP (A) and LS180 cells (B) are shown. 
Cells were treated for 6 days followed by measurement of Light Units using Cell-titre 
glo assay (Promega, UK). Data represents 3 independent experiments were n=3. 
Figures are presented as %RLU relative to vehicle control. Statistical analysis was 











4.4 Discussion  
 
NRF2 signalling pathway represents a critical cyto-protective system that neutralizes 
intracellular imbalance between oxidant production and antioxidant mechanisms 
(Ahmed et al., 2017). Prolonged or severe exposure to OS influences cellular health 
and numerous clinical consequences (Berridge, 2015).  Induction of OS-related genes 
through NRF2 activation is the key to cellular redox homeostatic control (Tebay et al., 
2015). A number of UGT1A isoforms, such as UGT1A1, UGT1A7, UGT1A8 and 
UGT1A10 function as detoxification enzymes in response to NRF2 regulation through 
cis-acting AREs within their 5’-flanking promoter regions (Kalthof et al., 2010, Yueh 
and Tukey, 2007). NRF2 knock out mice that posses a deficiency in this protective 
genetic profile acquired severe OS damage (Iizuka et al., 2005).   
 
In this study VDR and NRF2, signalling interplay was characterized through 
evaluating their respective and combined effects on the UGT1A regulation, expression 
of NRF2 target genes and interactions through VDRE and ARE reporter constructs.  
These data show that this cross-talk appears to be gene specific, owing to the presence 
of distinct ARE and VDRE motifs within the promoter region (UGT1A1).  In VDR 
(e.g. CYP24A1, CYP3A4) or NRF2 (NQO1, HMOX1 and GCLC) specific targets, our 
studies of combinatorial effects intimate inhibitory effects suggestive of indirect 
regulatory mechanisms. Our reporter based and growth inhibitory assays suggest that 
VDR does not enhance NRF2 mediated signalling responses, other than UGT1A1.  
  
Both the cell viability assay and titration curve (See Figure 4.1 and 4.2) establish the 
non-cytotoxic concentrations of NRF2 ligand whilst also confirming ARE 
functionality in LS180 cells. Our data show that 10μM SFN was an optimal ARE 
activating, yet non-toxic concentration, however, to fully explore the potential ARE 
responses without reaching ‘plateau’ of activation, NRF2 responses were mainly 
investigated using 6μM.  Although SFN concentrations >5μM is not likely to be 
realistically derived through dietary doses, examination of in vitro NRF2 responses 
was still possible. For instance, the study by Schwab et al (2008) using Caco-2 cells 
revealed a significant 1.6-fold increased expression of β-defensin 2 (also an NRF2 
target) using the same concentration.  TBHQ (40μM) was previously observed to 




this as a non-cytotoxic and NRF2/ARE activating concentration ideal for subsequent 
experiments.   
 
Interestingly 1,25D had modest, although significant effects on ARE activity, although 
the effects plateaued at 10-7M. (See Figure 4.2). Ectopic VDR expression in HEK293 
cells which otherwise express negligible amounts of VDR did not alter ARE activity. 
Our data suggests that ARE activation may involve a multi-factorial process, that is, 
1,25D may initiate non-genomic actions that converge on the NRF2/ARE signalling 
complex. Since indirect NRF2/ARE activation was observed via the c-JUN-N-
terminal kinase (JKN) pathways and 1,25D is known to activate other signalling 
pathways such as MAP kinases and c-JUN-N-terminal kinase (JKN) pathways, this 
could be a plausible explanation for our findings (Morelli et al.,2001 and Keum et al., 
2009).  The involvement of the two signalling pathways (VDR and NRF2) in this 
context could mean enhanced inflammatory responses, cell proliferation, 
differentiation and apoptosis.   
 
The participation of 1,25D in inducing ARE activity led us to analyse the effects of 
1,25D pre-treatment in NRF2 induced LS180 cells.  1,25D through the activation of 
VDR initiates the expression of NRF2, which in turn increases the expression of genes 
involved in redox and detoxification pathways (Nakai et al., 2014 and Berridge, 2016).  
Therefore, we proposed that, priming cells with 1,25D would further enhance NRF2 
and its signalling in our cell model system.  
 
Pre-treatment with 1,25D resulted in a non-significant trend towards enhanced ARE 
reporter activity (See Figure 4.3). These findings suggest that maintenance of optimum 
1,25D levels in colon cells does not in itself improve antioxidant responses. 1,25D 
may increase cytosolic NRF2 expression, but not affect its translocation as Teixeria et 
al., (2017) would suggest.   
 
It was previously shown that NRF2 genes are induced by bile acids (Weerachayaphorn 
et al., 2012).  Here we identified that the secondary bile acid, 3kLCA significantly 
alters ARE activity more potently that 1,25D (See Figure 4.4).  Our findings imply 




to initiate colon carcinogenesis may be counteracted by NRF2/ARE signalling (Tan et 
al., 2007).  Since bile acids activate several cell signalling pathways including FXR, 
PXR and VDR, NRF2 signalling could also converge to regulate a complex colonic 
bile acid metabolism network (Zhao et al., 2014; Wagner et al., 2005 and Makishima 
et al., 2002). 
 
Next, we tested whether (simultaneous) co-treatment of NRF2 and VDR ligands 
augment ARE signalling in LS180 cells (See Figure 4.5). Contrary to Lee et al., (2015) 
who observed a synergistic mediation of the Wnt-pathway, we observed that 
combinatorial treatment significantly diminished ARE reporter activity.  Co-treatment 
may induce an adaptive mechanism to suppress an overwhelming NRF2 response in 
LS180 cells.  Our results were similar to Furue et al., (2018) who verified that dioxin 
and cinnamaldehyde co-treatment (AhR and NRF2 ligands respectively) inhibited 
AhR-CYP1A1 OS neutralization axis, in this case, to control dioxin activity on NRF2 
activation, which is difficult to degrade.  Furthermore our findings indicate that SFN 
or tBHQ treatment alone is more effective than VDR ligands in inducing ARE activity.  
We predict that our inconsistencies with the work of Lee et al., (2015), who utilized 
Caco-2 cells exposed to 1-2.5μM SFN, are a result of our use of supraphysiological 
SFN concentrations. The dietary SFN concentration is approximately 2.5μM 
(Yagishita et al., 2019). However, Chiang et al., (2019) co-treated melanoma cells 
with 5μM SFN and 5-aza-2’-deoxycytidine (DAC) and yielded a combinatorial effect, 
suggestive of a cell specific issue rather than concentration.  The fact that tBHQ 
(40μM) in combination with VDR ligands produced a similar effect to SFN further 
implies that there is cross-talk between VDR and NRF2 at least within a colonic 
context.   Whether this happens through direct ligand interaction or recruitment of co-
repressors is still in question. Our findings do not support the proposed hypothesis that 
VDR enhances NRF2 responses.   
 
The mutagenesis experiments in our study indicate that the presence of both ARE and 
VDRE is essential for a VDR mediated UGT1A1 induction, however VDRE is not 
required for UGT1A1 regulation by activated NRF2 (See Figure 4.6).  However, from 
our data, VDR signalling is surprisingly dependant on an intact ARE.  For future 




electrophoretic mobility shift assay (EMSA) will confirm the nature of VDR 
interdependency.   
 
Given that, VDR and NRF2 ligands individually activate ARE to differing degrees, 
co-treatment reduced this activity, and interdependency between the two signalling 
pathways was observed, we evaluated if these effects could be noted for the expression 
of endogenous metabolic genes in LS180 cells.  Our results reveal a conspicuous trend 
in gene expression, in which combinatorial treatment inhibits the expression of VDR 
specific genes (CYP3A4, CYP24A1, UGT1A4 and VDR itself), but further enhanced 
UGT1A1 where both VDRE and ARE are present, suggesting that there is 
collaborative control of its expression.  Combinatorial also treatment enhanced 
UGT1A protein expression, although given the unavailability of specific UGT1A 
isoform antibodies, we cannot absolutely verify that this is solely due to effects on 
UGT1A1.  Our in vitro model demonstrates inhibition of VDR protein after SFN 
exposure, contradicting Schwab et al., (2008) data who identified increased VDR 
expression leading to enhanced β-defensin 2 expression (See Figure 4.7). Collectively 
our findings on SFN inhibitory effects suggest that SFN may interact with VDR itself, 
limiting its transcriptional activity and expression.   
 
SFN exhibits histone deacetylase inhibitor (HDACI) activity by facilitating the 
formation of histone acetyltransferase/co-activator (HAT/CoA) complexes which 
induce hyper acetylation.   This was evidenced to regulate TF binding, gene 
transactivation, proliferation, differentiation and apoptosis in HCT-116 and PC-3 
prostate cancer cells, the latter which also corresponds to the non-classical properties 
of vitamin D (Myzak et al., 2004; Myzak et al., 2006; Dashwood and Ho, 2007).  The 
unexpected SFN inhibitory properties in our data suggest that our chosen model 
systems may not be the best to investigate collaborative properties with vitamin D, 
and examining the response in vivo may yield the expected evidence.  
 
What could be driving the enhanced UGT1A1 response in the combinatorial 
experiments is the involvement of the multiple AREs within UGT1A1 promoter 
region, previously characterized by Yueh and Tukey (2007).  In expanding upon the 




using a VDRE minimal promoter.  Zhou et al., (2007) previously characterized 
antagonistic effects of SFN on PXR mediated CYP3A4 expression.  We replicated this 
experiment in our LS180 cells in addition to characterization of VDR and NRF2 
mediated effects upon VDRE-mediated signalling (Figure 4.9).  Our results are 
analogous to that of Zhou et al., (2007).  SFN significantly inhibited PXR mediated 
signalling in a concentration dependant manner. Additionally, SFN slightly 
suppressed VDRE signalling in 1,25D treated LS180 cells, although this was not 
significant, contrary to the dramatic effect noted on 3kLCA.  Our findings suggest that 
SFN may compete with rifampicin and 3kLCA for binding to the LBD of PXR and 
VDR, respectively, but is a less effective inhibitor of 1,25D association with VDR. 
Interestingly, Kahlon et al., (2005) identified cruciferous in vitro vegetable binding of 
bile acids. Since SFN, as already mentioned is a sulphur-rich compound derived from 
vegetables, findings on its inhibitory effects on 3kLCA suggest that SFN may possibly 
bind to 3kLCA, preventing re-circulation, which results in reduced re-absorption, 
facilitate in its excretion, as another chemo-preventative measure (Kahlon et al., 
2005).   
 
We also showed that pre-treatment with 1,25D significantly achieved higher levels of 
UGT1A1 promoter activation from subsequent treatment with NRF2 ligand ( Figure 
4.10). This is most likely due to collaborative effects of both binding motifs as opposed 
to effects of 1,25D priming SFN and tBHQ mediated UGT1A1 induction.  Our gene 
expression analysis under pre-treatment experimental conditions suggests that SFN 
has no effect on VDR-specific genes (CYP3A4, CYP24A1 and UGT1A4) ( Figure 
4.11). Interestingly SFN significantly inhibited CYP3A4 and UGT1A4 1,25D mediated 
effects.  CYP24A1 mRNA expression was not altered by dosage with SFN.  On the 
other hand, the expressions of NRF2-specific genes (NQO1, HMOX1 and GCLC) were 
significantly increased by SFN in a dose-related manner. 1,25D pre-treatment did not 
alter mRNA expression levels; contradictory to our proposed hypothesis ( Figure 
4.11). Our data did not reproduce the findings of Chen et al., (2019) who demonstrated 
that 1,25D transcriptionally up-regulated NRF2.  This discrepant result may be a 
consequence of the fact that Chen et al., (2007), and Nakai et al., (2010) used mouse 
models for this analysis.  Species-specific regulation may be an explanation, and 




results of this study suggest that any interaction between VDR and NRF2 is likely 
complex and difficult to assess through mRNA expression.   
 
Aldo-keto reductases (AKRs) are phase 1 metabolic NAD (P) H-dependent 
oxidoreductases that convert aldehydes and ketones to primary and secondary alcohols 
for subsequent phase II metabolic reactions (Penning et al., 2017).  AKRs are 
consistently the most overexpressed in response to NRF2 activation (Penning et al., 
2017). Tian et al., (2016) previously described their presence in breast and prostatic 
context. Our data show that AKR1C1 is highly abundant in LS180 cells (Figure 4.11C). 
1,25D pre-treatment unexpectedly does not enhance AKR1C1 mRNA expression 
levels although previous knowledge shows that AKR1C1, AKR1C2 and AKR1C3 were 
enhanced by 1,25D in breast carcinoma fibroblasts (Campos et al., 2013).  AKR1C1 
was regulated by NRF2 activation in a dose-dependent manner (See Figure 4.11C).  
Our data correspond to that of Agyeman et al., (2012) who conducted transcriptomic 
gene expression by microarray in MCF10A cells treated with SFN or Keap1 siRNA 
who observed a dramatic 15-fold increase and 37.4-fold increase respectively.  Our 
data show a 29.6-, 59.7- and 71.54-fold increase following SFN (3-,6-, and 9μM) 
exposure alone in LS180 cells.  In silico analysis by Tebay et al., (2015) identified 
distal consensus ARE within AKR promoters. On the other hand, no functional VDRE 
have yet been reported within AKR1C1, suggestive that any 1,25D effects may be 
mediated through indirect regulatory mechanisms, which are overwhelmed by direct 
SFN mediated regulation. 1,25D pre-treatment enhanced NRF2 mediated UGT1A1 
mRNA and UGT1A protein expression, certainly through binding motifs collaborative 
effects (See Figure 4.11D).  Our data uncovers that UGT1A1 up-regulation is likely a 
result of multiple binding motifs present for each pathway.  Our correlative findings 
motivate the functional evaluation of response elements to determine if and how they 
work together to regulate gene expression.  
 
Whilst it is common, that NRF2 protects cells from carcinogens by upregulating 
cytoprotective genes,  and a substational body of research supports an inverse 
relationship between VDR activation and malignancy, our study aimed to evaluate 
collaborative effects of BIRC5 expression, an anti-apoptotic  gene known to promote 




that BIRC5 is a Wnt/β-catenin dependent target gene in malignant cell types. This 
conserved regulatory pathway governs numerous normal cell fate processes.   Lee et 
al., (2015) demonstrated that 1,25D and SFN dosage of Caco-2 cells repressed Wnt-
pathway-related genes. We used our pre-treatment conditions in LS180 cells to 
investigate this synergistic effect. Our data showed a decrease in BIRC5 mRNA 
expression both SFN and 1,25D treatment alone, although a dose-related response was 
not observed (Figure 4.12).  Furthermore, pre-treatment had little further impact, with 
the synergistic effects observed by Lee et al., (2005) absent in our study.   
 
The Wnt/β-catenin pathway is down regulated by 1,25D through VDR/β-catenin 
binding, thus reducing β-catenin binding to T-cell factor (TCF) (Larriba et al., 2013). 
1,25D also controls Wnt inhibitor, Dickkopf WNT Signalling Pathway Inhibitor 1 
(DKK-1) and of Transcription Factor 4 (TCF4) gene expression (Larriba et al., 2011, 
Larriba et al., 2013).  The effects of 1,25D upon the CDH1 gene that encodes the E-
cadherin protein, which sequesters β-catenin at the plasma membrane adherens 
junction regulation is already well-characterized in cancer cell lines.  Increasing doses 
of SFN did not affect CDH1 increase suggesting that NRF2 signaling does not affect 
Wnt/β-catenin pathway (Figure 4.12B and C).   
 
Although the anticipated consequence, that VDR activation enhances NRF2 signaling 
in detoxification responses was marginal in most cases, much of the fold changes were 
not statistically significant thus, it was difficult to accept the proposed hypothesis 
based on these findings alone.  VDR alone was more effective in inducing VDR 
specific genes and NRF2 activators were more effective alone in inducing NRF2-
specific genes.  The absence of synergism or additive effects of both signaling 
pathways may be ligand concentration dependent.  Overall, in LS180 cells, our 
findings reveal an indirect interplay, contradictory to the phenotypic stability 
hypothesis (Berridge, 2015).   
 
To eliminate cell specific limitations of our study, we tested our hypothesis in a 
prostatic cellular context were OS is one of the several hallmarks of aggressive 
phenotype due to progression and negative response to therapy (Khandrika et al., 




LNCaP cells, which were confirmed by significantly enhanced reporter activity by 
both SFN (6.5-fold), and 1,25D (2-fold) (See Figure 4.13A).  
 
While 1,25D is able to stimulate NRF2 and g-glutamylcysteine synthetase (gGCSh) 
for GSH synthesis, our data confirm its ability to significantly enhance ARE 
signalling, although, similar to LS180 cells indirect mechanisms may be responsible, 
although not fully elucidated (Yang et al.,2005).   On the other hand, SFN 
downregulated acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FASN) and 
carnitine palmitoyltransferase 1A (CPT1A), which facilitates fatty acid uptake by 
mitochondria for β-oxidation, were also decreased, indication chemoprevention in 
LNCaP and 22Rv1 PCa cells Singh et al., (2018). 
 
Whilst OS is a hallmark of aggressive PCa phenotype, NRF2/ARE is a promising 
strategy for cancer prevention, although other findings link it to the survival of cancer 
cells (Yang et al., 2005). We investigated NRF2 downstream gene expression in 
LNCaP cells pre-treated with 1,25D exposed to 6μM SFN for another 24 hours (See 
Figure 4.14).  In agreement with Nakai et al., (2010), Chen et al., (2019) and 
Berridge’s (2015) hypothesis, NRF2 was responsive to 1,25D alone.  However, 
priming cells with 1,25D did not further enhance SFN mediated NRF2 expression. It 
was expected that GCLC mRNA expression would be altered by 1,25D pre-treatment, 
since Jain and Micinski (2013) previously identified that it was induced in U937 
monocytes. Contrary to Teixeria et al., (2017) who observed a significant HMOX1 and 
NQO1 induction in 1,25D pre-treatment in human umbilical vein endothelial cells 
(HUVECs) (4- and 2-fold respectively), there was no effect in our LNCaP cells, in 
fact, and significant downregulation of NQO1 was observed. Our findings suggest 
that, although the two ligands poses chemo-preventative effects, VDR and NRF2 
signalling acts independently in mediating antioxidant activity. 1,25D pre-treatment 
altered NRF2 expression, implying that 1,25D may initiate the activity of NRF2 in 
inhibition androgen receptor (AR) signalling which is responsible for PCa initiation 
and progression (Zhou et al., 2015; Khurana and Sikka, 2018). UGT1A1 and UGT1A4 
are highly sensitive to 1,25D in LS180 cells but in LNCaP were not responsive 
compared to CYP3A4, owing to the low basal levels for the former.  Our findings 




4.15). As shown in Figure 4.15, both in LNCaP and LS180 cells, 1,25D and SFN both 
significantly enhanced growth inhibition, although the effects of SFN was more 
dramatic.  Combination of both ligands did not produce a synergistic effect although 
inhibition was still significant.  These findings suggest that VDR and NRF2 activation 
may be useful for cancer therapy but 1,25D does not enhance the functional response 
of NRF2 activity as previously proposed.  It is also noteworthy that our experiments 
using LS180 cells were conducted in minimum essential media (MEM) also 
supplemented with 10% foetal bovine serum (FBS), whereas our LNCaP cells were 
treated in a steroid-depleted charcoal stripped FBS (CSS). The functionality of the 
androgen receptor (AR) in LNCaP cells has a broad steroid binding specificity which 
may influence gene transcription.  Therefore, conducting our experiments in a steroid 
depleted environment allowed independent analysis without the influence of steroids 
(Lee et al., 2007).  This may have contributed towards variable experimental outcomes 
between our chosen cell model systems and data reproducibility with the work of 
others.    Furthermore, exogenous VDR and NRF2 protein expression levels were not 
analysed in this study and should be considered in the future to in order to verify the 
relevance VDR and NRF2 cross-talk or the absence thereof.   
 
In summary, this study characterized VDR and NRF2 interplay in mediating 
detoxification pathways, mainly through UGT1A1 regulation and involvement in 
enhancing other anti-oxidant and chemo-preventative pathways.  Mutagenesis of 
functional ARE and VDRE motifs responsible for UGT1A1 induction revealed the 
dependency of VDR to NRF2 signalling, which was unexpected.  The inhibitory trend 
observed in combinatorial and other gene specific responses provides insight into 
possible interactions between ligands or indirect molecular mechanisms that also 
contribute to cellular defence systems.  Although in this case our findings do not fully 
agree with the proposed hypothesis, these findings alone are not enough to elucidate 
this interplay.  Further experiments to streghthen our findings include use of 
mammalian cell lines that express both a high level of NRF2 and VDR such as 
KYSE70 human oesophageal squamous cell carcinoma cell line (Kalthoff et al., 
2010).  NRF2 gene expression levels are neglible in our chosen LS180 cell lines, and 
also NRF2 protein expression levels were not measured, it is difficult to conclude on 




combinatorial treatments and VDR protein expression was suppressed by NRF2 
ligands.  It is worth employing a competitive binding assay which will identify 
whether NRF2 agonists bind to VDR protein to cause this effect.  The affinity of NRF2 
ligands for VDR can be determined by measuring the their ability to compete with 











4.5 Summary of key findings  
 
• Both VDR (1,25D and 3kLCA) and NRF2 (SFN and tBHQ) ligands activate 
ARE driven activity. 
• VDR does not enhance NRF2 mediated signalling other than UGT1A1 
gene and UGT1A protein expression (in both combinatorial or pre-
treatment experiments) 
• Co-treatment with VDR and NRF2 ligands inhibits ARE signalling. 
• VDR signalling is dependent upon an intact ARE.   
• SFN inhibits VDR specific genes (CYP3A4, CYP24A1, UGT1A4 and VDR), 
VDR protein and VDRE/PXRE signalling.  
• NRF2 and VDR signalling independently enhance anti-tumoural activities 
(BIRC5 suppression and CDH1 expression). 
• 1,25D does not enhance redox/detoxification pathway genes mediated 
by NRF2 in LNCap cells.  
• 1,25D and SFN inhibit LNCap and LS180 growth, but there are no 





















5: Chapter 5 
 
















As already established, glucuronidation represents a major pathway through which the 
body detoxifies a range of hydrophobic compounds such as dietary chemicals, drugs, 
environmental toxins, steroids, bilirubin and bile acids (Kutsuno et al., 2014).  
Modifications of such structurally diverse chemicals are mediated through the 
differentially expressed UGT1A isoenzymes (Levesque et al., 2007).   The differences 
in their alternative first exon, in addition to specific tissue expression contributes 
towards their differential glucuronidation capacity (Rouleau et al., 2013 and Levesque 
et al., 2007).  Additionally, the presence of a TATA-box approximately 30bp upstream 
of each first exon sequence further indicates individual transcriptional regulation of 
each UGT1A gene (Kiran et al., 2006). 
 
In light of their clinical significance, UGT1A gene family members have been well 
characterized in a hepatic context (Strassburg et al., 1998). Evidence suggests that the 
5’-flanking region of each UGT1A alternative first exon contains response elements 
capable of regulating their own expression. (Tan et al., 2006).  Earlier work by 
Gregory et al., (2003) also identified differential UGT1A8, UGT1A9 and UGT1A10 
promoter activity. The UGT1A8 and UGT1A10 contained Sp1/initiator-like sites 
involved in gene induction.  This was absent within the UGT1A9 promoter region, 
thus affecting its inducibility.  Promoter activity for Rat UGT1A6 and UGT1A7 has 
been demonstrated to mediate their transcription in liver cells (Gregory et al., 2003).  
Bellemare et al., (2010) further described alternative spliced isoforms (UGT1A_i2s) 
that utilized an alternative exon 5b.  Although devoid of glucuronidation activity, 
detail for their clinical relevance and regulatory mechanisms are still rudimentary.  
Altogether, these findings further suggests complex differential regulation of each 
UGT1A isoform.     
 
On-going research in our laboratory and others have examined the gtPBREM cluster 
within UGT1A1 290bp distal enhancer sequence (-3483/-3194) containing binding 
sites for a number of ligand activated transcription factors (TFs), that we demonstrate 
to include VDR (Sugatani et al., 2005).  From our data, within the UGT1A7-UGT1A10 
cluster, UGT1A7 was the only isoform induced by activated VDR. This finding is 




enhanced by activated VDR in LS180 cells. Additionally, our data show that UGT1A4 
was the most sensitively induced isoform compared to UGT1A3, despite low 
expression in LS180 cells (Figure 3.1).   Surprisingly, UGT1A3 and UGT1A4 share 
95% sequence similarities and for UGT1A7-UGT1A10 cluster, a 90% shared sequence 
similarity was observed (Oda et al., 2017).  What has not been well characterized is 
fine detail for how transcriptional expression of the different members of the UGT1A 
family are modulated through vitamin D/VDR. 
 
VDR mediates its activity through recognition of specific DNA sequences within the 
promoter region of its target genes (Pike et al., 2017). The DNA sequences, known as 
VDRE (See Section 1.4.2) are commonly composed of two hexameric core binding 
nucleotide half-sites 5′-AGGTCA-3′ separated by three nucleotides (DR3-type) (Peng 
et al., 2004 and Carlberg and Campbell, 2013). Upon VDR/RXR heterodimer 
formation, the RXR binds to the 5’ side of the VDRE DBD while the VDR binds to 
the 3’ side of the VDRE DBD (Stees et al., 2012). This binding leads to the recruitment 
of co-regulatory proteins that facilitate gene transcription (See Section 1.4.2) 
(Campbell, 2015). There are other less common VDREs such as the ER6-type motif 
that are characterized by everted repeats of the nucleotide half-sites separated by six 
nucleotides. Nonetheless, characterization of VDR target genes has been possible 
through the identification of functional VDREs (Nurminen et al., 2019; Thompson et 
al., 2002 and Pike et al., 2016).    
 
Efforts by Kim et al., (2006), using DNA micro-array across the entire Rankl gene 
locus identified this gene involves up to five distal VDRE enhancers, one containing 
a specific element capable of direct transactivation.  For LRP5, potent VDRE 
enhancers were located 30kb downstream of an intronic region (Zella et al., (2006).  
As already mentioned, VDR binding to these enhancers increases hitstone acetylation 
and recruitment of RNA polymerase II, thus these enhancers facilitate direct gene 
transcriptional control, through chromatin-looping (Zella et al., 2010).  
 
More specific to our study are findings by Meyer et al., (2012) who conducted a 
genome-wide study using LS180 cells, which identified 1674 VDR/RXR binding 




established target genes such as CYP24A1, TRPV6 and CYP3A4 (Meyer et al., 2012).  
Upon further in silico analysis, Meyer et al., (2012) identified that the predominant 
VDR/RXR binding motif is the DR3-type motif.  Interestingly, these binding sites 
overlapped with those of genes involved in cell proliferation (e.g. c-FOS, c-MYC and 
SOX9), giving sight to the role of vitamin D in cellular health in an intestinal context 
(Prevostel et al., 2016; Ohri et al., 2002).   
 
While Meyer et al., (2012) (Pike laboratory) did not show UGT1A binding sites from 
their genome wide data, upon our request; they kindly examined VDR/RXR binding 
sites within the UGT1A locus.  LS180 ChIP-seq profile obtained from the Pike 
laboratory based on their LS180 data set revealed a number of elements within the 
UGT1A gene locus that bind to VDR/RXR in a 1,25D dependant manner, evidently 
with a potential major cis-regulatory module noted up-stream to UGT1A1.  However, 
their involvement with respect to regulation of the different UGT1A family members 
is not clear, although it all suggests a complex mode of regulation.  Thus, a significant 
remaining challenge in this study is to connect the identified binding sites and 
determine their individual contributions to regulation of the different UGT1A genes. 
 
Additionally, to examine the VDR binding elements in their native cellular context, 
we explored the utility of a Clustered Regularly Interspaced Short Palindromic 
Repeats interference (CRISPRi) based approach.  CRISPRi involves the use of an 
endonucleotic activity-deficient dead-Cas9 (dCas9) that contains two point mutations 
within the RuvC-like (D10A) and HNH nuclease (H840A) domains (Riberio et al., 
2018). DCas9 will not cleave but rather block the targeted DNA sequence after fusing 
with single guide RNA (sgRNA), which consists of crispr RNA (crRNA), a 20 
nucleotide sequence complementary to the target DNA, in this case VDRE, and a tracr 
RNA which binds dCas9 (Riberio et al., 2018) (See Figure 5.1).  This approach does 
not alter the DNA sequence while functionally interrogating the regulatory region in 
situ (Carleton et al., 2017). Theoretically, multiple VDR binding sites become 
simultaneously targeted.   If the targeted DNA represents a regulatory motif important 





Our chosen approach intended to expand upon our knowledge of the regulation of 
UGT1A4, since it was the most sensitively induced by VDR ligands and previous 
studies suggest that this isoform may be involved in the autoregulation of vitamin D 
(Wang et al., 2014).  We were interested in the identification and characterization of 
functional binding motifs within the identified UGT1A CRM that contributed to this 









Figure 5.1: CRISPRi –based approach model. The simplified CRISPRi model 
depicted here describes the fusion of the nuclease defiant form of Cas9 (dCas9) to the 
DNA targeting sgRNA (VDRE ; peak A, B and C). Co-expression of dCas9 and sgRNA 
efficiently disrupts gene transcription by blocking VDR/RXR binding on the VDRE. 
The blockage is determined by sgRNA which is juxtaposed to the VDRE, while the 














5.2 Results  
 
5.2.1 The UGT1A locus is regulated by novel VDR/RXR binding 
 
We used the Regulatory Sequence Analysis Tool (RSAT) bioinformatics tool to scan 
potential VDREs within the target UGT1A fragment and identified 10 putative 
hexameric half-site VDRE sequences, as depicted in Figure 5.2. This further 
confirmed our speculation that multiple VDREs may act as distal enhancers for a 
number of isoforms, particularly UGT1A4 that is the most responsive to vitamin 













Figure 5.2: RSAT output of putative VDREs within UGT1A4 promoter region 
 
As previously stated, LS180 cells are an ideal model for examining transcriptional 
mechanisms pertaining to 1,25D/VDR signalling (Meyer et al., 2012).  In the previous 
chapters, we have described the induction of several UGT1A genes by 1,25D.  As 
shown below, our in-silico analysis reveals that the potential functional VDRE for 
UGT1A1 assessed through reporter assays as detailed in chapter 3 is within ‘peak 1’, 
as depicted below (Figure 5.3). Meyer et al., (2012) also quantified the number of 
DNA binding sites for VDR and its heterodimer partner RXR across the LS180 
genome using ChIP-seq analysis.  The Pike laboratory shared with us data ‘tracks’ 
obtained for the UGT1A locus.  As shown in Figure 5.3a, a total of 5 binding sites 




characterize the relevance of the additional peaks noted within the UGT1A loci, with 
particular attention to the regulation of UGT1A4, through cloning a 1532bp fragment 



























Figure 5.3:  UGT1A loci is regulated by VDR/RXR binding motifs. A represents 
ChiP-seq data kindly provided by Pike’s laboratory. The data shows a number of 
1,25D-dependant VDR/RXR binding elements within the UGT1A locus (labelled 1-5) 
with a potential major cis-regulatory module observed upstream to UGT1A1 gene.  B 
represents an output from the Santa Cruz human genome browser database that 
corresponds to the UGT1A locus.  We aimed to investigate the involvement of peak ‘4’ 





‘4’ which was used for cloning and characterization of this regulation.  2 represents 
the occupancy of histone 3 lysine 27 acetylation (H3k27Ac) marks that signify active 
promoters and distal enhancers. 3 shows enhancers that also overlap the H3k27Ac 
mark. 4 and 5 show evidence of regulatory elements/enhancers from the GeneHancer 
database that specifically interact with UGT1A4.  This data overlaps our target DNA 
sequence, providing evidence for potential binding sites involved in the significant 
UGT1A4 increase in expression by 1,25D 
 
 UGT1A primers were designed using Primer3 Software, to amplify this region and 
(See Table 2.9) devoid of restriction enzyme overhangs.  The LS180 genomic DNA 
was amplified with Taq DNA polymerase, which generated 3’-dA overhangs. The 
amplified PCR product was purified then was subjected to the DNA blunting enzyme 
prior to ligation with the vector.  The blunt ends generated were universally compatible 
with the donor vector (pJET1.2/blunt vector) used in this study (Dallmeier and Neyts, 
2013).  The 5’ ends of the pJET1.2/blunt vector contain phosphoryl groups; therefore, 
phosphorylation of PCR primers was not required. We sought to ligate the PCR 
product to the vector to generate a UGT1A_pJET vector (See Figure 5.4).    
 
We attempted ligation reactions based upon 3:1, 3:3 and 1:1 molar ratios of purified 
DNA fragment and pJET1.2/blunt vector, respectively however, upon verification 
using a control PCR product efficient blunting and/or ligation was not achieved.  The 
transformation of the ligation mixtures using Library Efficiency® DH5α E.coli did 
not produce recombinant clones.  
  
If successful, the presence and orientation of isolated recombinant clones would have 
been analysed through DNA sequencing (See Section 2.9) using pJET1.2/blunt 
specific primers and validated using the NCBI blast tool.  Successful recombinant 
clones would have led to the construction of a luciferase gene-reporter assay vector 
through further sub-cloning as detailed below (See Figure 5.4).  
 
Briefly, our planned scheme was to involve ligation of the DNA insert to the pJET 
blunt vector. Restriction enzyme digestion is performed to excise the DNA insert from 




using PCR to increase the number of copies of the DNA fragment.  Restriction enzyme 
digestion is performed on both the insert and recipient pGL3-Basic vector, creating a 
set of complementary restriction sites for cloning.  Following gel purification of the 
digested pGL3-Basic vector, the insert and the recipient vector are ligated using the 
desired molar ratio.  Confirmation of successful ligation and orientation is performed 
by PCR amplification using specific primers (e.g. UGT1A primers in this case: Table 
2.9). The observation of the expected DNA insert product size after colony screening 
would confirm the presence of the insert and verifies orientation in the recipient 
plasmid (See Figure 5.4). 
 
Since the Pike laboratory’s ChiP-seq data identified VDR/RXR bindings sites driven 
by 1,25D, our successful cloning would have led to characterization of VDR induction 
on the UGT1A DNA fragment in in vitro experiments.  Furthermore, the identification 
and characterization of functional VDREs and verification through mutagenesis may 
support the involvement of multiple binding sites in the expression of UGT1A4, 
mediated by VDR agonists.  Based on the Pike Laboratory ChIP-seq data and evidence 
of UGT1A4 distal interaction (See Figure 5.3), it is reasonable to assume that multiple 
regulatory sites potentially regulate a single gene.  However, to evaluate the 
relationship between these binding sites, use of CRISPRi, in combination with reporter 
gene experiments based on the UGT1A_pGL3-Basic Vector could potentially shed 
light upon the involved mechanisms this complexity that underpin the sensitive 
responsiveness of UGT1A4 to 1,25D.  Co-transfection of cells with our library of 
expression constructs encoding NRs (VDR, PXR, FXR or LXR) will directly examine 
whether this region is exclusively VDR-driven.  Additionally, since our data suggest 
that the 1532bp UGT1A fragment predominantly overlaps UGT1A4 interaction, a 
comparison with responses obtained for the UGT1A1_2K or 290-promoter vector 
(Figure 3.4) may highlight differences in the regulated expression of these genes 
through VDR ligands.  Whether such VDR-mediated expression of UGT1A4 is cell 
specific could be evaluated in other cellular contexts. Apart from the liver, UGT1A4, 
is predominantly expressed in the gastro-intestinal tract (Benoit-Biancomano et al., 
2018). Co-transfection of the UGT1A-pGL3_Basic vector in other intestinal cell line 




UGT1A4 expression is also abundant in the kidneys, the use of kidney derived cell 
lines  could be analysed to better understand this regulation (Jiang et al., 2015).   
 
 
Figure 5.4: UGT1A plasmid construction by sub-cloning (A) shows the 
pJET1.2/blunt cloning vector which acts as a donor plasmid. It comprises of an 
eco47IR lethal restriction enzyme, which is disrupted by ligation of DNA fragment to 
the cloning site. (B) The recipient plasmid, pGL3-Basic vector includes coding region 
for firefly luciferase for measurement of luciferase activity in transfected cells.  The 
Basic vector also includes restriction enzyme sites to clone the promoter of interest.  
Sub-cloning steps include (C) Digestion of DNA into the pJET1.2/blunt cloning vector, 
(D) Isolating the UGT1A insert and vector by gel purification and (E) Ligation of the 





   
Figure 5.5: RT-PCR product of amplified of the 1532bp DNA fragment of the 
UGT1A locus.  
 
Multiple ligation conditions were attempted, however limited to time in the scope of 
this study, we were only successful in amplifying the 1532bp DNA fragment as shown 
in Figure 5.5.  In the future, it is worth considering the addition of a 5’-phosphorylated 
termini. This was absent in the PCR primers designed. It is suggested that the addition 
of 5’phosphate groups promotes successful ligation.  The designed UGT1A PCR 
primers amplified DNA fragments that lack overhangs, and although Q5 high fidelity 
DNA polymerase with proofreading acitivity was used for DNA amplification, this 
may have caused lower ligation efficiencies upon insertion to the pJet1.2/ blunt vector.  
In the future, the incubation of DNA fragment with Taq DNA polymerase and dATP 
(3’dA tailing) for 30 minutes 72°C followed by purification will improve ligation 
efficiency (Thermo Fischer Scientific, 2020).   
 
5.2.2 Characterization of the UGT1A gene using CRISPRi 
 
With the intention to characterize UGT1A4 regulation by VDR-1,25D, we 
incorporated CRISPRi-based technique, which enables the simultaneous deactivation 
of multiple elements that may serve as functional VDRE-based UGT1A4 enhancers 
(See Figure 5.1) (Carleton et al., 2017). SgRNA guides that target the classic 
functional DR3-type motif (GGTTCATAAAGGGTA; sgRNA guide 1) were 





activity in response to VDR ligands (Figure 3.5).  We questioned whether the same 
motif is involved in UGT1A4 regulation.  Additionally, a sgRNA guide 
(AAAGGGTA; guide 2) targeting the 3’ hexameric half-site was used in this study. 
This enabled us to examine the effects of inhibiting only binding of the VDR 
component of the heterodimeric complex and how that would affect overall gene 
transcription. Lastly, a non-targeting sgRNA with a sequence not found in our region 
of interest (1532bp DNA fragment) was included as a negative control.  We designed 
sgRNA guides using the using CRISPR.MIT.EDU software by Zhang lab (2019). 
sgRNA guides scoring <70 ‘on target’ in addition to a ‘low off-target’ score were 
screened, from which suitable guides that were followed by a PAM sequence (NGG) 
targeted by dCas9, were selected.  A high ‘off-target’ score indicates that the sgRNA 
could potentially target sequences outside of our gene of interest (UGT1A1) and 
therefore not suitable for this experiment.  
 
The CRISPRi technique simultaneously targets multiple VDREs of similar sequence 
without altering genomic sequences, allowing critical examination of the extent to 
which the entire VDRE (or its half-site) is involved in UGT1A4 induction.   
For our luciferase-based activity assay, LS180 cells were co-transfected with the RNP 
complex (sgRNA/dCas9) and the UGT1A1-290 promoter vector (U290) (See Figure 
5.7).  The U290 promoter vector (previously mention in Chapter 3) contains the 
targeted DR3-type motif VDRE.  Transfected cells were either exposed to 1,25D (10-
8M) or vehicle (EtOH) for 24 hours prior to obtaining luciferase activity.   
 
The gene reporter activity within LS180 cells that expressed the sgRNA guides 1 and 
2, was significantly altered by 70% and 40% respectively relative to LS180 cells 
transfected with the non-targeting sgRNA (guide 3). The non-targeting sgRNA was 
associated with UGT1A1 promoter activity that was enhanced by 5-fold following 
1,25D treatment. This data shows that UGT1A1 induction achieved through 1,25D 
















Figure 5.6: Lipofection procedure for CRISPRi technique.  A ribonucleoprotein 
(RNP) complex combining sgRNA and dCas9 is formed, and then mixed with 
lipofectamine reagent to form liposomes.  Upon delivery to the LS180 cells, the RNPs 
diffuse through the cytoplasm to the cell’s nucleus, where the sgRNA guide the RNP 
to the complementary DNA sequence to which dCas9 binds.   
 
To assess the effects of this approach upon the expression of the corresponding VDR 
responsive endogenous genes, LS180 cells were transfected with the RNP CRISPRi 
complex, then exposed to 1,25D (10-8M) or EtOH and subsequently analysed through 
RNA extraction and real-time Q-PCR.  We chose to examine UGT1A1 gene 
expression, as the targeted VDRE is directly involved in its regulation (See Chapter 
3). More importantly, we sought to investigate whether the CRISPRi interrogated 
VDRE identified within the UGT1A1 promoter region is responsible for distal 
regulation of UGT1A4.   Lastly, CYP3A4 gene expression was also examined as a 







Figure 5.7: Deactivation of the VDRE using CRISPRi.  LS180 cells were transfected 
with dCas9/sgRNA complex, then subsequently treated with 1,25D (10-8M) or vehicle 
control for 24 hours. UGT1A1 promoter luciferase activity was obtained using Dual-
Glo Luciferase Assay (Promega, UK). Data represents 1 independent experiments 
were n=3. %RLU are relative to vehicle control. Statistical analysis was obtained from 
Student’s two-tailed t.test where is *P<0.05, **P<0.005, ***P<0.0005, 
****P<0.0001. 
 
The response of CYP3A4 to 1,25D treatment was not significantly impacted, 
irrespective of the targeting or non-targeting sgRNA applied (160- and 180-fold 
increase respectively) (See Figure 5.8).  UGT1A1 was also significantly responsive to 
1,25D, both in CRISPRi deactivated VDRE and the non-targeting guide by 3-fold and 
4 fold respectively.. Similarly, UGT1A4 whose regulation is suspected to involve 
multiple VDREs, a 19% reduction in expression in CRISPRi interrogated VDRE was 
















Figure 5.8: CRISPRi and gene expression analysis in LS180 cells.  For gene 
expression analysis, cells, RNA was extracted in LS180 cells transfected with 
dCas9/sgRNA complex and subsequently treated with treated with 1,25D (10-8M) or 




HPRT as a house-keeping gene. Fold induction represented are relative to each 
vehicle control. Statistical analysis was obtained from Student’s two-tailed t.test were 

































Among the examined nuclear receptors (NRs), we find VDR to be the most potent 
modulator of UGT1A expression.  Although the regulatory mechanisms are not well 
established, Chip-Seq data obtained from the Pike laboratory indicate multiple 
VDR/RXR binding sites, the relevance of which remain to be fully characterized.  In 
this study, we aimed to examine these binding sites as isolated enhancer fragments 
through; a) cloning of the UGT1A locus and b) its manipulation in its native context 
using the CRISPRi-based approach. This data aimed to reveal the complexity in 
control of UGT1A expression by extrahepatic VDR. In an attempt to analyse the 
regulatory elements through which VDR modulates UGT1A4 expression, we 
amplified a 1532bp DNA fragment that contains one of the regulatory enhancers (peak 
4) for VDR and its heterodimer partner RXR (See Figure 5.4). 
 
Of the 1532bp fragment of the UGT1A regulatory sequence, in silico analysis revealed 
putative VDREs, which we thought may be contributory to UGT1A regulation (Figure 
5.2).   Additionally UGT1A4 enhancer elements also correlated well within this region 
(See Figure 5.3B).  The targeted region was successfully amplified (Figure 5.5); 
however, our attempts to ligate and clone the amplified PCR product to the 
pJET1.2/blunt were unsuccessful; therefore it was not possible to proceed with this 
type of analysis. The cloned UGT1A locus would have served as a template for 
manipulating the enhancer modules within cell based reporter assay analysis. 
Application of mutagenesis on putative VDREs, thereby measuring transactivity 
would have expanded our knowledge of collaborative actions of binding sites in 
UGT1A regulation.  Our question for the robust UGT1A4 induction remain 
unanswered, although, our findings and the GeneHancer database does speculate that 
multiple binding sites are involved.  Important detail from these findings demonstrates 
a unique and complex mechanism that involves an element located within the UGT1A1 
promoter could possibly modulate the expression of a distant gene (UGT1A4).   
 
These correlative findings motivated the functional evaluation for how potential 
VDRE motifs in their native context, may function in combination to determine overall 
UGT1A gene regulation.  CRISPRi enables simultaneous interruption of distal 




already identified functional DR3-type VDRE across the UGT1A locus (Figure 5.2).  
We found that CRISPRi reporter based activity was significantly specific in targeting, 
when assessed through plasmid-based reporter analysis, but had little effect on the 
endogenous gene when assessed through Q-PCR.  Our data suggests that transfection 
efficiency was relatively low to achieve any effects on an endogenous gene. In 
reporter-based assays, the read-out was specifically from successfully transfected cells 
that presumably contain reporter and the RNP complexes, whereas endogenous gene 
expression levels were obtained from all viable cells regardless of transfection.  Our 
data may also point to the fact that other VDREs are involved and contribute towards 
gene expression.  With multiple elements within the UGT1A locus as evidenced from 
Pike’s laboratory, this explanation may be plausible.  Fusion of the RNP complex with 
Krüppel-associated box (KRAB) domain could in the future successfully repressed 
gene expression more efficiently that dCas9 alone.  KRAB facilitates in the 
recruitment of co-repressor complexes as if often implemented in CRISPRi technques 
for gene repression (Ying et al., 2015).   
 
The less dramatic differences between non-targeting versus targeting sgRNA in gene 
expression make it difficult to draw a conclusion.  Although CRISPRi is very 
informative, in that, there are no DNA alterations, allowing for examination in native 
context, this approach requires extensive optimization in LS180 cells.  The cost and 
time constraint, considering the scope of the study limited us from pursuing this 
approach further.  This system does show potential for characterizing 1,25D regulated 
UGT1A expression.  However, there are other regulatory factors involved in this gene 
expression beyond VDR/RXR binding.  CRISPRi can be used to effectively screen 
putative VDREs and interrogate their functions in UGT1A induction without 
abrogating gene functions.   
 
What is worth reinforcing from our limited data is that UGT1A luciferase activity was 
not abolished by CRISPRi, although the reduction was significant.  Our findings 
reinforce that other elements that do not conform to classical VDRE arrangements 
may also be involved in this regulation.  Interrogating multiple other putative  VDREs  
within the UGT1A locus in combination, will enable full dissection of functional 




putative VDREs within the UGT1A locus followed by measurement of UGT1A 
luciferase activity or endogenous gene expression will characterize these binding sites 
as functional VDREs, if indeed there is diminished promoter activity/gene expression.  
 
The simultaneous deactivation of multiple VDREs within the entire UGT1A locus and 
evaluating the gene expression will define which binding motifs contribute towards 
the direct increase in UGT1A gene expression.  Furthermore, a question as to whether 
multiple VDREs are involved in UGT1A gene regulation and also whether multiple 
binding sites contribute towards synergistic or additive effects will be answered by 
designing and co-transfecting multiple sgRNAs at a time, followed by q-PCR analysis 
of the UGT1A gene family members.  This, together with implementing co-repressors 
KRAB and SID in the CRISPRi approach will further strenghthen the findings of this 
study.  While the physical mechanisms underlying the observed genetic interactions 
between VDREs remain unclear, our data suggest functional VDREs are directly 
involved in UGT1A regulation and this pathway may be utilized implemented in 
clinical cases were UGT1A is compromised. 
 
Finally, as already mentioned, to successfully clone the targeted 1532bp DNA 
fragment, which overlaps one of the 1,25D dependent binding sites identified by 
Pike’s laboratory, the addition of 5’phosphate groups to the designed PCR primers 
should promote successful ligation.  Additionally, adjusting PCR conditions such as 
incubation of DNA fragments with Taq DNA polymerase and 3’dA tailing will 




























5.4 Summary of key findings  
 
• Multiple 1,25D dependent VDR/RXR binding sites identified within the 
UGT1A locus. 
• UGT1A locus is rich in transcriptional activity and distal enhancers  
• UGT1A4 distal enhancers and interaction sites are potentially 
responsible for robust  response to VDR activity  
• CRISPRi deactivated VDRE significantly diminished UGT1A1 promoter 

















6: Chapter 6 
 



















The established and classical endocrine effects of 1,25D govern bone mineral health 
(Ryan et al., 2013).  However, over the past twenty years, a host of population and 
laboratory-based data have highlighted relatively uncharacterized but potential 
important activities with respect to xenobiotic detoxification, neutralization of 
oxidative stress (OS) immuno-regulatory and cardiovascular control.  (Wang et al., 
2012; Berridge, 2016; Grishkan et al., 2013; Wang et al., 2020).  Additionally, the 
Cancer Genome Atlas (TCGA) datasets also insinuate the impact of vitamin D 
receptor (VDR) in cancer prevention (Narvaez et al., 2014).  The modulation of many 
of the genes regulated by 1,25D/VDR have been assessed, however, the potential 
molecular pathways modulated in this manner have been attempted but not fully 
understood (Carlberg et al., 2017).   
 
Previously, our laboratory and others have identified VDR activation to enhance the 
expression of a number of phase I metabolic enzymes, principally members of the 
CYP3A family (Thompson et al., 2002, Maguire et al., 2012 and Doherty et al., 2014).  
Maguire et al., (2012) found that VDR can direct these phase I metabolic enzymes in 
a prostatic context, to limit the bioavailability of growth promoting androgens within 
the tumour environment. This further confirmed the direct involvement of DR3 and 
ER6 motifs found 10kb upstream of the CYP3A4 promoter region (Thompson et al., 
2002). Additionally, Matsubara et al., (2008) identified an enhanced expression of rat 
intestinal Cyp3a1 and Cyp3a2 mRNA following VDR activation.  Roizin et al., (2018) 
later observed an increase in Cyp3a11 intestinal mRNA expression in mice by both 
VDR and PXR ligands. Phase I metabolites require further metabolism to allow easy 
excretion from the body. Hence, the phase II metabolic enzymes facilitate in 
conjugation reactions catalysed by a large group of transferases including Uridine 5’-
diphosphoglucuronosyltransferase 1A (UGT1A), UGT2 sulfotransferases (SULTs) 
and glutathione-S-transferases (GST) (Hirschmann et al., 2014; Wang et al., 2014; 
Agusa et al., 2010). Upon conjugation of the polar functional groups of the susceptible 
substances, hydrophilic metabolites are produced that can undergo bilary or urinary 







This study critically examines the capacity of activated VDR to regulate expression of 
the UGT1A family of genes, in LS180 cells.  UGT1A1, UGT1A3, UGT1A4, UGT1A5 
and UGT1A7 were significantly affected by VDR ligands (1,25D, 3kLCA and more 
potently by EB1089), UGT1A4 exhibiting the highest fold increased expression in 
response to VDR activation. Since UGT1A4 is responsible for the homeostatic control 
of endogenous androstanediol, progesterone as well as exogenous drugs including 
Lamotrigine (anti-epileptic drug),  functionally, our findings highlight a key role for 
VDR in maintaining homeostatic control of these hormones and facilitating in drug 
metabolism (Finel et al., 2015 and Franklin et al., 2007).  
 
 Considering our study was predominantly in LS180 colon cells and UGT1A4 is 
abundant in the gastro-intestinal tract, it is reasonable to assume our may have some 
relevance in a physiological context.   However, functional experiments to determine 
whether VDR, through its ability to modulate UGT1A expression, does result in 
glucuronidation will need investigated further. Human ex-vivo experiments on normal 
GI biopsies will determine the clinical relevance of our findings. So far we know that 
Wang et al., (2016) showed that 1,25D (10-8M) facilitated the UGT1A8 and UGT1A10 
mediated glucuronidation of myophenolic acid (MPA) in human colorectal mucosa 
tissue samples.   
   
Although the expressions of UGT1A8 and UGT1A10 were not modulated by VDR 
ligands in our study, Wang et al., (2016) previously reported 13 putative VDREs 
within the UGT1A8-UGT1A10 cluster promoter region in addition to increased mRNA 
expression in LS180, CaCo-2 and HCT-116 cell lines. There were no identified 
differences in technical approaches, since in both cases real-time q-PCR was 
performed in LS180 cells exposed to 1,25D (10-8M) for 24 hours.  However, the 
experimental set-up including seeding cell density was not specified and could have 
contributed to the differences in our findings (Wang et al., 2016). 
 
 Our data show that UGT1A7 is also responsive to VDR ligands however, in contrast 
the work of Kutuzova and Deluca (2006), who employed microarray technology to 
investigate detoxification genes mediated by 1,25D, identified that UGT1A7 was 




UGT1A3 and UGT1A4 enzymes were the primary isoforms responsible for 
modification of 25-OHD3, resulting in 25-OHD3-25-glucronide, 25OHD3-3-
glucuronide, and 5,6-trans-25OHD3-25-glucuronide metabolites detected in the bile.  
Together with our gene expression data, these finding suggest that UGT1A3 and 
UGT1A4 may contribute towards an important 25OHD3 clearance pathway.  25OHD3-
3-glucuronide has high affinity binding towards vitamin D binding protein (VDBP) 
which extends 25OHD3 half-life and promotes hepatic re-uptake (Wang et al., 2013).  
25OHD3-3-glucuronide in the bile could induce the paracrine signaling loop which 
up-regulates classical VDR target genes and perhaps intestinal metabolic genes 
including, CYPs and other UGT1As (Wang et al., 2014).  
 
ChIP-Seq data from various cell lines performed in the presence and absence of 1,25D 
have revealed much on the VDR cistrome (Meyer et al., 2012 and Singh et al., 2017). 
Interrogation of the LS180 ChIP-seq data set obtained from the Pike study revealed to 
us multiple VDR/RXR binding sites within the UGT1A locus.  These findings 
prompted our characterization of UGT1A4 regulation further as it was the most 
sensitive to regulation by VDR ligands. We adapted the Clustered Regularly 
Interspaced Short Palindromic Repeats Interference (CRISPRi) approach, which 
enabled simultaneous interruption of the functional DR3-type VDRE 
(GGTTCATAAAGGGTA) and the 5’ hexameric half-site (GGTTCATAA) without 
modifying the gene.  CRISPRi in-cooperates fusion of (1) the catalytically inactive 
deadCas9 (dCas9) which blocks binding of the targeted sequence and (2) short guide 
RNA (sgRNA) that directs dCas9 by binding to the complementary target sequence 
(Larson et al., 2013).   We found that CRISPRi significantly diminished the ligand 
responsiveness of the UGT1A promoter based luciferase reporter however; when 
applied in context of endogenous gene the mRNA expression levels were unaffected.  
These findings suggest that other non-targeted VDREs are involved in UGT1A 
regulation and that dCas9 on its own may be insufficient in repressing transcriptional 
activity.  In support of the former, according to in silico analysis by Wang et al., (2016) 
there are 83 other DR3-type VDREs within the entire UGT1A locus. Their ChIP-seq 
findings further predicted non-DR3-type VDREs, suggesting that ER6-type (everted 
repeat of 2 hexameric half-sites with a spacer of 6 nucleotides) maybe involved in 





In the future, fusing sgRNA/dCas9 with repressive domains such as SID, which 
promotes H3K27ac and enhancer deactivation together with Krüppel associated box 
(KRAB) repressor, which forms heterochromatin, could successfully repress UGT1A 
transcription as employed by Carleton et al., (2017) who successfully to targeted 
multiple estrogen receptor alpha binding motifs in Ishikawa cells.  As shown in Figure 
5.3 our target 1532bp DNA fragment within the UGT1A locus overlaps one of the 
VDR/RXR binding motifs highlighted in tracks based on VDR/Chip-seq data. 
Additionally, H3K27ac marks are present in this region and signify active enhancer 
activity (Pradeepa et al., 2016).  The targeted sequence also harbours UGT1A4 distal 
enhancers and is rich in transcription factor (TF) binding sites (See Figure 5.3). Upon 
scanning the region for potential VDREs, 10 potential VDREs were identified 
(AGGTCA). If functional, the VDREs will also explain the dramatic UGT1A4 mRNA 
expression (See Figure 5.4). It is possible that results from our CRISPRi approach can 
be explained by these binding motifs clustered within the 1532bp UGT1A fragment, 
which can act as supportive sites, and as such compensate for the CRISPRi 
interrogated direct site. Nonetheless, the putative VDREs will need to be characterized 
to better understand this mechanism.  What is crucial at this stage is that our findings 
suggest a unique and complex UGT1A4 regulatory mechanism by VDR ligands that 
may involve distal VDREs located within the UGT1A1 promoter region. The 
involvement of these elements together with those within the UGT1A4 promoter 
region itself could explain the significantly enhanced UGT1A4 gene expression.   
 
We also evaluated yet another role of VDR in UGT1A regulation; that is, its ability to 
work in conjunction with the oxidative stress (OS) sensor, nuclear factor erythroid 2-
related factor 2 (NRF2) (Vomund et al., 2017).  NRF2 is a TF that has gained its 
recognition in neutralization of OS, but also in detoxification pathways (Vomund et 
al., 2017; Zhang et al., 2009). Numerous studies have associated NRF2 with VDR. 
Particularly, Chen et al., (2019) who identified that 1,25D activates NRF2 signalling, 
increasing the expression of p16, p53 and p21 which all regulate the cell cycle and 
function as tumour suppressors.   Additionally, Nakai et al., (2014) identified that 
1,25D activates the NRF2/ARE signaling pathway, which in turn combats 




level of UGT1A in cells. Kalthof et al., (2010) further confirmed that expression of 
UGT1A8 and UGT1A10 can be enhanced by NRF2 and more significantly in 
conjunction with AhR, in KYSE70 colonic cells.   These findings support the 
previously stated ‘phenotypic stability hypothesis that states that 1,25D activates 
induces Klotho and NRF2 which are both important for an extensive cellular health, 
functioning as an anti-aging, OS neutralization and mineral health regulator (Berridge, 
2015).   
 
We here hypothesized that both VDR and NRF2 significantly enhance UGT1A gene 
expression in LS180 cells. We confirmed that, 1,25D enhances (anti-oxidant response 
element) ARE signaling in both LS180 and LNCaP cell. Exogenous VDR only slightly 
increases this signaling in both LS180 and HEK293 cells.  Sulforaphane (SFN) and 
tert-butlyhydroquione (tBHQ) are effectors of ARE/NRF2 signaling.  Additionally, 
3kLCA also significantly increased NRF2/ARE signaling, although minor compared 
to SFN and tBHQ responses.  In a colonic context, NRF2/ARE signaling affects 
secondary bile acid reabsorption through regulation of the apical sodium-dependent 
bile acid transporter (ASBT) (Weerahayapom et al., 2012).  3kLCA, by enhancing 
ARE activity may be able to facilitate a feedback system that ensures its own 
metabolism and excretion through increased expression of NRF2 expressing 
detoxification-related genes (Kamisako et al., 2014).  What is not certain from our 
data is whether 3kLCA modulation of ARE activity is a direct or indirect effect. 
Additionally, whether VDR is directly implicated in 3kLCA effects in this manner 
will also need to be investigated further.   
 
Surprisingly our site-directed mutagenesis experiment suggest that rather than a 
dependency of NRF2-directed signaling on an intact VDR pathway, we find that 
modulation of UGT1A expression by VDR ligands is dependent upon an intact ARE, 
also present within the promoter fragment that contains the VDRE. In our colonic 
context, this suggests that the antioxidant system is the primary defense mechanism 
against toxic endogenous and exogenous compounds, together with reactive oxygen 
species that may disrupt cellular integrity.  Although we analyzed the expression of 
numerous VDR and NRF2 target genes, inhibitory effects of SFN were consistently 




and VDR.  In the case of UGT1A however, its protein expression became notably 
increased following such co-treatments. The mechanisms that underpin the inhibitory 
properties of SFN upon VDR signaling were not investigated, however our speculation 
is that SFN competes with the VDR binding site, or is involved indirectly through 
competition for binding to co-regulatory proteins recruited to the VDR/RXR 
heterodimer, thus suppressing overall gene expression.  Use of the mammalian-two 
hybrid assay or assessment of the impact of the exogenous expression of candidate 
shared accessory protein factors could be used to help explain these inhibitory events.   
 
The NRF2 target genes, HMOX1, NQO1 and GCLC were not affected by 1,25D 
exposure in our LS180 and LNCaP cells although Jain and Micinski, (2013) had 
previously shown that GCLC and GR expression are increased by 1,25D in U937 
monocytes. The differences may suggest that 1,25D modulates these NRF2 target 
genes in a cell-specific manner.   What we did confirm in both LS180 cells and LNCaP 
cells were the potential anti-apoptotic properties of both VDR and NRF2 signaling 
pathways through the suppression of BIRC5 gene expression.  Our data also point to 
the fact that 1,25D and SFN elicit growth inhibitory properties in both a colonic and 
prostatic cellular context; however, the effects will require further examination at 
functional level to observe whether these ligands increase apoptosis.  Additionally, 
further use of animal models will confirm these compounds as potential use as a 
chemotherapeutic measure, that is, to inhibit tumor growth.  Whilst our data on the 
interplay of NRF2 and VDR is somewhat encouraging, the approaches are not enough 
to support the proposed hypothesis.   
 
6.2 Clinical relevance  
  
This study establishes 1,25D/VDR signaling as critical in maintaining overall cellular 
health.  The human body is constantly exposed to various exogenous substances in 
addition to endogenous components such as bilirubin, bile acids and hormones, which 
need to be excreted (Haas et al., 2006; Wang et al., 2016; Amandito et al., 2019).  In 
this thesis, we seek to translate our findings into a clinical context, whereby, 
maintenance of optimal 1,25D levels will further maintain a healthy equilibrium of 





UGT1A1 expression is delayed in new-borns, hence over 80% present with abnormally 
high levels of serum bilirubin, causing a benign condition clinically known as neonatal 
jaundice, characterized by yellowing of the skin, whites of eyes, inside the mouth, 
soles of feet and palm of hands (Fujiwara et al., 2015). This manifests because of the 
delayed UGT1A1 expression, (UGT1A1 is the only isoform involved in the 
homeostatic control of bilirubin (See Figure 6.1)) (de Souza et al., 2017).  Neonatal 
jaundice is usually managed by invasive intense phototherapy or exchange transfusion 
(Mitra and Rennie, 2017).  Severe cases, usually observed in neonates lead to a fatal 
condition known as kernicterus, characterized by brain damage (Fujiwara et al., 2015). 
Breast-feeding also contributes to neonatal jaundice by suppressing UGT1A1 
expression (Fujiwara et al., 2012). Previous studies by Kumral et al., (2009) Apaydin 
et al., (2012) and Wilson et al., (1992) suggested that the presence of steroids, fats, 
cytokines and β-glucuronidase in breast milk correlates with an increased bilirubin re-
uptake through enterohepatic circulation, decreased bilirubin excretion from the body 
and the inhibitory effects on UGT1A1 enzymatic activity.  These effects are 
disadvantageous as breast-feeding comes with developmental benefits, maternal-
infant bonding and a rich nutritional gain.  Our findings suggest that vitamin D or its 
synthetic analogue (EB1089) could be used to revive UGT1A1 expression, leading to 
efficient bilirubin metabolism, therefore preventing kernicterus development or 
neonatal jaundice altogether. Additionally the VDR may counter-act the UGT1A1 
inhibitory effects from breast milk.  
  
UGT1A1 genetic polymorphisms have been linked with impaired enzymatic activity 
and are associated with hereditary hyperbilirubinemia (serum bilirubin levels above 
5ml/dL) (Sanchez-Dominguez et al., (2017).  More specifically, Gilbert’s Syndrome 
(GS), caused by a UGT1A1*28 promoter polymorphism and Crigler Najjar Syndrome 
(CNS: type I and type II). (Wagner et al., 2018). CNS I and CNS II are commonly 
linked with UGT1A1*34 and UGT1A1*35 genetic polymorphisms (Ciotti et al., 1999).   
GS presents as a benign form, with symptoms (jaundice) manifesting well in to 
adolescence usually triggered by stress or fasting (Fujiwara et al., 2015).  By 
comparison, individuals with mutations that cause CNS II also present with mild 




CNS I lead to complete loss of UGT1A1 acitivity (Maruo et al., 2015). This results in 
serum levels ranging between 30 to 50mg/dL, which often lead to the fatal 
encephalopathy (Maruo et al., 2015).  If our findings translate to a functional context, 
vitamin D/VDR could be used to manage hereditary hyperbilirubinemia and prevent 
fatal encephalopathy in individuals with CNS I. 
 
So far, efforts to revive UGT1A expression were attempted by Aoshima et al., (2014) 
who observed that glucose administration enhanced extrahepatic UGT1A expression. 
This also correlated with a decrease in unconjugated bilirubin.  Studies by Fujiwara et 
al., (2012) and Sumida et al., (2013) identified that extrahepatic (small intestinal and 
skin) UGT1A1 expression are involved in bilirubin metabolism.  More importantly, 
these findings are a reinforcement to our study, implying that extrahepatic UGT1A, 
can be involved in bilirubin metabolism. Furthermore, VDR agonists could be an 
alternative treatment measure for neonatal jaundice and hyperbilirubinemia-related 
conditions.  
 
UGT1A polymorphisms are also typically correlated with reduced capacity of 
glucuronidation (Mehboob et al., 2017). As such, UGT1A gene polymorphism usually 
present a potential marker for cancer susceptibility (Strassburg et al., 1998 and Garcia 
et al., 2018).  For example, colorectal cancer, which develops due to altered exposure 
to dietary or harmful exogenous factors (Wang et al., 2013 and Angstadt et al., 2014).  
Reduced UGT1A6 activity is linked to lung cancer and its polymorphism is a 
biomarker for high risk in its development (Kua et al., 2012).  Moreover, low levels 
of UGT1A7 and UGT1A10 expression are linked to the development oesophageal and 
oestrogen related cancers respectively (Vogel et al., 2002 and Staland-Davenport et 
al., 2007). Our findings link vitamin D to chemotherapy and chemoprevention through 
UGT1A enhanced expression.   
 
The role of drug-metabolism is well documented with over 50% of clinically 
administered drugs being metabolised by UGT1A genes (Sanchez-Dominguez et al., 
2018).  Numerous studies have linked UGT1A expression with the metabolism of 
chemotherapeutic compounds in cancer model systems (Chen et al., 2013 and Takano 




leads to an active metabolite 7-ethyl-10-hydroxycamptothecin, (SN-38), finally 
leading to an inactive glucuronide, SN-38-G (Tanaka et al., 2013). GS patients are 
usually susceptible to irinotecan-induced toxicity and present with diarrhoea, 
diaphoresis and abdominal pain (Takano et al., 2017).  Defective clearance results in 
cancer development (Takano et al, 2017).   Normal clearance of drugs susceptible to 
glucuronidation facilitated by normal UGT1A expression will prevent drug-toxicity 
(Wang et al., 2016; Konaka et al., 2019) (See Table 1.3).  Our UGT1A expression 
profile implies that co-administration of vitamin D with these drugs should be 
carefully considered to avoid drug-drug interactions.  Whilst this study encourages the 
use of vitamin D, it is noteworthy that its synthetic analogue EB1089 enhanced 
UGT1A expression more potently and may be a better therapeutic measure in 
conditions where UGT1A expression is compromised.  Compared to vitamin D, 
EB1089 has low calcaemic activity and as such, hypercalcemia, which causes kidney 
failure, abnormal heart rhythms and coma can be avoided (Abdaimi et al., 1999 and 
Ghous et al., 2008).  The synthetic analogue has already shown promising therapeutic 
effects in mice models with c-MET-β-catenin driven hepatocellular cancer (Matsuda 
et al., 2019).   
 
SFN is equally an inducer of UGT1A1 as 1,25D, however did not significantly affect 
other UGT1A isoforms (Wang et al., 2005).  From this study, we can deduce that SFN 
is a significantly potent chemo protective agent, through its growth inhibition 
properties observed both in LNCaP and LS180 cell lines.  The co-treatment of both 
SFN and 1,25D does not increase this effect as anticipated. However, the inhibitory 
effects between SFN and 3kLCA do imply that the ARE/NRF2 signalling is involved 
in BA homeostatic control or may act indirectly to bind 3kLCA, supressing its 
carcinogenic properties. Further studies into the interplay between NRF2 and VDR 
will need to be addressed, perhaps more in-depth in various extrahepatic cell lines. 
What was possibly a challenge in this thesis to be able to translate these findings 







Figure 6.1: Bilirubin metabolism by UGT1A1. (A)The breakdown on red blood cells 
produces biliverdin, which is further metabolized by biliverdin reductase, producing 
bilirubin.  Bilirubin binds to albumin protein as is transported throughout the body. 
In the liver, it is metabolized by UGT1A1, forming mono-/di-bilirubin glucuronides 
that are secreted via the biliary tract.  The glucuronides are susceptible to 
hydroxylation by β-glucuronidates in the intestinal tract which facilitates its 
enterohepatic circulation. (B) UGT1A1 is the sole enzyme capable to metabolizing 
bilirubin, therefore, inactive or suppressed enzymatic activity results in devastative 
consequences including hyperbilirubinemia, GS and CNS.  (Image edited from Chen 
and Tukey, 2018) 
 
6.3 Limitations of this study 
 
This study had a number of limitations, particularly due to the time constraints and the 
availability of resources.  Experimentally, the thesis would have been more 
informative with successful assay approaches to detect glucuronidation, possibly the 
use of LC-MS/MS where the glucuronidation of specific compounds (e.g. bilirubin) 
could be measured in our chosen cell line.  Furthermore, the implementation of ex-
vivo samples, i.e. patient colonic biopsies to measure impact of vitamin D exposures 
on UGT1A expressions, would have extended the relevance of our cell based in-vitro 




normal colonic biopsies will clinically determine the relevance of UGT1A gene 
expression by VDR ligands.  In addition, the use of  previously generated transgenic 
UGT1A (hUGT1A) mice models that express the entire UGT1A locus  and Ugt1-null 
background would have provided the first appropriate animal model to study the 
mechanisms associated with 1,25D/VDR signalling (Chen and Tukey, 2018). There 
are a number of conclusions to draw from using hUGT1A mice models.  Firstly, 
whether at functional level the UGT1A induction is enhanced by VDR signalling, and 
secondly, the clinical consequences can be critically examined, such as the 
involvement of intestinal UGT1A expression in bilirubin metabolism, tumour 
inhibitory properties and redox signalling were NRF2 and VDR ligands are co-
administered.  Furthermore, comparative analysis of other UGT1A regulating TFs can 
be fully evaluated.  Altogether, data from transgenic mice will have favourable human 
relevance.   
 
Another major challenge in this study was the difficulty in cloning the promoter region 
that we postulated to mediate regulation of UGT1A4 due to many 
technical/optimisation challenges within the ligation stage.  The findings in this 
experiment would have been crucial in identifying additional functional cistromes and 
their effects on each UGT1A isoform expression.  The CRISPRi approach was an 
excellent choice; however, the limited resources and the expense of this approach 
meant we were limited in optimization in our LS180 cells.  Examining successful 
transfection is a challenge but is critical for this kind of approach, or fusing the 
ribonucleic protein (RNP) with repressor domains (SID and KRAB) that completely 
block co-regulatory complex formation. Lastly, our experiments were predominantly 
in LS180 cells, although in other experiments were included HEK293, CaCo-2 and 
LNCaP cell line models.  It is unclear how each cell line may relate to the actual 
physiological relevance of an UGT1A gene regulation by VDR and the interplay with 
NRF2.  
 
6.4 Future experiments  
 
This thesis added valued knowledge into understanding one of the many roles of VDR, 




mentioned, numerous studies have investigated individual isoforms, we here 
considered all the gene family members. However, with a few limitations and a 
number of gaps to fill, the experiments proposed below will further strengthen our 
findings.  These include exposing VDR (and NRF2) ligands to cells together with 
UGT1A susceptible compounds.  Measurement of glucuronidation activity through 
quantification of metabolite formation by LC-MS/MS will confirm that VDR does 
enhance UGT1A gene and protein expression level, but also functional activity will 
determine the physiological relevance of this regulation.  The quantification of 
metabolites upon co-treatment of VDR and NRF2 ligands will also be useful in 
determining cross-talk between the two signalling pathways at functional level.   
 
Another important approach to strengthen this study is the use of humanized UGT1A 
mice models with Ugt1-null background.  Previously, Cai et al., (2010) successfully 
used this transgenic mouse model expressing the UGT1A1*28 allele for assessing drug 
clearance by UGT1A1-dependant glucuronidation.  The transgenic mice presented 
with a hyperbilirubinemia phenotype. The use of these models in our study, 
particularly, the ingestion of Vitamin D or its synthetic analogues and monitoring 
physiological changes, including the presence of or rescue of UGT1A1 enzymatic 
activity, reduction in hyperbilirubinemia symptoms and measurement of serum 
bilirubin will further confirm that extrahepatic UGT1A1, regulated by VDR is 
physiologically relevant and can be used as a treatment option where UGT1A1 
expression is compromised. In the same manner, the glucuronidation substrate 
metabolites, including irinotecan, total serum bilirubin and various homornes (e.g 
estrogen) can be measured upon ingestion of Vitamin D or its analogues by transgenic 
mice.   Examination of 1,25D side effects compared to that of other VDR ligands (e.g. 
EB1089) will determine suitable treatment option in diseases where UGT1A 
expression is compromised.   
 
Other approaches to strenghthen this study include:  
 
• Ex-vivo experiments on extra-hepatic biopsies, measure mRNA, protein and 




• Identify a specific cell line with significant VDR and NRF2 levels to reliably 
examine the interplay of the two signalling pathways. 
• Investigate protein-protein interactions that may cause inhibitory effects 
between VDR and NRF2 ligands. 
• Silence the VDR to examine 3kLCA effects in ARE/NRF2 signaling. 
• Targeting more UGT1A isoforms to examine the involvement of the range of 
VDR/RXR binding sites within the UGT1A locus identified by Chip-Seq data. 
• Manipulate each individual binding site from the ChIP-seq data (Pike’s 
laboratory) to identify functional VDREs that contribute to the regulation of 
each isoform. 
• Include repression domains in CRISPRi approach to suppress H3K24ac marks 
and heterochromatin formation. 
 
6.5 Summary of key findings  
 
• VDR activation induces the expression of UGT1A1, UGT1A3, UGT1A4, 
UGT1A5 and UGT1A7 
• UGT1A1 is the most abundant and UGT1A4 is the most sensitive isoform in 
response to VDR ligands 
•  VDR directly influences UGT1A protein expression 
• The putative DR3-type element within the UGT1A1 promoter region is VDR 
specific 
• A functional VDRE was identified within the UGT1A1 (within position -
3483/-3194) promoter region. 
• VDR activity relies on an intact VDRE and ARE but the same is not true for 
NRF2 
• 1,25D and co-treatment of NRF2 and VDR ligands does not significantly 
enhance gene expression/activity 
• SFN has more potent growth inhibition properties than 1,25D in both a colonic 






6.6 Concluding Remarks  
 
The key focus for this study was to determine extrahepatic UGT1A regulation by VDR.  
We successfully define the gene family members induced in this manner and 
subsequently confirmed this regulation at protein and functional level.  We also 
observed modest to absent interaction between VDR and NRF2 signaling in enhancing 
detoxification genes including UGT1As, although VDR depended on an intact 
NRF2/ARE signalling.  This study has shed some light into extrahepatic detoxification 
pathways. The multiple VDR/RXR binding sites within the UGT1A locus potentially 
contribute to the robust response of UGT1A4 to VDR ligands. Clinically, these 
findings are advantageous in cases where UGT1A expression is crucial (i.e. 
























































1. Abbaoui, B., Telu, K.H., Lucas, C.R., Thomas-Ahner, J.M., Schwartz, S.J., 
Clinton, S.K., Freitas, M.A. and Mortazavi, A. (2017) The impact of cruciferous 
vegetable isothiocyanates on histone acetylation and histone phosphorylation in 
bladder cancer. Journal of Proteomics, 156, 94-103.  
2. Adzemovic, M.Z., Zeitelhofer, M., Hochmeister, S., Gustafsson, S.A. and Jagodic, 
M. (2013) Efficacy of vitamin D in treating multiple sclerosis-like 
neuroinflammation depends on developmental stage. Experimental Neurology, 
249, 39-48.  
3. Aguilera, O., Pena, C., Garcia, J.M., Larriba, M.J., Ordonez-Moran, P., Navarro, 
D., Barbachano, A., Lopez de Silanes, I., Ballestar, E., Fraga, M.F., Esteller, M., 
Gamallo, C., Bonilla, F., Gonzalez-Sancho, J.M. and Munoz, A. (2007) The Wnt 
antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 
associated to the differentiation of human colon cancer cells. Carcinogenesis, 
28(9), 1877-1884.  
4. Agusa, T., Iwata, H., Fujihara, J., Kunito, T., Takeshita, H., Minh, T.B., Trang, 
P.T., Viet, P.H. and Tanabe, S. (2010) Genetic polymorphisms in glutathione S-
transferase (GST) superfamily and arsenic metabolism in residents of the Red 
River Delta, Vietnam. Toxicology and Applied Pharmacology, 242(3), 352-362.  
5. Agyeman, A.S., Chaerkady, R., Shaw, P.G., Davidson, N.E., Visvanathan, K., 
Pandey, A. and Kensler, T.W. (2012) Transcriptomic and proteomic profiling of 
KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals 
common expression profiles. Breast Cancer Research and Treatment, 132(1), 175-
187.  
6. Ahmed, S.M., Luo, L., Namani, A., Wang, X.J. and Tang, X. (2017) Nrf2 signaling 
pathway: Pivotal roles in inflammation. Biochimica Et Biophysica Acta.Molecular 
Basis of Disease, 1863(2), 585-597.  
7. Ahn, J., Park, S., Zuniga, B., Bera, A., Song, C.S. and Chatterjee, B. (2016) 
Vitamin D in Prostate Cancer. Vitamins and Hormones, 100, 321-355.  
8. Ali, N.S. & Nanji, K., 2017. A Review on the Role of Vitamin D in Asthma. 
Cureus. 
9. Alvarez-Diaz, S., Valle, N., Ferrer-Mayorga, G., Lombardia, L., Herrera, M., 
Dominguez, O., Segura, M.F., Bonilla, F., Hernando, E. and Munoz, A. (2012) 




antimigratory and gene regulatory effects in colon cancer cells. Human Molecular 
Genetics, 21(10), 2157-2165.  
10. Al-Zoughool, M. and Talaska, G. (2006) 4-Aminobiphenyl N-glucuronidation by 
liver microsomes: optimization of the reaction conditions and characterization of 
the UDP-glucuronosyltransferase isoforms. Journal of Applied Toxicology : JAT, 
26(6), 524-532.  
11. Amandito, R., Rohsiswatmo, R., Carolina, E., Maulida, R., Kresnawati, W. and 
Malik, A. (2019) Profiling of UGT1A1(*)6, UGT1A1(*)60, UGT1A1(*)93, and 
UGT1A1(*)28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia 
Using Multiplex PCR Sequencing. Frontiers in Pediatrics, 7, 328.  
12. Anderson, P.H., O'Loughlin, P.D., May, B.K. and Morris, H.A. (2004) 
Determinants of circulating 1,25-dihydroxyvitamin D3 levels: the role of renal 
synthesis and catabolism of vitamin D. The Journal of Steroid Biochemistry and 
Molecular Biology, 89-90(1-5), 111-113.  
13. Angstadt, A.Y., Hartman, T.J., Lesko, S.M., Muscat, J.E., Zhu, J., Gallagher, C.J. 
and Lazarus, P. (2014) The effect of UGT1A and UGT2B polymorphisms on 
colorectal cancer risk: haplotype associations and gene-environment interactions. 
Genes, Chromosomes & Cancer, 53(6), 454-466.  
14. Aoshima, N., Fujie, Y., Itoh, T., Tukey, R.H. and Fujiwara, R. (2014) Glucose 
induces intestinal human UDP-glucuronosyltransferase (UGT) 1A1 to prevent 
neonatal hyperbilirubinemia. Scientific Reports, 4, 6343.  
15. Aueviriyavit, S., Furihata, T., Morimoto, K., Kobayashi, K. and Chiba, K. (2007) 
Hepatocyte nuclear factor 1 alpha and 4 alpha are factors involved in 
interindividual variability in the expression of UGT1A6 and UGT1A9 but not 
UGT1A1, UGT1A3 and UGT1A4 mRNA in human livers. Drug Metabolism and 
Pharmacokinetics, 22(5), 391-398.  
16. Bacchetta, J., Sea, J.L., Chun, R.F., Lisse, T.S., Wesseling-Perry, K., Gales, B., 
Adams, J.S., Salusky, I.B. and Hewison, M. (2013) Fibroblast growth factor 23 
inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. 
Journal of Bone and Mineral Research : The Official Journal of the American 




17. Barbarino, J.M., Haidar, C.E., Klein, T.E. and Altman, R.B. (2014) PharmGKB 
summary: very important pharmacogene information for UGT1A1. 
Pharmacogenetics and Genomics, 24(3), 177-183.  
18. Barbier, O., Villeneuve, L., Bocher, V., Fontaine, C., Torra, I.P., Duhem, C., 
Kosykh, V., Fruchart, J.C., Guillemette, C. and Staels, B. (2003) The UDP-
glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated 
receptor alpha and gamma target gene. The Journal of Biological Chemistry, 
278(16), 13975-13983.  
19. Bedi, S., Hostetler, H.A. and Rider, S.D.,Jr. (2017) Mutations in Liver X Receptor 
Alpha that Impair Dimerization and Ligand Dependent Transactivation. Nuclear 
Receptor Research, 4, 10.11131/2017/101302.  
20. Bellemare, J., Rouleau, M., Harvey, M., Tetu, B. and Guillemette, C. (2010) 
Alternative-splicing forms of the major phase II conjugating UGT1A gene 
negatively regulate glucuronidation in human carcinoma cell lines. The 
Pharmacogenomics Journal, 10(5), 431-441.  
21. Bellezza, I. (2018) Oxidative Stress in Age-Related Macular Degeneration: Nrf2 
as Therapeutic Target. Frontiers in Pharmacology, 9, 1280.  
22. Bellezza, I., Scarpelli, P., Pizzo, S.V., Grottelli, S., Costanzi, E. and Minelli, A. 
(2017) ROS-independent Nrf2 activation in prostate cancer. Oncotarget, 8(40), 
67506-67518.  
23. Berridge, M.J. (2015) Vitamin D: a custodian of cell signalling stability in health 
and disease. Biochemical Society Transactions, 43(3), 349-358.  
24. Berridge, M.J. (2016) Vitamin D, reactive oxygen species and calcium signalling 
in ageing and disease. Philosophical Transactions of the Royal Society of 
London.Series B, Biological Sciences, 371(1700), 10.1098/rstb.2015.0434.  
25. Beurel, E., Grieco, S.F. and Jope, R.S. (2015) Glycogen synthase kinase-3 
(GSK3): regulation, actions, and diseases. Pharmacology & Therapeutics, 148, 
114-131.  
26. Bischoff-Ferrari, H.A., Giovannucci, E., Willett, W.C., Dietrich, T. and Dawson-
Hughes, B. (2006) Estimation of optimal serum concentrations of 25-
hydroxyvitamin D for multiple health outcomes. The American Journal of Clinical 




27. Bishayee, A., Bhatia, D., Thoppil, R.J., Darvesh, A.S., Nevo, E. and Lansky, E.P. 
(2011) Pomegranate-mediated chemoprevention of experimental 
hepatocarcinogenesis involves Nrf2-regulated antioxidant mechanisms. 
Carcinogenesis, 32(6), 888-896.  
28. Blaine, J., Chonchol, M. and Levi, M. (2015) Renal control of calcium, phosphate, 
and magnesium homeostasis. Clinical Journal of the American Society of 
Nephrology : CJASN, 10(7), 1257-1272.  
29. Boucher, B.J. (2018) Vitamin D status and its management for achieving optimal 
health benefits in the elderly. Expert Review of Endocrinology & Metabolism, 
13(6), 279-293.  
30. Boyce, B.F. and Xing, L. (2008) Functions of RANKL/RANK/OPG in bone 
modeling and remodeling. Archives of Biochemistry and Biophysics, 473(2), 139-
146.  
31. Buckley, D.B. and Klaassen, C.D. (2009) Induction of mouse UDP-
glucuronosyltransferase mRNA expression in liver and intestine by activators of 
aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, 
peroxisome proliferator-activated receptor alpha, and nuclear factor erythroid 2-
related factor 2. Drug Metabolism and Disposition: The Biological Fate of 
Chemicals, 37(4), 847-856.  
32. Campbell, M.J. (2014) Vitamin D and the RNA transcriptome: more than mRNA 
regulation. Frontiers in Physiology, 5, 181.  
33. Campos, L.T., Brentani, H., Roela, R.A., Katayama, M.L., Lima, L., Rolim, C.F., 
Milani, C., Folgueira, M.A. and Brentani, M.M. (2013) Differences in 
transcriptional effects of 1alpha,25 dihydroxyvitamin D3 on fibroblasts associated 
to breast carcinomas and from paired normal breast tissues. The Journal of Steroid 
Biochemistry and Molecular Biology, 133, 12-24.  
34. Canning, P., Sorrell, F.J. and Bullock, A.N. (2015) Structural basis of Keap1 
interactions with Nrf2. Free Radical Biology & Medicine, 88(Pt B), 101-107.  
35. Canu, G., Minucci, A., Zuppi, C. and Capoluongo, E. (2013) Gilbert and Crigler 
Najjar syndromes: an update of the UDP-glucuronosyltransferase 1A1 (UGT1A1) 




36. Carlberg, C. and Campbell, M.J. (2013) Vitamin D receptor signaling 
mechanisms: integrated actions of a well-defined transcription factor. Steroids, 
78(2), 127-136.  
37. Carlberg, C., Seuter, S. and Heikkinen, S. (2012) The first genome-wide view of 
vitamin D receptor locations and their mechanistic implications. Anticancer 
Research, 32(1), 271-282.  
38. Carleton, J.B., Berrett, K.C. and Gertz, J. (2017) Multiplex Enhancer Interference 
Reveals Collaborative Control of Gene Regulation by Estrogen Receptor alpha-
Bound Enhancers. Cell Systems, 5(4), 333-344.e5.  
39. Cattaneo, D., Ripamonti, D., Baldelli, S., Cozzi, V., Conti, F. and Clementi, E. 
(2010) Exposure-related effects of atazanavir on the pharmacokinetics of 
raltegravir in HIV-1-infected patients. Therapeutic Drug Monitoring, 32(6), 782-
786.  
40. Cengiz, B., Yumrutas, O., Bozgeyik, E., Borazan, E., Igci, Y.Z., Bozgeyik, I. and 
Oztuzcu, S. (2015) Differential expression of the UGT1A family of genes in 
stomach cancer tissues. Tumour Biology : The Journal of the International Society 
for Oncodevelopmental Biology and Medicine, 36(8), 5831-5837.  
41. Chai, X., Zeng, S. and Xie, W. (2013) Nuclear receptors PXR and CAR: 
implications for drug metabolism regulation, pharmacogenomics and beyond. 
Expert Opinion on Drug Metabolism & Toxicology, 9(3), 253-266.  
42. Chandrasekar, V. and John, S., 2020. Gilbert Syndrome. [online] Statpearls.com. 
Available at: <https://www.statpearls.com/kb/viewarticle/22249> [Accessed 9 
April 2020]. 
43. Chen, L., Yang, R., Qiao, W., Zhang, W., Chen, J., Mao, L., Goltzman, D. and 
Miao, D. (2019) 1,25-Dihydroxyvitamin D exerts an antiaging role by activation 
of Nrf2-antioxidant signaling and inactivation of p16/p53-senescence signaling. 
Aging Cell, 18(3), e12951.  
44. Chen, S., Beaton, D., Nguyen, N., Senekeo-Effenberger, K., Brace-Sinnokrak, E., 
Argikar, U., Remmel, R.P., Trottier, J., Barbier, O., Ritter, J.K. and Tukey, R.H. 
(2005) Tissue-specific, inducible, and hormonal control of the human UDP-
glucuronosyltransferase-1 (UGT1) locus. The Journal of Biological Chemistry, 




45. Chen, S., Yueh, M.F., Evans, R.M. and Tukey, R.H. (2012) Pregnane-x-receptor 
controls hepatic glucuronidation during pregnancy and neonatal development in 
humanized UGT1 mice. Hepatology (Baltimore, Md.), 56(2), 658-667.  
46. Chen, X., Duan, N., Zhang, C. and Zhang, W. (2016) Survivin and Tumorigenesis: 
Molecular Mechanisms and Therapeutic Strategies. Journal of Cancer, 7(3), 314-
323.  
47. Chen, Y., Rao, X., Huang, K., Jiang, X., Wang, H. and Teng, L. (2017) FH535 
Inhibits Proliferation and Motility of Colon Cancer Cells by Targeting Wnt/beta-
catenin Signaling Pathway. Journal of Cancer, 8(16), 3142-3153.  
48. Chen, Z., Ye, X., Tang, N., Shen, S., Li, Z., Niu, X., Lu, S. and Xu, L. (2014) The 
histone acetylranseferase hMOF acetylates Nrf2 and regulates anti-drug responses 
in human non-small cell lung cancer. British Journal of Pharmacology, 171(13), 
3196-3211.  
49. Cheng, J., Fang, Z.Z., Kim, J.H., Krausz, K.W., Tanaka, N., Chiang, J.Y. and 
Gonzalez, F.J. (2014) Intestinal CYP3A4 protects against lithocholic acid-induced 
hepatotoxicity in intestine-specific VDR-deficient mice. Journal of Lipid 
Research, 55(3), 455-465.  
50. Chiang, T.C., Koss, B., Su, L.J., Washam, C.L., Byrum, S.D., Storey, A. and 
Tackett, A.J. (2019) Effect of Sulforaphane and 5-Aza-2'-Deoxycytidine on 
Melanoma Cell Growth. Medicines (Basel, Switzerland), 6(3), 
10.3390/medicines6030071.  
51. Choi, K.C. and Jeung, E.B. (2008) Molecular mechanism of regulation of the 
calcium-binding protein calbindin-D9k, and its physiological role(s) in mammals: 
a review of current research. Journal of Cellular and Molecular Medicine, 12(2), 
409-420.  
52. Choi, M., Yamamoto, K., Masuno, H., Nakashima, K., Taga, T. and Yamada, S. 
(2001) Ligand recognition by the vitamin D receptor. Bioorganic & Medicinal 
Chemistry, 9(7), 1721-1730.  
53. Chorley, B.N., Campbell, M.R., Wang, X., Karaca, M., Sambandan, D., Bangura, 
F., Xue, P., Pi, J., Kleeberger, S.R. and Bell, D.A. (2012) Identification of novel 
NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. 




54. Chouinard, S., Barbier, O. and Belanger, A. (2007) UDP-glucuronosyltransferase 
2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen 
response in prostate cancer LNCaP cells. The Journal of Biological Chemistry, 
282(46), 33466-33474.  
55. Chowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A. and Hayes, 
J.D. (2013) Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its 
Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene, 
32(32), 3765-3781.  
56. Chowdhury, A.M.M.A., Katoh, H., Hatanaka, A., Iwanari, H., Nakamura, N., 
Hamakubo, T., Natsume, T., Waku, T. and Kobayashi, A. (2017) Multiple 
regulatory mechanisms of the biological function of NRF3 (NFE2L3) control 
cancer cell proliferation. Scientific Reports, 7(1), 12494-017-12675-y.  
57. Christakos, S., Dhawan, P., Porta, A., Mady, L. and Seth, T., 2011. Vitamin D And 
Intestinal Calcium Absorption. 
58. Ciotti, M., Basu, N., Brangi, M. and Owens, I.S. (1999) Glucuronidation of 7-
ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-
glucuronosyltransferases encoded at the UGT1 locus. Biochemical and 
Biophysical Research Communications, 260(1), 199-202.  
59. Court, M.H. (2010) Interindividual variability in hepatic drug glucuronidation: 
studies into the role of age, sex, enzyme inducers, and genetic polymorphism using 
the human liver bank as a model system. Drug Metabolism Reviews, 42(1), 209-
224.  
60. Cox, A.J., Ng, M.C., Xu, J., Langefeld, C.D., Koch, K.L., Dawson, P.A., Carr, J.J., 
Freedman, B.I., Hsu, F.C. and Bowden, D.W. (2013) Association of SNPs in the 
UGT1A gene cluster with total bilirubin and mortality in the Diabetes Heart Study. 
Atherosclerosis, 229(1), 155-160.  
61. Danoff, T.M., Campbell, D.A., McCarthy, L.C., Lewis, K.F., Repasch, M.H., 
Saunders, A.M., Spurr, N.K., Purvis, I.J., Roses, A.D. and Xu, C.F. (2004) A 
Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced 
hyperbilirubinemia. The Pharmacogenomics Journal, 4(1), 49-53.  
62. de Souza, M.M., Vaisberg, V.V., Abreu, R.M., Ferreira, A.S., daSilvaFerreira, C., 




relationship with abnormal total bilirubin levels in chronic hepatitis C patients: 
Outcomes from a case-control study. Medicine, 96(11), e6306.  
63. Delanghe, J.R., Speeckaert, R. and Speeckaert, M.M. (2015) Behind the scenes of 
vitamin D binding protein: more than vitamin D binding. Best Practice & 
Research.Clinical Endocrinology & Metabolism, 29(5), 773-786.  
64. Dluzen, D.F., Sun, D., Salzberg, A.C., Jones, N., Bushey, R.T., Robertson, G.P. 
and Lazarus, P. (2014) Regulation of UDP-glucuronosyltransferase 1A1 
expression and activity by microRNA 491-3p. The Journal of Pharmacology and 
Experimental Therapeutics, 348(3), 465-477.  
65. Doherty, D., Dvorkin, S.A., Rodriguez, E.P. and Thompson, P.D. (2014) Vitamin 
D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" 
metabolism. The Prostate, 74(3), 273-285.  
66. Donate-Correa, J., Martin-Nunez, E., Hernandez-Carballo, C., Ferri, C., Tagua, 
V.G., Delgado-Molinos, A., Lopez-Castillo, A., Rodriguez-Ramos, S., Cerro-
Lopez, P., Lopez-Tarruella, V.C., Felipe-Garcia, R., Arevalo-Gomez, M.A., 
Perez-Delgado, N., Mora-Fernandez, C. and Navarro-Gonzalez, J.F. (2019) 
Fibroblast growth factor 23 expression in human calcified vascular tissues. Aging, 
11(18), 7899-7913.  
67. Dong, J., Wong, S.L., Lau, C.W., Lee, H.K., Ng, C.F., Zhang, L., Yao, X., Chen, 
Z.Y., Vanhoutte, P.M. and Huang, Y. (2012) Calcitriol protects renovascular 
function in hypertension by down-regulating angiotensin II type 1 receptors and 
reducing oxidative stress. European Heart Journal, 33(23), 2980-2990.  
68. Du, P., Wang, A., Ma, Y. and Li, X. (2019) Association between the UGT1A1*28 
allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a 
meta-analysis. Bioscience Reports, 39(5), 10.1042/BSR20182105. Print 2019 May 
31.  
69. Duguay, Y., McGrath, M., Lepine, J., Gagne, J.F., Hankinson, S.E., Colditz, G.A., 
Hunter, D.J., Plante, M., Tetu, B., Belanger, A., Guillemette, C. and De Vivo, I. 
(2004) The functional UGT1A1 promoter polymorphism decreases endometrial 
cancer risk. Cancer Research, 64(3), 1202-1207.  
70. Echchgadda, I., Song, C.S., Roy, A.K. and Chatterjee, B. (2004) 
Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction 




71. Edwards, P.A., Kennedy, M.A. and Mak, P.A. (2002) LXRs; oxysterol-activated 
nuclear receptors that regulate genes controlling lipid homeostasis. Vascular 
Pharmacology, 38(4), 249-256.  
72. Eeckhoute, J., Formstecher, P. and Laine, B. (2004) Hepatocyte nuclear factor 
4alpha enhances the hepatocyte nuclear factor 1alpha-mediated activation of 
transcription. Nucleic Acids Research, 32(8), 2586-2593.  
73. Ehmer, U., Kalthoff, S., Fakundiny, B., Pabst, B., Freiberg, N., Naumann, R., 
Manns, M.P. and Strassburg, C.P. (2012) Gilbert syndrome redefined: a complex 
genetic haplotype influences the regulation of glucuronidation. Hepatology 
(Baltimore, Md.), 55(6), 1912-1921.  
74. Erichsen, T.J., Aehlen, A., Ehmer, U., Kalthoff, S., Manns, M.P. and Strassburg, 
C.P. (2010) Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 
by the farnesoid X receptor and bile acids. Journal of Hepatology, 52(4), 570-578.  
75. Fan, Z., Wirth, A.K., Chen, D., Wruck, C.J., Rauh, M., Buchfelder, M. and 
Savaskan, N. (2017) Nrf2-Keap1 pathway promotes cell proliferation and 
diminishes ferroptosis. Oncogenesis, 6(8), e371.  
76. Ferrer-Mayorga, G., Gomez-Lopez, G., Barbachano, A., Fernandez-Barral, A., 
Pena, C., Pisano, D.G., Cantero, R., Rojo, F., Munoz, A. and Larriba, M.J. (2017) 
Vitamin D receptor expression and associated gene signature in tumour stromal 
fibroblasts predict clinical outcome in colorectal cancer. Gut, 66(8), 1449-1462.  
77. Fetahu, I.S., Hobaus, J. and Kallay, E. (2014) Vitamin D and the epigenome. 
Frontiers in Physiology, 5, 164.  
78. Finel, M., Li, X., Gardner-Stephen, D., Bratton, S., Mackenzie, P.I. and 
Radominska-Pandya, A. (2005) Human UDP-glucuronosyltransferase 1A5: 
identification, expression, and activity. The Journal of Pharmacology and 
Experimental Therapeutics, 315(3), 1143-1149.  
79. Fishilevich, S., Nudel, R., Rappaport, N., Hadar, R., Plaschkes, I., Iny Stein, T., 
Rosen, N., Kohn, A., Twik, M., Safran, M., Lancet, D. and Cohen, D. (2017) 
GeneHancer: genome-wide integration of enhancers and target genes in 
GeneCards. Database : The Journal of Biological Databases and Curation, 2017, 
10.1093/database/bax028.  
80. Fleet, J.C. (2017) The role of vitamin D in the endocrinology controlling calcium 




81. Fleet, J.C. and Schoch, R.D. (2010) Molecular mechanisms for regulation of 
intestinal calcium absorption by vitamin D and other factors. Critical Reviews in 
Clinical Laboratory Sciences, 47(4), 181-195.  
82. Flores, O., Wang, Z., Knudsen, K.E. and Burnstein, K.L. (2010) Nuclear targeting 
of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 
localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology, 
151(3), 896-908.  
83. Fujiwara, R., Chen, S., Karin, M. and Tukey, R.H. (2012) Reduced expression of 
UGT1A1 in intestines of humanized UGT1 mice via inactivation of NF-kappaB 
leads to hyperbilirubinemia. Gastroenterology, 142(1), 109-118.e2.  
84. Fujiwara, R., Nakajima, M., Oda, S., Yamanaka, H., Ikushiro, S., Sakaki, T. and 
Yokoi, T. (2010) Interactions between human UDP-glucuronosyltransferase 
(UGT) 2B7 and UGT1A enzymes. Journal of Pharmaceutical Sciences, 99(1), 
442-454.  
85. Fujiwara, R., Nguyen, N., Chen, S. and Tukey, R.H. (2010) Developmental 
hyperbilirubinemia and CNS toxicity in mice humanized with the UDP 
glucuronosyltransferase 1 (UGT1) locus. Proceedings of the National Academy of 
Sciences of the United States of America, 107(11), 5024-5029.  
86. Fujiwara, R., Yokoi, T. and Nakajima, M. (2016) Structure and Protein-Protein 
Interactions of Human UDP-Glucuronosyltransferases. Frontiers in 
Pharmacology, 7, 388.  
87. Furue, M., Fuyuno, Y., Mitoma, C., Uchi, H. and Tsuji, G. (2018) Therapeutic 
Agents with AHR Inhibiting and NRF2 Activating Activity for Managing 
Chloracne. Antioxidants (Basel, Switzerland), 7(7), 10.3390/antiox7070090.  
88. Garland, C.F., Kim, J.J., Mohr, S.B., Gorham, E.D., Grant, W.B., Giovannucci, 
E.L., Baggerly, L., Hofflich, H., Ramsdell, J.W., Zeng, K. and Heaney, R.P. (2014) 
Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D. 
American Journal of Public Health, 104(8), e43-50.  
89. Gil, A., Plaza-Diaz, J. and Mesa, M.D. (2018) Vitamin D: Classic and Novel 
Actions. Annals of Nutrition & Metabolism, 72(2), 87-95.  
90. Glerup, H., Mikkelsen, K., Poulsen, L., Hass, E., Overbeck, S., Thomsen, J., 
Charles, P. and Eriksen, E., 2000. Commonly Recommended Daily Intake Of 




91. Goeman, F., De Nicola, F., D'Onorio De Meo, P., Pallocca, M., Elmi, B., 
Castrignano, T., Pesole, G., Strano, S., Blandino, G., Fanciulli, M. and Muti, P. 
(2014) VDR primary targets by genome-wide transcriptional profiling. The 
Journal of Steroid Biochemistry and Molecular Biology, 143, 348-356.  
92. Gombart, A.F. (2009) The vitamin D-antimicrobial peptide pathway and its role 
in protection against infection. Future Microbiology, 4(9), 1151-1165.  
93. Green, M. (2011) Cod liver oil and tuberculosis. BMJ (Clinical Research Ed.), 
343, d7505.  
94. Gregory, P.A., Gardner-Stephen, D.A., Lewinsky, R.H., Duncliffe, K.N. and 
Mackenzie, P.I. (2003) Cloning and characterization of the human UDP-
glucuronosyltransferase 1A8, 1A9, and 1A10 gene promoters: differential 
regulation through an interior-like region. The Journal of Biological Chemistry, 
278(38), 36107-36114.  
95. Grishkan, I.V., Fairchild, A.N., Calabresi, P.A. and Gocke, A.R. (2013) 1,25-
Dihydroxyvitamin D3 selectively and reversibly impairs T helper-cell CNS 
localization. Proceedings of the National Academy of Sciences of the United States 
of America, 110(52), 21101-21106.  
96. Guo, G.L., Lambert, G., Negishi, M., Ward, J.M., Brewer, H.B.,Jr, Kliewer, S.A., 
Gonzalez, F.J. and Sinal, C.J. (2003) Complementary roles of farnesoid X 
receptor, pregnane X receptor, and constitutive androstane receptor in protection 
against bile acid toxicity. The Journal of Biological Chemistry, 278(46), 45062-
45071.  
97. Haas, S., Pierl, C., Harth, V., Pesch, B., Rabstein, S., Bruning, T., Ko, Y., Hamann, 
U., Justenhoven, C., Brauch, H. and Fischer, H.P. (2006) Expression of xenobiotic 
and steroid hormone metabolizing enzymes in human breast carcinomas. 
International Journal of Cancer, 119(8), 1785-1791.  
98. Hanel, A., Malmberg, H.R. and Carlberg, C. (2020) Genome-wide effects of 
chromatin on vitamin D signaling. Journal of Molecular Endocrinology,  
99. Hanioka, N., Iwabu, H., Hanafusa, H., Nakada, S. and Narimatsu, S. (2012) 
Expression and inducibility of UDP-glucuronosyltransferase 1As in MCF-7 
human breast carcinoma cells. Basic & Clinical Pharmacology & Toxicology, 




100. Haq, A., Wimalawansa, S.J., Pludowski, P. and Anouti, F.A. (2018) Clinical 
practice guidelines for vitamin D in the United Arab Emirates. The Journal of 
Steroid Biochemistry and Molecular Biology, 175, 4-11.  
101. Hashizume, T., Xu, Y., Mohutsky, M.A., Alberts, J., Hadden, C., Kalhorn, 
T.F., Isoherranen, N., Shuhart, M.C. and Thummel, K.E. (2008) Identification of 
human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-
dihydroxyvitamin D3 conjugation. Biochemical Pharmacology, 75(5), 1240-1250.  
102. Haussler, M., Saini, R., Sabir, M., Dussik, C., Khan, Z., Whitfield, G., Griffin, 
K., Kaneko, I. and Jurutka, P., 2020. Vitamin D Nutrient-Gene Interactions And 
Healthful Aging. 
103. Haussler, M.R., Whitfield, G.K., Kaneko, I., Forster, R., Saini, R., Hsieh, J.C., 
Haussler, C.A. and Jurutka, P.W. (2012) The role of vitamin D in the FGF23, 
klotho, and phosphate bone-kidney endocrine axis. Reviews in Endocrine & 
Metabolic Disorders, 13(1), 57-69.  
104. Hayes, J.D. and Dinkova-Kostova, A.T. (2017) Epigenetic Control of NRF2-
Directed Cellular Antioxidant Status in Dictating Life-Death Decisions. Molecular 
Cell, 68(1), 5-7.  
105. Hayes, J.D. and McMahon, M. (2009) NRF2 and KEAP1 mutations: 
permanent activation of an adaptive response in cancer. Trends in Biochemical 
Sciences, 34(4), 176-188.  
106. Hirotsu, Y., Katsuoka, F., Funayama, R., Nagashima, T., Nishida, Y., 
Nakayama, K., Engel, J.D. and Yamamoto, M. (2012) Nrf2-MafG heterodimers 
contribute globally to antioxidant and metabolic networks. Nucleic Acids 
Research, 40(20), 10228-10239.  
107. Hirschmann, F., Krause, F. and Papenbrock, J. (2014) The multi-protein family 
of sulfotransferases in plants: composition, occurrence, substrate specificity, and 
functions. Frontiers in Plant Science, 5, 556.  
108. Hoenderop, J.G., Nilius, B. and Bindels, R.J. (2005) Calcium absorption across 
epithelia. Physiological Reviews, 85(1), 373-422.  
109. Holick, M.F. (1981) The cutaneous photosynthesis of previtamin D3: a unique 




110. Holick, M.F. (2004) Vitamin D: importance in the prevention of cancers, type 
1 diabetes, heart disease, and osteoporosis. The American Journal of Clinical 
Nutrition, 79(3), 362-371.  
111. Holick, M.F., Biancuzzo, R.M., Chen, T.C., Klein, E.K., Young, A., Bibuld, 
D., Reitz, R., Salameh, W., Ameri, A. and Tannenbaum, A.D. (2008) Vitamin D2 
is as effective as vitamin D3 in maintaining circulating concentrations of 25-
hydroxyvitamin D. The Journal of Clinical Endocrinology and Metabolism, 93(3), 
677-681.  
112. Holick, M.F., Binkley, N.C., Bischoff-Ferrari, H.A., Gordon, C.M., Hanley, 
D.A., Heaney, R.P., Murad, M.H., Weaver, C.M. and Endocrine Society. (2011) 
Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine 
Society clinical practice guideline. The Journal of Clinical Endocrinology and 
Metabolism, 96(7), 1911-1930.  
113. Holick, M.F., Smith, E. and Pincus, S. (1987) Skin as the site of vitamin D 
synthesis and target tissue for 1,25-dihydroxyvitamin D3. Use of calcitriol (1,25-
dihydroxyvitamin D3) for treatment of psoriasis. Archives of Dermatology, 
123(12), 1677-1683a.  
114. Hollis, B.W. (1984) Comparison of equilibrium and disequilibrium assay 
conditions for ergocalciferol, cholecalciferol and their major metabolites. Journal 
of Steroid Biochemistry, 21(1), 81-86.  
115. Hu, D.G., Mackenzie, P.I., Lu, L., Meech, R. and McKinnon, R.A. (2015) 
Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by 
cytotoxic anticancer drugs in liver cancer HepG2 cells. Drug Metabolism and 
Disposition: The Biological Fate of Chemicals, 43(5), 660-668.  
116. Hustert, E., Zibat, A., Presecan-Siedel, E., Eiselt, R., Mueller, R., Fuss, C., 
Brehm, I., Brinkmann, U., Eichelbaum, M., Wojnowski, L. and Burk, O. (2001) 
Natural protein variants of pregnane X receptor with altered transactivation 
activity toward CYP3A4. Drug Metabolism and Disposition: The Biological Fate 
of Chemicals, 29(11), 1454-1459.  
117. Ichiki, A., Miyazaki, T., Nodera, M., Suzuki, H. and Yanagisawa, H. (2008) 
Ascorbate inhibits apoptosis of Kupffer cells during warm ischemia/reperfusion 




118. Iizuka, T., Ishii, Y., Itoh, K., Kiwamoto, T., Kimura, T., Matsuno, Y., 
Morishima, Y., Hegab, A.E., Homma, S., Nomura, A., Sakamoto, T., Shimura, M., 
Yoshida, A., Yamamoto, M. and Sekizawa, K. (2005) Nrf2-deficient mice are 
highly susceptible to cigarette smoke-induced emphysema. Genes to Cells : 
Devoted to Molecular & Cellular Mechanisms, 10(12), 1113-1125.  
119. Ikushiro, S., Emi, Y., Kato, Y., Yamada, S. and Sakaki, T. (2006) 
Monospecific antipeptide antibodies against human hepatic UDP-
glucuronosyltransferase 1A subfamily (UGT1A) isoforms. Drug Metabolism and 
Pharmacokinetics, 21(1), 70-74.  
120. Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J.D. and 
Yamamoto, M. (1999) Keap1 represses nuclear activation of antioxidant 
responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. 
Genes & Development, 13(1), 76-86.  
121. Iyanagi, T. (2007) Molecular mechanism of phase I and phase II drug-
metabolizing enzymes: implications for detoxification. International Review of 
Cytology, 260, 35-112.  
122. Izukawa, T., Nakajima, M., Fujiwara, R., Yamanaka, H., Fukami, T., 
Takamiya, M., Aoki, Y., Ikushiro, S., Sakaki, T. and Yokoi, T. (2009) Quantitative 
analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression 
levels in human livers. Drug Metabolism and Disposition: The Biological Fate of 
Chemicals, 37(8), 1759-1768.  
123. Jain, S.K. and Micinski, D. (2013) Vitamin D upregulates glutamate cysteine 
ligase and glutathione reductase, and GSH formation, and decreases ROS and 
MCP-1 and IL-8 secretion in high-glucose exposed U937 monocytes. Biochemical 
and Biophysical Research Communications, 437(1), 7-11.  
124. Jean, G., Souberbielle, J. and Chazot, C., 2020. Vitamin D In Chronic Kidney 
Disease And Dialysis Patients. 
125. Jelinek, G.A., Marck, C.H., Weiland, T.J., Pereira, N., van der Meer, D.M. and 
Hadgkiss, E.J. (2015) Latitude, sun exposure and vitamin D supplementation: 
associations with quality of life and disease outcomes in a large international 
cohort of people with multiple sclerosis. BMC Neurology, 15, 132-015-0394-1.  
126. Jiang, L., Liang, S.C., Wang, C., Ge, G.B., Huo, X.K., Qi, X.Y., Deng, S., Liu, 




simultaneously determine the O-glucuronidation activity of human UGT1A3 and 
UGT1A4. Scientific Reports, 5, 9627.  
127. Jiraskova, A., Bortolussi, G., Dostalova, G., Eremiasova, L., Golan, L., 
Danzig, V., Linhart, A. and Vitek, L. (2017) Serum Bilirubin Levels and Promoter 
Variations in HMOX1 and UGT1A1 Genes in Patients with Fabry Disease. 
Oxidative Medicine and Cellular Longevity, 2017, 9478946.  
128. Jones, G., Prosser, D.E. and Kaufmann, M. (2014) Cytochrome P450-mediated 
metabolism of vitamin D. Journal of Lipid Research, 55(1), 13-31.  
129. Kadakol, A., Ghosh, S.S., Sappal, B.S., Sharma, G., Chowdhury, J.R. and 
Chowdhury, N.R. (2000) Genetic lesions of bilirubin uridine-
diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar 
and Gilbert syndromes: correlation of genotype to phenotype. Human Mutation, 
16(4), 297-306.  
130. Kaeding, J., Belanger, J., Caron, P., Verreault, M., Belanger, A. and Barbier, 
O. (2008) Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen 
glucuronidation in prostate cancer cells. Molecular Cancer Therapeutics, 7(2), 
380-390.  
131. Kahlon, T.S., Chiu, M.C. and Chapman, M.H. (2008) Steam cooking 
significantly improves in vitro bile acid binding of collard greens, kale, mustard 
greens, broccoli, green bell pepper, and cabbage. Nutrition Research (New York, 
N.Y.), 28(6), 351-357.  
132. Kalousova, M., Dusilova-Sulkova, S., Zakiyanov, O., Kostirova, M., Safranek, 
R., Tesar, V. and Zima, T., 2020. Vitamin D Binding Protein Is Not Involved In 
Vitamin D Deficiency In Patients With Chronic Kidney Disease 
133. Kalthoff, S., Ehmer, U., Freiberg, N., Manns, M.P. and Strassburg, C.P. (2010) 
Interaction between oxidative stress sensor Nrf2 and xenobiotic-activated aryl 
hydrocarbon receptor in the regulation of the human phase II detoxifying UDP-
glucuronosyltransferase 1A10. The Journal of Biological Chemistry, 285(9), 
5993-6002.  
134. Kalthoff, S., Ehmer, U., Freiberg, N., Manns, M.P. and Strassburg, C.P. (2010) 
Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon 





135. Kansanen, E., Kuosmanen, S.M., Leinonen, H. and Levonen, A.L. (2013) The 
Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. 
Redox Biology, 1, 45-49.  
136. Keppler, D. (2014) The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in 
conjugated hyperbilirubinemia. Drug Metabolism and Disposition: The Biological 
Fate of Chemicals, 42(4), 561-565.  
137. Kerner, S.A., Scott, R.A. and Pike, J.W. (1989) Sequence elements in the 
human osteocalcin gene confer basal activation and inducible response to 
hormonal vitamin D3. Proceedings of the National Academy of Sciences of the 
United States of America, 86(12), 4455-4459.  
138. Keum, Y.S., Owuor, E.D., Kim, B.R., Hu, R. and Kong, A.N. (2003) 
Involvement of Nrf2 and JNK1 in the activation of antioxidant responsive element 
(ARE) by chemopreventive agent phenethyl isothiocyanate (PEITC). 
Pharmaceutical Research, 20(9), 1351-1356.  
139. Khan, A.A., Dragt, B.S., Porte, R.J. and Groothuis, G.M. (2010) Regulation of 
VDR expression in rat and human intestine and liver--consequences for CYP3A 
expression. Toxicology in Vitro : An International Journal Published in 
Association with BIBRA, 24(3), 822-829.  
140. Khedkar, S.A., Samad, M.A., Choudhury, S., Lee, J.Y., Zhang, D., Thadhani, 
R.I., Karumanchi, S.A., Rigby, A.C. and Kang, P.M. (2017) Identification of 
Novel Non-secosteroidal Vitamin D Receptor Agonists with Potent 
Cardioprotective Effects and devoid of Hypercalcemia. Scientific Reports, 7(1), 
8427-017-08670-y.  
141. Khurana, N. and Sikka, S.C. (2018) Targeting Crosstalk between Nrf-2, NF-
kappaB and Androgen Receptor Signaling in Prostate Cancer. Cancers, 10(10), 
10.3390/cancers10100352.  
142. Khurana, N., Talwar, S., Chandra, P.K., Sharma, P., Abdel-Mageed, A.B., 
Mondal, D. and Sikka, S.C. (2016) Sulforaphane increases the efficacy of anti-
androgens by rapidly decreasing androgen receptor levels in prostate cancer cells. 
International Journal of Oncology, 49(4), 1609-1619.  
143. Kim, S., Yamazaki, M., Zella, L.A., Shevde, N.K. and Pike, J.W. (2006) 




dihydroxyvitamin D3 is mediated through multiple long-range enhancers. 
Molecular and Cellular Biology, 26(17), 6469-6486.  
144. Kim, S., Yamazaki, M., Zella, L.A., Shevde, N.K. and Pike, J.W. (2006) 
Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-
dihydroxyvitamin D3 is mediated through multiple long-range enhancers. 
Molecular and Cellular Biology, 26(17), 6469-6486.  
145. Kim, S.G., Kim, B.K., Kim, K. and Fang, S. (2016) Bile Acid Nuclear 
Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver 
Disease. Endocrinology and Metabolism (Seoul, Korea), 31(4), 500-504.  
146. Kiran, K., Ansari, S.A., Srivastava, R., Lodhi, N., Chaturvedi, C.P., Sawant, 
S.V. and Tuli, R. (2006) The TATA-box sequence in the basal promoter 
contributes to determining light-dependent gene expression in plants. Plant 
Physiology, 142(1), 364-376.  
147. Kitamura, H. and Motohashi, H. (2018) NRF2 addiction in cancer cells. 
Cancer Science, 109(4), 900-911.  
148. Koenig, G. and Seneff, S., 2015. Gamma-Glutamyltransferase: A Predictive 
Biomarker Of Cellular Antioxidant Inadequacy And Disease Risk. 
149. Konaka, K., Sakurada, T., Saito, T., Mori, S., Imanishi, M., Kakiuchi, S., 
Fushitani, S. and Ishizawa, K. (2019) Study on the Optimal Dose of Irinotecan for 
Patients with Heterozygous Uridine Diphosphate-Glucuronosyltransferase 1A1 
(UGT1A1). Biological & Pharmaceutical Bulletin, 42(11), 1839-1845.  
150. Kraft, A.D., Johnson, D.A. and Johnson, J.A. (2004) Nuclear factor E2-related 
factor 2-dependent antioxidant response element activation by tert-
butylhydroquinone and sulforaphane occurring preferentially in astrocytes 
conditions neurons against oxidative insult. The Journal of Neuroscience : The 
Official Journal of the Society for Neuroscience, 24(5), 1101-1112.  
151. Kraichely, D.M., Collins, J.J.,3rd, DeLisle, R.K. and MacDonald, P.N. (1999) 
The autonomous transactivation domain in helix H3 of the vitamin D receptor is 
required for transactivation and coactivator interaction. The Journal of Biological 
Chemistry, 274(20), 14352-14358.  
152. Krasowski, M.D., Ai, N., Hagey, L.R., Kollitz, E.M., Kullman, S.W., Reschly, 




X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) 
and other non-mammalian species. BMC Biochemistry, 12, 5-2091-12-5.  
153. Krasowski, M.D., Yasuda, K., Hagey, L.R. and Schuetz, E.G. (2005) 
Evolutionary selection across the nuclear hormone receptor superfamily with a 
focus on the NR1I subfamily (vitamin D, pregnane X, and constitutive androstane 
receptors). Nuclear Receptor, 3, 2-1336-3-2.  
154. Krishnan, A.V., Shinghal, R., Raghavachari, N., Brooks, J.D., Peehl, D.M. and 
Feldman, D. (2004) Analysis of vitamin D-regulated gene expression in LNCaP 
human prostate cancer cells using cDNA microarrays. The Prostate, 59(3), 243-
251.  
155. Kubo, E., Chhunchha, B., Singh, P., Sasaki, H. and Singh, D.P. (2017) 
Sulforaphane reactivates cellular antioxidant defense by inducing 
Nrf2/ARE/Prdx6 activity during aging and oxidative stress. Scientific Reports, 
7(1), 14130-017-14520-8.  
156. Kutsuno, Y., Itoh, T., Tukey, R.H. and Fujiwara, R. (2014) Glucuronidation of 
drugs and drug-induced toxicity in humanized UDP-glucuronosyltransferase 1 
mice. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 42(7), 
1146-1152.  
157. Kutuzova, G.D. and DeLuca, H.F. (2007) 1,25-Dihydroxyvitamin D3 
regulates genes responsible for detoxification in intestine. Toxicology and Applied 
Pharmacology, 218(1), 37-44.  
158. Lacko, M., Oude Ophuis, M.B., Peters, W.H. and Manni, J.J. (2009) Genetic 
polymorphisms of smoking-related carcinogen detoxifying enzymes and head and 
neck cancer susceptibility. Anticancer Research, 29(2), 753-761.  
159. Lagishetty, V., Liu, N. and Hewison, M., 2011. Vitamin D Metabolism And 
Innate Immunity. 
160. Lazarus, P., Blevins-Primeau, A.S., Zheng, Y. and Sun, D. (2009) Potential 
role of UGT pharmacogenetics in cancer treatment and prevention: focus on 
tamoxifen. Annals of the New York Academy of Sciences, 1155, 99-111.  
161. Lee, W.C., Mokhtar, S.S., Munisamy, S., Yahaya, S. and Rasool, A.H.G. 
(2018) Vitamin D status and oxidative stress in diabetes mellitus. Cellular and 




162. Lehmann, J.M.(.1.)., Watson, M.A.(.1.)., Kliewer, S.A. ( 1,4 ), McKee, 
D.D.(.2.)., Moore, J.T.(.2.). and Willson, T.M.(.3.). (1998) The human orphan 
nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene 
expression and cause drug interactions. Journal of Clinical Investigation, 102(5), 
1016-1023.  
163. Levesque, E., Girard, H., Journault, K., Lepine, J. and Guillemette, C. (2007) 
Regulation of the UGT1A1 bilirubin-conjugating pathway: role of a new splicing 
event at the UGT1A locus. Hepatology (Baltimore, Md.), 45(1), 128-138.  
164. Levresse, V., Marek, L., Blumberg, D. and Heasley, L.E. (2002) Regulation of 
platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun 
signaling pathway in small-cell lung cancer cells. Molecular Pharmacology, 62(3), 
689-697.  
165. Li, F., Ling, X., Huang, H., Brattain, L., Apontes, P., Wu, J., Binderup, L. and 
Brattain, M.G. (2005) Differential regulation of survivin expression and apoptosis 
by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. 
Oncogene, 24(8), 1385-1395.  
166. Linus Pauling Institute. 2020. Vitamin D. [online] Available at: 
<https://lpi.oregonstate.edu/mic/vitamins/vitamin-D> [Accessed 8 April 2020]. 
167. Littlejohns, T.J., Henley, W.E., Lang, I.A., Annweiler, C., Beauchet, O., 
Chaves, P.H., Fried, L., Kestenbaum, B.R., Kuller, L.H., Langa, K.M., Lopez, 
O.L., Kos, K., Soni, M. and Llewellyn, D.J. (2014) Vitamin D and the risk of 
dementia and Alzheimer disease. Neurology, 83(10), 920-928.  
168. Liu, G.H., Qu, J. and Shen, X. (2008) NF-kappaB/p65 antagonizes Nrf2-ARE 
pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to 
MafK. Biochimica Et Biophysica Acta, 1783(5), 713-727.  
169. Liu, Y. and Coughtrie, M.W.H. (2017) Revisiting the Latency of Uridine 
Diphosphate-Glucuronosyltransferases (UGTs)-How Does the Endoplasmic 
Reticulum Membrane Influence Their Function? Pharmaceutics, 9(3), 
10.3390/pharmaceutics9030032.  
170. Liu, Z., Zhou, T., Ziegler, A.C., Dimitrion, P. and Zuo, L. (2017) Oxidative 
Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical 




171. Liu, Z.G., Jiang, G., Tang, J., Wang, H., Feng, G., Chen, F., Tu, Z., Liu, G., 
Zhao, Y., Peng, M.J., He, Z.W., Chen, X.Y., Lindsay, H., Xia, Y.F. and Li, X.N. 
(2016) c-Fos over-expression promotes radioresistance and predicts poor 
prognosis in malignant glioma. Oncotarget, 7(40), 65946-65956.  
172. Loboda, A., Damulewicz, M., Pyza, E., Jozkowicz, A. and Dulak, J. (2016) 
Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: 
an 73(17), 3221-3247.  
173. Lou, H., Du, S., Ji, Q. and Stolz, A. (2006) Induction of AKR1C2 by phase II 
inducers: identification of a distal consensus antioxidant response element 
regulated by NRF2. Molecular Pharmacology, 69(5), 1662-1672.  
174. Lu, K., Alcivar, A.L., Ma, J., Foo, T.K., Zywea, S., Mahdi, A., Huo, Y., 
Kensler, T.W., Gatza, M.L. and Xia, B. (2017) NRF2 Induction Supporting Breast 
Cancer Cell Survival Is Enabled by Oxidative Stress-Induced DPP3-KEAP1 
Interaction. Cancer Research, 77(11), 2881-2892.  
175. Luo, G., Cunningham, M., Kim, S., Burn, T., Lin, J., Sinz, M., Hamilton, G., 
Rizzo, C., Jolley, S., Gilbert, D., Downey, A., Mudra, D., Graham, R., Carroll, K., 
Xie, J., Madan, A., Parkinson, A., Christ, D., Selling, B., LeCluyse, E. and Gan, 
L.S. (2002) CYP3A4 induction by drugs: correlation between a pregnane X 
receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug 
Metabolism and Disposition: The Biological Fate of Chemicals, 30(7), 795-804.  
176. Luo, Y., Eggler, A.L., Liu, D., Liu, G., Mesecar, A.D. and van Breemen, R.B. 
(2007) Sites of alkylation of human Keap1 by natural chemoprevention agents. 
Journal of the American Society for Mass Spectrometry, 18(12), 2226-2232.  
177. Ma, J.Q., Tuersun, H., Jiao, S.J., Zheng, J.H., Xiao, J.B. and Hasim, A. (2015) 
Functional Role of NRF2 in Cervical Carcinogenesis. PloS One, 10(8), e0133876.  
178. Maguire, O., Pollock, C., Martin, P., Owen, A., Smyth, T., Doherty, D., 
Campbell, M.J., McClean, S. and Thompson, P. (2012) Regulation of CYP3A4 
and CYP3A5 expression and modulation of "intracrine" metabolism of androgens 
in prostate cells by liganded vitamin D receptor. Molecular and Cellular 
Endocrinology, 364(1-2), 54-64.  
179. Makishima, M., Lu, T.T., Xie, W., Whitfield, G.K., Domoto, H., Evans, R.M., 
Haussler, M.R. and Mangelsdorf, D.J. (2002) Vitamin D receptor as an intestinal 




180. Malfatti, M.A., Ubick, E.A. and Felton, J.S. (2005) The impact of 
glucuronidation on the bioactivation and DNA adduction of the cooked-food 
carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in vivo. 
Carcinogenesis, 26(11), 2019-2028.  
181. Marton, M., Tihanyi, N., Gyulavari, P., Banhegyi, G. and Kapuy, O. (2018) 
NRF2-regulated cell cycle arrest at early stage of oxidative stress response 
mechanism. PloS One, 13(11), e0207949.  
182. Masuno, H., Ikura, T., Morizono, D., Orita, I., Yamada, S., Shimizu, M. and 
Ito, N. (2013) Crystal structures of complexes of vitamin D receptor ligand-
binding domain with lithocholic acid derivatives. Journal of Lipid Research, 
54(8), 2206-2213.  
183. Mattevi, V.S. and Tagliari, C.F. (2017) Pharmacogenetic considerations in the 
treatment of HIV. Pharmacogenomics, 18(1), 85-98.  
184. McMullan, C.J., Borgi, L., Curhan, G.C., Fisher, N. and Forman, J.P. (2017) 
The effect of vitamin D on renin-angiotensin system activation and blood pressure: 
a randomized control trial. Journal of Hypertension, 35(4), 822-829.  
185. Meyer, M.B., Goetsch, P.D. and Pike, J.W. (2012) VDR/RXR and TCF4/beta-
catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and 
c-MYC gene expression. Molecular Endocrinology (Baltimore, Md.), 26(1), 37-
51.  
186. Morelli, S., Buitrago, C., Boland, R. and de Boland, A.R. (2001) The 
stimulation of MAP kinase by 1,25(OH)(2)-vitamin D(3) in skeletal muscle cells 
is mediated by protein kinase C and calcium. Molecular and Cellular 
Endocrinology, 173(1-2), 41-52.  
187. Morris, H.A. and Anderson, P.H. (2010) Autocrine and paracrine actions of 
vitamin d. The Clinical Biochemist.Reviews, 31(4), 129-138.  
188. Mottino, A.D. and Rodriguez Garay, E.A. (1987) Influence of uridine 
diphosphoglucuronic acid on bilirubin glucuronidation in liver microsomes from 
normal and spironolactone-treated rats. Acta Physiologica Et Pharmacologica 
Latinoamericana : Organo De La Asociacion Latinoamericana De Ciencias 





189. Mundy, G. and Guise, T., 2020. Hormonal Control Of Calcium Homeostasis. 
[online] Indiana University School of Medicine. Available at: 
<https://indiana.pure.elsevier.com/en/publications/hormonal-control-of-calcium-
homeostasis> [Accessed 9 April 2020]. 
190. Murphy, J.F., Hughes, I., Verrier Jones, E.R., Gaskell, S. and Pike, A.W. 
(1981) Pregnanediols and breast milk jaundice. Archives of Disease in Childhood, 
56(6), 474-476.  
191. Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E. Sulforaphane inhibits 
histone deacetylase in BPH-1, LNCaP and PC-3 prostate epithelial cells. 
Carcinogenesis. 2006;27:811–9. 
192. Myzak MC, Karplus PA, Chung FL, Dashwood RH. A novel mechanism of 
chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res. 
2004;64:5767–74. 
193. Nakai, K., Fujii, H., Kono, K., Goto, S., Kitazawa, R., Kitazawa, S., Hirata, 
M., Shinohara, M., Fukagawa, M. and Nishi, S. (2014) Vitamin D activates the 
Nrf2-Keap1 antioxidant pathway and ameliorates nephropathy in diabetic rats. 
American Journal of Hypertension, 27(4), 586-595.  
194. Nakamura, A., Nakajima, M., Yamanaka, H., Fujiwara, R. and Yokoi, T. 
(2008) Expression of UGT1A and UGT2B mRNA in human normal tissues and 
various cell lines. Drug Metabolism and Disposition: The Biological Fate of 
Chemicals, 36(8), 1461-1464.  
195. Narvaez, C.J., Matthews, D., LaPorta, E., Simmons, K.M., Beaudin, S. and 
Welsh, J. (2014) The impact of vitamin D in breast cancer: genomics, pathways, 
metabolism. Frontiers in Physiology, 5, 213.  
196. Nguyen, T.T., Ung, T.T., Kim, N.H. and Jung, Y.D. (2018) Role of bile acids 
in colon carcinogenesis. World Journal of Clinical Cases, 6(13), 577-588.  
197. Nioi, P., McMahon, M., Itoh, K., Yamamoto, M. and Hayes, J.D. (2003) 
Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the 
mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE 
consensus sequence. The Biochemical Journal, 374(Pt 2), 337-348.  
198. Nioi, P., Nguyen, T., Sherratt, P.J. and Pickett, C.B. (2005) The carboxy-
terminal Neh3 domain of Nrf2 is required for transcriptional activation. Molecular 




199. Norman, A.W. (2008) From vitamin D to hormone D: fundamentals of the 
vitamin D endocrine system essential for good health. The American Journal of 
Clinical Nutrition, 88(2), 491S-499S.  
200. Nutrition classics from The Journal of Biological Chemistry 15:167-175, 1913. 
The necessity of certain lipins in the diet during growth. By E. V. McCollum and 
Marguerite Davis. (1973) Nutrition Reviews, 31(9), 280-281.  
201. Oda, S., Kato, Y., Hatakeyama, M., Iwamura, A., Fukami, T., Kume, T., 
Yokoi, T. and Nakajima, M. (2017) Evaluation of expression and glycosylation 
status of UGT1A10 in Supersomes and intestinal epithelial cells with a novel 
specific UGT1A10 monoclonal antibody. Drug Metabolism and Disposition: The 
Biological Fate of Chemicals, 45(9), 1027-1034.  
202. Ohri, S., Sharma, D. and Dixit, A. (2002) Modulation of c-myc and c-fos gene 
expression in regenerating rat liver by 2-mercaptopropionylglycine. Cell Biology 
International, 26(2), 187-192.  
203. Onal, M., St John, H.C., Danielson, A.L., Markert, J.W., Riley, E.M. and Pike, 
J.W. (2016) Unique Distal Enhancers Linked to the Mouse Tnfsf11 Gene Direct 
Tissue-Specific and Inflammation-Induced Expression of RANKL. 
Endocrinology, 157(2), 482-496.  
204. Osanai, M. and Lee, G.H. (2016) CYP24A1-induced vitamin D insufficiency 
promotes breast cancer growth. Oncology Reports, 36(5), 2755-2762.  
205. Palmer, S.C., McGregor, D.O., Craig, J.C., Elder, G., Macaskill, P. and 
Strippoli, G.F. (2009) Vitamin D compounds for people with chronic kidney 
disease requiring dialysis. The Cochrane Database of Systematic Reviews, 
(4):CD005633. doi(4), CD005633.  
206. Pan, H., Wang, H., Wang, X., Zhu, L. and Mao, L. (2012) The absence of Nrf2 
enhances NF-kappaB-dependent inflammation following scratch injury in mouse 
primary cultured astrocytes. Mediators of Inflammation, 2012, 217580.  
207. Papageorgiou, I. and Court, M.H. (2017) Identification and validation of 
microRNAs directly regulating the UDP-glucuronosyltransferase 1A subfamily 
enzymes by a functional genomics approach. Biochemical Pharmacology, 137, 93-
106.  
208. Pascussi, J.M., Drocourt, L., Fabre, J.M., Maurel, P. and Vilarem, M.J. (2000) 




expression in human hepatocytes: Synergistic increase of CYP3A4 induction by 
pregnane X receptor activators. Molecular Pharmacology, 58(2), 361-372.  
209. Paul, S., Ghosh, S., Mandal, S., Sau, S. and Pal, M. (2018) NRF2 
transcriptionally activates the heat shock factor 1 promoter under oxidative stress 
and affects survival and migration potential of MCF7 cells. The Journal of 
Biological Chemistry, 293(50), 19303-19316.  
210. Pena, C., Garcia, J.M., Silva, J., Garcia, V., Rodriguez, R., Alonso, I., Millan, 
I., Salas, C., de Herreros, A.G., Munoz, A. and Bonilla, F. (2005) E-cadherin and 
vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: 
clinicopathological correlations. Human Molecular Genetics, 14(22), 3361-3370.  
211. Penner, N., Xu, L. and Prakash, C. (2012) Radiolabeled absorption, 
distribution, metabolism, and excretion studies in drug development: why, when, 
and how? Chemical Research in Toxicology, 25(3), 513-531.  
212. Penning, T.M. (2017) Aldo-Keto Reductase Regulation by the Nrf2 System: 
Implications for Stress Response, Chemotherapy Drug Resistance, and 
Carcinogenesis. Chemical Research in Toxicology, 30(1), 162-176.  
213. Petschnigg, J., Groisman, B., Kotlyar, M., Taipale, M., Zheng, Y., Kurat, C.F., 
Sayad, A., Sierra, J.R., Mattiazzi Usaj, M., Snider, J., Nachman, A., Krykbaeva, 
I., Tsao, M.S., Moffat, J., Pawson, T., Lindquist, S., Jurisica, I. and Stagljar, I. 
(2014) The mammalian-membrane two-hybrid assay (MaMTH) for probing 
membrane-protein interactions in human cells. Nature Methods, 11(5), 585-592.  
214. Pike, J.W. (2011) Genome-wide principles of gene regulation by the vitamin 
D receptor and its activating ligand. Molecular and Cellular Endocrinology, 
347(1-2), 3-10.  
215. Pike, J.W. and Meyer, M.B. (2012) The vitamin D receptor: new paradigms 
for the regulation of gene expression by 1,25-dihydroxyvitamin D3. Rheumatic 
Diseases Clinics of North America, 38(1), 13-27.  
216. Pike, J.W., Meyer, M.B., Benkusky, N.A., Lee, S.M., St John, H., Carlson, A., 
Onal, M. and Shamsuzzaman, S. (2016) Genomic Determinants of Vitamin D-
Regulated Gene Expression. Vitamins and Hormones, 100, 21-44.  
217. Prevostel, C., Rammah-Bouazza, C., Trauchessec, H., Canterel-Thouennon, 




tumor suppressor controlling the oncogenic Wnt/ss-catenin signaling. Oncotarget, 
7(50), 82228-82243.  
218. Priemel, M., von Domarus, C., Klatte, T.O., Kessler, S., Schlie, J., Meier, S., 
Proksch, N., Pastor, F., Netter, C., Streichert, T., Puschel, K. and Amling, M. 
(2010) Bone mineralization defects and vitamin D deficiency: histomorphometric 
analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 
patients. Journal of Bone and Mineral Research : The Official Journal of the 
American Society for Bone and Mineral Research, 25(2), 305-312.  
219. Protiva, P., Cross, H.S., Hopkins, M.E., Kallay, E., Bises, G., Dreyhaupt, E., 
Augenlicht, L., Lipkin, M., Lesser, M., Livote, E. and Holt, P.R. (2009) 
Chemoprevention of colorectal neoplasia by estrogen: potential role of vitamin D 
activity. Cancer Prevention Research (Philadelphia, Pa.), 2(1), 43-51.  
220. Rachez, C., Gamble, M., Chang, C.P., Atkins, G.B., Lazar, M.A. and 
Freedman, L.P. (2000) The DRIP complex and SRC-1/p160 coactivators share 
similar nuclear receptor binding determinants but constitute functionally distinct 
complexes. Molecular and Cellular Biology, 20(8), 2718-2726.  
221. Radominska-Pandya, A., Bratton, S.M., Redinbo, M.R. and Miley, M.J. (2010) 
The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end 
is the first mammalian UGT target to be revealed: the significance for human 
UGTs from both the 1A and 2B families. Drug Metabolism Reviews, 42(1), 133-
144.  
222. Ramagopalan, S.V., Heger, A., Berlanga, A.J., Maugeri, N.J., Lincoln, M.R., 
Burrell, A., Handunnetthi, L., Handel, A.E., Disanto, G., Orton, S.M., Watson, 
C.T., Morahan, J.M., Giovannoni, G., Ponting, C.P., Ebers, G.C. and Knight, J.C. 
(2010) A ChIP-seq defined genome-wide map of vitamin D receptor binding: 
associations with disease and evolution. Genome Research, 20(10), 1352-1360.  
223. Ramchandani, R.P., Wang, Y., Booth, B.P., Ibrahim, A., Johnson, J.R., 
Rahman, A., Mehta, M., Innocenti, F., Ratain, M.J. and Gobburu, J.V. (2007) The 
role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level 
in predicting severe irinotecan toxicity. Journal of Clinical Pharmacology, 47(1), 
78-86.  
224. Raynal, C., Pascussi, J.M., Leguelinel, G., Breuker, C., Kantar, J., Lallemant, 




and Evrard, A. (2010) Pregnane X Receptor (PXR) expression in colorectal cancer 
cells restricts irinotecan chemosensitivity through enhanced SN-38 
glucuronidation. Molecular Cancer, 9, 46-4598-9-46.  
225. Reschly, E.J. and Krasowski, M.D. (2006) Evolution and function of the NR1I 
nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to 
metabolism of xenobiotics and endogenous compounds. Current Drug 
Metabolism, 7(4), 349-365.  
226. Ribeiro, L.F., Ribeiro, L.F.C., Barreto, M.Q. and Ward, R.J. (2018) Protein 
Engineering Strategies to Expand CRISPR-Cas9 Applications. International 
Journal of Genomics, 2018, 1652567.  
227. Riera, P., Salazar, J., Virgili, A.C., Tobena, M., Sebio, A., Gallano, P., 
Barnadas, A. and Paez, D. (2018) Relevance of CYP3A4*20, UGT1A1*37 and 
UGT1A1*28 variants in irinotecan-induced severe toxicity. British Journal of 
Clinical Pharmacology, 84(6), 1389-1392.  
228. Roizen, J.D., Casella, A., Lai, M., Long, C., Tara, Z., Caplan, I., O'Lear, L. 
and Levine, M.A. (2018) Decreased Serum 25-Hydroxyvitamin D in Aging Male 
Mice Is Associated With Reduced Hepatic Cyp2r1 Abundance. Endocrinology, 
159(8), 3083-3089.  
229. Rondini, E.A., Fang, H., Runge-Morris, M. and Kocarek, T.A. (2014) 
Regulation of human cytosolic sulfotransferases 1C2 and 1C3 by nuclear signaling 
pathways in LS180 colorectal adenocarcinoma cells. Drug Metabolism and 
Disposition: The Biological Fate of Chemicals, 42(3), 361-368.  
230. Rouleau, M., Collin, P., Bellemare, J., Harvey, M. and Guillemette, C. (2013) 
Protein-protein interactions between the bilirubin-conjugating UDP-
glucuronosyltransferase UGT1A1 and its shorter isoform 2 regulatory partner 
derived from alternative splicing. The Biochemical Journal, 450(1), 107-114.  
231. Rowland, n., Miners, J. and Mackenzie, P., 2020. UDP-
Glucuronosyltransferases : Their Role In Drug Metabolism And Etoxification. 
[online] Semanticscholar.org. Available at: 
<https://www.semanticscholar.org/paper/UDP-glucuronosyltransferases-%3A-
Their-role-in-drug-Rowland-





232. Royalsocietypublishing.org. 2020. Crystalline Vitamin D | Proceedings Of The 
Royal Society Of London. Series B, Containing Papers Of A Biological Character. 
[online] Available at: 
<https://royalsocietypublishing.org/doi/10.1098/rspb.1932.0008> [Accessed 9 
April 2020]. 
233. Ryan, J.W., Anderson, P.H. and Morris, H.A. (2015) Pleiotropic Activities of 
Vitamin D Receptors - Adequate Activation for Multiple Health Outcomes. The 
Clinical Biochemist.Reviews, 36(2), 53-61.  
234. Ryan, J.W., Reinke, D., Kogawa, M., Turner, A.G., Atkins, G.J., Anderson, 
P.H. and Morris, H.A. (2013) Novel targets of vitamin D activity in bone: action 
of the vitamin D receptor in osteoblasts, osteocytes and osteoclasts. Current Drug 
Targets, 14(14), 1683-1688.  
235. Ryu, H., Lee, J., Zaman, K., Kubilis, J., Ferrante, R.J., Ross, B.D., Neve, R. 
and Ratan, R.R. (2003) Sp1 and Sp3 are oxidative stress-inducible, antideath 
transcription factors in cortical neurons. The Journal of Neuroscience : The 
Official Journal of the Society for Neuroscience, 23(9), 3597-3606.  
236. Saeki, M., Kurose, K., Tohkin, M. and Hasegawa, R. (2008) Identification of 
the functional vitamin D response elements in the human MDR1 gene. 
Biochemical Pharmacology, 76(4), 531-542.  
237. Saini, S.P., Mu, Y., Gong, H., Toma, D., Uppal, H., Ren, S., Li, S., Poloyac, 
S.M. and Xie, W. (2005) Dual role of orphan nuclear receptor pregnane X receptor 
in bilirubin detoxification in mice. Hepatology (Baltimore, Md.), 41(3), 497-505.  
238. Sakakibara, Y., Katoh, M., Imai, K., Kondo, Y., Asai, Y., Ikushiro, S. and 
Nadai, M. (2016) Expression of UGT1A subfamily in rat brain. Biopharmaceutics 
& Drug Disposition, 37(5), 314-319.  
239. Sampietro, M. and Iolascon, A. (1999) Molecular pathology of Crigler-Najjar 
type I and II and Gilbert's syndromes. Haematologica, 84(2), 150-157.  
240. Sanchez-Dominguez, C.N., Gallardo-Blanco, H.L., Salinas-Santander, M.A. 
and Ortiz-Lopez, R. (2018) Uridine 5'-diphospho-glucronosyltrasferase: Its role in 
pharmacogenomics and human disease. Experimental and Therapeutic Medicine, 
16(1), 3-11.  
241. Sanchez-Dominguez, C.N., Gallardo-Blanco, H.L., Salinas-Santander, M.A. 




pharmacogenomics and human disease. Experimental and Therapeutic Medicine, 
16(1), 3-11.  
242. Santoro, A.B., Vargens, D.D., Barros Filho Mde, C., Bulzico, D.A., Kowalski, 
L.P., Meirelles, R.M., Paula, D.P., Neves, R.R., Pessoa, C.N., Struchine, C.J. and 
Suarez-Kurtz, G. (2014) Effect of UGT1A1, UGT1A3, DIO1 and DIO2 
polymorphisms on L-thyroxine doses required for TSH suppression in patients 
with differentiated thyroid cancer. British Journal of Clinical Pharmacology, 
78(5), 1067-1075.  
243. Schmiedlin-Ren, P., Thummel, K.E., Fisher, J.M., Paine, M.F., Lown, K.S. 
and Watkins, P.B. (1997) Expression of enzymatically active CYP3A4 by Caco-2 
cells grown on extracellular matrix-coated permeable supports in the presence of 
1alpha,25-dihydroxyvitamin D3. Molecular Pharmacology, 51(5), 741-754.  
244. Schwab, M., Reynders, V., Loitsch, S., Steinhilber, D., Schroder, O. and Stein, 
J. (2008) The dietary histone deacetylase inhibitor sulforaphane induces human 
beta-defensin-2 in intestinal epithelial cells. Immunology, 125(2), 241-251.  
245. Seldon, M.P., Silva, G., Pejanovic, N., Larsen, R., Gregoire, I.P., Filipe, J., 
Anrather, J. and Soares, M.P. (2007) Heme oxygenase-1 inhibits the expression of 
adhesion molecules associated with endothelial cell activation via inhibition of 
NF-kappaB RelA phosphorylation at serine 276. Journal of Immunology 
(Baltimore, Md.: 1950), 179(11), 7840-7851.  
246. Seo, Y.K., Mirkheshti, N., Song, C.S., Kim, S., Dodds, S., Ahn, S.C., Christy, 
B., Mendez-Meza, R., Ittmann, M.M., Abboud-Werner, S. and Chatterjee, B. 
(2013) SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced 
expression in prostate cancer. Molecular Endocrinology (Baltimore, Md.), 27(6), 
925-939.   
247. Seuter, S., Neme, A. and Carlberg, C. (2017) Epigenomic PU.1-VDR crosstalk 
modulates vitamin D signaling. Biochimica Et Biophysica Acta.Gene Regulatory 
Mechanisms, 1860(4), 405-415.  
248. Shen, G. and Kong, A.N. (2009) Nrf2 plays an important role in coordinated 
regulation of Phase II drug metabolism enzymes and Phase III drug transporters. 
Biopharmaceutics & Drug Disposition, 30(7), 345-355.  
249. Shen, J., Rasmussen, M., Dong, Q.R., Tepel, M. and Scholze, A. (2017) 




Human Chronic Kidney Disease. Oxidative Medicine and Cellular Longevity, 
2017, 9091879.  
250. Shigematsu, T., Horiuchi, N., Ogura, Y., Miyahara, T. and Suda, T. (1986) 
Human parathyroid hormone inhibits renal 24-hydroxylase activity of 25-
hydroxyvitamin D3 by a mechanism involving adenosine 3',5'-monophosphate in 
rats. Endocrinology, 118(4), 1583-1589.  
251. Shin, J. et al., 2010. Vitamin D effects on pregnancy and the placenta. 
Placenta, 31(12), pp.1027–1034. 
252. Singh, R.P. and Agarwal, R. (2005) Prostate cancer and inositol 
hexaphosphate: efficacy and mechanisms. Anticancer Research, 25(4), 2891-
2903.  
253. Sita, G., Hrelia, P., Tarozzi, A. and Morroni, F. (2016) Isothiocyanates Are 
Promising Compounds against Oxidative Stress, Neuroinflammation and Cell 
Death that May Benefit Neurodegeneration in Parkinson's Disease. International 
Journal of Molecular Sciences, 17(9), 10.3390/ijms17091454.  
254. Sonoda, J., Pei, L. and Evans, R.M. (2008) Nuclear receptors: decoding 
metabolic disease. FEBS Letters, 582(1), 2-9.  
255. Spiro, A. and Buttriss, J.L. (2014) Vitamin D: An overview of vitamin D status 
and intake in Europe. Nutrition Bulletin, 39(4), 322-350.  
256. Sridar, C., Hanna, I. and Hollenberg, P.F. (2013) Quantitation of UGT1A1 in 
human liver microsomes using stable isotope-labelled peptides and mass 
spectrometry based proteomic approaches. Xenobiotica; the Fate of Foreign 
Compounds in Biological Systems, 43(4), 336-345.  
257. Stees, J.S., Varn, F., Huang, S., Strouboulis, J. and Bungert, J. (2012) 
Recruitment of transcription complexes to enhancers and the role of enhancer 
transcription. Biology, 1(3), 778-793.  
258. Strassburg, C.P., Manns, M.P. and Tukey, R.H. (1998) Expression of the UDP-
glucuronosyltransferase 1A locus in human colon. Identification and 
characterization of the novel extrahepatic UGT1A8. The Journal of Biological 
Chemistry, 273(15), 8719-8726.  
259. Strassburg, C.P., Nguyen, N., Manns, M.P. and Tukey, R.H. (1998) 
Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus 




260. Strassburg, C.P., Oldhafer, K., Manns, M.P. and Tukey, R.H. (1997) 
Differential expression of the UGT1A locus in human liver, biliary, and gastric 
tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. 
Molecular Pharmacology, 52(2), 212-220.  
261. Strassburg, C.P., Strassburg, A., Kneip, S., Barut, A., Tukey, R.H., Rodeck, B. 
and Manns, M.P. (2002) Developmental aspects of human hepatic drug 
glucuronidation in young children and adults. Gut, 50(2), 259-265.  
262. Strassburg, C.P., Strassburg, A., Nguyen, N., Li, Q., Manns, M.P. and Tukey, 
R.H. (1999) Regulation and function of family 1 and family 2 UDP-
glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. The 
Biochemical Journal, 338 ( Pt 2)(Pt 2), 489-498.  
263. Strassburg, C.P., Vogel, A., Kneip, S., Tukey, R.H. and Manns, M.P. (2002) 
Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in 
colorectal cancer. Gut, 50(6), 851-856.  
264. Sueyoshi, T. and Negishi, M. (2001) Phenobarbital response elements of 
cytochrome P450 genes and nuclear receptors. Annual Review of Pharmacology 
and Toxicology, 41, 123-143.  
265. Sugatani, J., Mizushima, K., Osabe, M., Yamakawa, K., Kakizaki, S., Takagi, 
H., Mori, M., Ikari, A. and Miwa, M. (2008) Transcriptional regulation of human 
UGT1A1 gene expression through distal and proximal promoter motifs: 
implication of defects in the UGT1A1 gene promoter. Naunyn-Schmiedeberg's 
Archives of Pharmacology, 377(4-6), 597-605.  
266. Sugatani, J., Sueyoshi, T., Negishi, M. and Miwa, M. (2005) Regulation of the 
human UGT1A1 gene by nuclear receptors constitutive active/androstane 
receptor, pregnane X receptor, and glucocorticoid receptor. Methods in 
Enzymology, 400, 92-104.  
267. Sugatani, J., Uchida, T., Kurosawa, M., Yamaguchi, M., Yamazaki, Y., Ikari, 
A. and Miwa, M. (2012) Regulation of pregnane X receptor (PXR) function and 
UGT1A1 gene expression by posttranslational modification of PXR protein. Drug 
Metabolism and Disposition: The Biological Fate of Chemicals, 40(10), 2031-
2040.  
268. Sugatani, J., Yamakawa, K., Tonda, E., Nishitani, S., Yoshinari, K., Degawa, 




glucuronosyltransferase 1A1 mediated through a distal enhancer module by 
flavonoids and xenobiotics. Biochemical Pharmacology, 67(5), 989-1000.  
269. Sumida, K., Kawana, M., Kouno, E., Itoh, T., Takano, S., Narawa, T., Tukey, 
R.H. and Fujiwara, R. (2013) Importance of UDP-glucuronosyltransferase 1A1 
expression in skin and its induction by UVB in neonatal hyperbilirubinemia. 
Molecular Pharmacology, 84(5), 679-686.  
270. Sun, L., Li, M., Zhang, L., Teng, X., Chen, X., Zhou, X., Ma, Z., Qi, L. and 
Wang, P. (2017) Differences in UGT1A1 gene mutations and pathological liver 
changes between Chinese patients with Gilbert syndrome and Crigler-Najjar 
syndrome type II. Medicine, 96(45), e8620.  
271. Sutiman, N., Lim, J.S.L., Muerdter, T.E., Singh, O., Cheung, Y.B., Ng, R.C.H., 
Yap, Y.S., Wong, N.S., Ang, P.C.S., Dent, R., Schroth, W., Schwab, M., Khor, 
C.C. and Chowbay, B. (2016) Pharmacogenetics of UGT1A4, UGT2B7 and 
UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer 
Patients. Clinical Pharmacokinetics, 55(10), 1239-1250.  
272. Suzuki, T., Mihara, K., Nagai, G., Kagawa, S., Nakamura, A., Nemoto, K. and 
Kondo, T. (2019) Relationship Between UGT1A4 and UGT2B7 Polymorphisms 
and the Steady-State Plasma Concentrations of Lamotrigine in Patients With 
Treatment-Resistant Depressive Disorder Receiving Lamotrigine as 
Augmentation Therapy. Therapeutic Drug Monitoring, 41(1), 86-90.  
273. Swami, S., Raghavachari, N., Muller, U.R., Bao, Y.P. and Feldman, D. (2003) 
Vitamin D growth inhibition of breast cancer cells: gene expression patterns 
assessed by cDNA microarray. Breast Cancer Research and Treatment, 80(1), 49-
62.  
274. Takahashi, N., Udagawa, N. and Suda, T. (2014) Vitamin D endocrine system 
and osteoclasts. BoneKEy Reports, 3, 495.  
275. Tan, J.S., Mohandas, N. and Conboy, J.G. (2006) High frequency of alternative 
first exons in erythroid genes suggests a critical role in regulating gene function. 
Blood, 107(6), 2557-2561.  
276. Tan, K.P., Yang, M. and Ito, S. (2007) Activation of nuclear factor (erythroid-
2 like) factor 2 by toxic bile acids provokes adaptive defense responses to enhance 





277. Tang, W., Fu, Y.P., Figueroa, J.D., Malats, N., Garcia-Closas, M., Chatterjee, 
N., Kogevinas, M., Baris, D., Thun, M., Hall, J.L., De Vivo, I., Albanes, D., Porter-
Gill, P., Purdue, M.P., Burdett, L., Liu, L., Hutchinson, A., Myers, T., Tardon, A., 
Serra, C., Carrato, A., Garcia-Closas, R., Lloreta, J., Johnson, A., Schwenn, M., 
Karagas, M.R., Schned, A., Black, A., Jacobs, E.J., Diver, W.R., Gapstur, S.M., 
Virtamo, J., Hunter, D.J., Fraumeni, J.F.,Jr, Chanock, S.J., Silverman, D.T., 
Rothman, N. and Prokunina-Olsson, L. (2012) Mapping of the UGT1A locus 
identifies an uncommon coding variant that affects mRNA expression and protects 
from bladder cancer. Human Molecular Genetics, 21(8), 1918-1930.  
278. Tebay, L.E., Robertson, H., Durant, S.T., Vitale, S.R., Penning, T.M., 
Dinkova-Kostova, A.T. and Hayes, J.D. (2015) Mechanisms of activation of the 
transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and 
the pathways through which it attenuates degenerative disease. Free Radical 
Biology & Medicine, 88(Pt B), 108-146.  
279. Tebben, P.J., Singh, R.J. and Kumar, R. (2016) Vitamin D-Mediated 
Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Endocrine Reviews, 
37(5), 521-547.  
280. Tebben, P.J., Singh, R.J. and Kumar, R. (2016) Vitamin D-Mediated 
Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Endocrine Reviews, 
37(5), 521-547.  
281. Teichert, A., Arnold, L.A., Otieno, S., Oda, Y., Augustinaite, I., Geistlinger, 
T.R., Kriwacki, R.W., Guy, R.K. and Bikle, D.D. (2009) Quantification of the 
vitamin D receptor-coregulator interaction. Biochemistry, 48(7), 1454-1461.  
282. Teixeira, T.M., da Costa, D.C., Resende, A.C., Soulage, C.O., Bezerra, F.F. 
and Daleprane, J.B. (2017) Activation of Nrf2-Antioxidant Signaling by 1,25-
Dihydroxycholecalciferol Prevents Leptin-Induced Oxidative Stress and 
Inflammation in Human Endothelial Cells. The Journal of Nutrition, 147(4), 506-
513.  
283. Thimmulappa, R.K., Lee, H., Rangasamy, T., Reddy, S.P., Yamamoto, M., 
Kensler, T.W. and Biswal, S. (2006) Nrf2 is a critical regulator of the innate 
immune response and survival during experimental sepsis. The Journal of Clinical 




284. Thompson, P.D., Jurutka, P.W., Whitfield, G.K., Myskowski, S.M., Eichhorst, 
K.R., Dominguez, C.E., Haussler, C.A. and Haussler, M.R. (2002) Liganded VDR 
induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 
vitamin D responsive elements. Biochemical and Biophysical Research 
Communications, 299(5), 730-738.  
285. Thompson, P.D., Jurutka, P.W., Whitfield, G.K., Myskowski, S.M., Eichhorst, 
K.R., Dominguez, C.E., Haussler, C.A. and Haussler, M.R. (2002) Liganded VDR 
induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 
vitamin D responsive elements. Biochemical and Biophysical Research 
Communications, 299(5), 730-738.  
286. Thummel, K.E., Brimer, C., Yasuda, K., Thottassery, J., Senn, T., Lin, Y., 
Ishizuka, H., Kharasch, E., Schuetz, J. and Schuetz, E. (2001) Transcriptional 
control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. 
Molecular Pharmacology, 60(6), 1399-1406.  
287. Tian, H., Li, X., Jiang, W., Lv, C., Sun, W., Huang, C. and Chen, R. (2016) 
High expression of AKR1C1 is associated with proliferation and migration of 
small-cell lung cancer cells. Lung Cancer (Auckland, N.Z.), 7, 53-61.  
288. To, C., Ringelberg, C.S., Royce, D.B., Williams, C.R., Risingsong, R., Sporn, 
M.B. and Liby, K.T. (2015) Dimethyl fumarate and the oleanane triterpenoids, 
CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but 
have opposite effects in the A/J model of lung carcinogenesis. Carcinogenesis, 
36(7), 769-781.  
289. Tong, K.I., Kobayashi, A., Katsuoka, F. and Yamamoto, M. (2006) Two-site 
substrate recognition model for the Keap1-Nrf2 system: a hinge and latch 
mechanism. Biological Chemistry, 387(10-11), 1311-1320.  
290. Torino, C., Pizzini, P., Cutrupi, S., Tripepi, R., Vilasi, A., Tripepi, G., 
Mallamaci, F. and Zoccali, C. (2017) Effect of Vitamin D Receptor Activation on 
the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease 
Patients. Oxidative Medicine and Cellular Longevity, 2017, 2801324.  
291. Tripkovic, L., Lambert, H., Hart, K., Smith, C.P., Bucca, G., Penson, S., 
Chope, G., Hypponen, E., Berry, J., Vieth, R. and Lanham-New, S. (2012) 




hydroxyvitamin D status: a systematic review and meta-analysis. The American 
Journal of Clinical Nutrition, 95(6), 1357-1364.  
292. Tsujikawa, H., Kurotaki, Y., Fujimori, T., Fukuda, K. and Nabeshima, Y., 
2003. Klotho, A Gene Related To A Syndrome Resembling Human Premature 
Aging, Functions In A Negative Regulatory Circuit Of Vitamin D Endocrine 
System. 
293. Tukey, R.H. and Strassburg, C.P. (2000) Human UDP-
glucuronosyltransferases: metabolism, expression, and disease. Annual Review of 
Pharmacology and Toxicology, 40, 581-616.  
294. Turgeon, D., Carrier, J.S., Levesque, E., Hum, D.W. and Belanger, A. (2001) 
Relative enzymatic activity, protein stability, and tissue distribution of human 
steroid-metabolizing UGT2B subfamily members. Endocrinology, 142(2), 778-
787.  
295. Ullah, S., Rahman, K. and Hedayati, M. (2016) Hyperbilirubinemia in 
Neonates: Types, Causes, Clinical Examinations, Preventive Measures and 
Treatments: A Narrative Review Article. Iranian Journal of Public Health, 45(5), 
558-568.  
296. Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T., Mazur, M. and Telser, J. 
(2007) Free radicals and antioxidants in normal physiological functions and human 
disease. The International Journal of Biochemistry & Cell Biology, 39(1), 44-84.  
297. VanWagner, L.B. and Green, R.M. (2015) Evaluating elevated bilirubin levels 
in asymptomatic adults. Jama, 313(5), 516-517.  
298. Veldurthy, V., Wei, R., Oz, L., Dhawan, P., Jeon, Y.H. and Christakos, S. 
(2016) Vitamin D, calcium homeostasis and aging. Bone Research, 4, 16041.  
299. Verreault, M., Senekeo-Effenberger, K., Trottier, J., Bonzo, J.A., Belanger, J., 
Kaeding, J., Staels, B., Caron, P., Tukey, R.H. and Barbier, O. (2006) The liver X-
receptor alpha controls hepatic expression of the human bile acid-glucuronidating 
UGT1A3 enzyme in human cells and transgenic mice. Hepatology (Baltimore, 
Md.), 44(2), 368-378.  
300. Vomund, S., Schafer, A., Parnham, M.J., Brune, B. and von Knethen, A. 
(2017) Nrf2, the Master Regulator of Anti-Oxidative Responses. International 




301. Vukic, M., Neme, A., Seuter, S., Saksa, N., de Mello, V.D., Nurmi, T., 
Uusitupa, M., Tuomainen, T.P., Virtanen, J.K. and Carlberg, C. (2015) Relevance 
of vitamin D receptor target genes for monitoring the vitamin D responsiveness of 
primary human cells. PloS One, 10(4), e0124339.  
302. Vukovic, M., Radlovic, N., Lekovic, Z., Vucicevic, K., Maric, N., Kotur, N., 
Gasic, V., Ugrin, M., Stojiljkovic, M., Dokmanovic, L., Zukic, B. and Pavlovic, 
S. (2018) UGT1A1 (TA)n Promoter Genotype: Diagnostic and Population 
Pharmacogenetic Marker in Serbia. Balkan Journal of Medical Genetics : BJMG, 
21(1), 59-68.  
303. Wagner, K.H., Shiels, R.G., Lang, C.A., Seyed Khoei, N. and Bulmer, A.C. 
(2018) Diagnostic criteria and contributors to Gilbert's syndrome. Critical Reviews 
in Clinical Laboratory Sciences, 55(2), 129-139.  
304. Wagner, M., Halilbasic, E., Marschall, H.U., Zollner, G., Fickert, P., Langner, 
C., Zatloukal, K., Denk, H. and Trauner, M. (2005) CAR and PXR agonists 
stimulate hepatic bile acid and bilirubin detoxification and elimination pathways 
in mice. Hepatology (Baltimore, Md.), 42(2), 420-430.  
305. Wakabayashi, N., Chartoumpekis, D.V. and Kensler, T.W. (2015) Crosstalk 
between Nrf2 and Notch signaling. Free Radical Biology & Medicine, 88(Pt B), 
158-167.  
306. Wakabayashi, N., Dinkova-Kostova, A.T., Holtzclaw, W.D., Kang, M.I., 
Kobayashi, A., Yamamoto, M., Kensler, T.W. and Talalay, P. (2004) Protection 
against electrophile and oxidant stress by induction of the phase 2 response: fate 
of cysteines of the Keap1 sensor modified by inducers. Proceedings of the 
National Academy of Sciences of the United States of America, 101(7), 2040-2045.  
307. Wallace, B.D., Betts, L., Talmage, G., Pollet, R.M., Holman, N.S. and 
Redinbo, M.R. (2013) Structural and functional analysis of the human nuclear 
xenobiotic receptor PXR in complex with RXRalpha. Journal of Molecular 
Biology, 425(14), 2561-2577.  
308. Walle, T., Otake, Y., Galijatovic, A., Ritter, J.K. and Walle, U.K. (2000) 
Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in 
the human hepatoma cell line hep G2. Drug Metabolism and Disposition: The 




309. Wang, H., Bian, T., Jin, T., Chen, Y., Lin, A. and Chen, C. (2014) Association 
analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human 
livers. Pharmacogenomics, 15(6), 785-798.  
310. Wang, L., Zhou, S. and Guo, B. (2020) Vitamin D Suppresses Ovarian Cancer 
Growth and Invasion by Targeting Long Non-Coding RNA CCAT2. International 
Journal of Molecular Sciences, 21(7), 10.3390/ijms21072334.  
311. Wang, M., Li, Y.Q., Zhong, N., Chen, J., Xu, X.Q. and Yuan, M.B. (2005) 
Induction of uridine 5'-diphosphate-glucuronosyltransferase gene expression by 
sulforaphane and its mechanism: experimental study in human colon cancel cells. 
Zhonghua Yi Xue Za Zhi, 85(12), 819-824.  
312. Wang, M., Li, Y.Q., Zhong, N., Chen, J., Xu, X.Q. and Yuan, M.B. (2005) 
Induction of uridine 5'-diphosphate-glucuronosyltransferase gene expression by 
sulforaphane and its mechanism: experimental study in human colon cancel cells. 
Zhonghua Yi Xue Za Zhi, 85(12), 819-824.  
313. Wang, T.T., Tavera-Mendoza, L.E., Laperriere, D., Libby, E., MacLeod, N.B., 
Nagai, Y., Bourdeau, V., Konstorum, A., Lallemant, B., Zhang, R., Mader, S. and 
White, J.H. (2005) Large-scale in silico and microarray-based identification of 
direct 1,25-dihydroxyvitamin D3 target genes. Molecular Endocrinology 
(Baltimore, Md.), 19(11), 2685-2695.  
314. Wang, X., Wang, H., Shen, B., Overholser, B.R., Cooper, B.R., Lu, Y., Tang, 
H., Zhou, C., Sun, X., Zhong, L., Favus, M.J., Decker, B.S., Liu, W. and Peng, Z. 
(2016) 1-Alpha, 25-dihydroxyvitamin D3 alters the pharmacokinetics of 
mycophenolic acid in renal transplant recipients by regulating two extrahepatic 
UDP-glucuronosyltransferases 1A8 and 1A10. Translational Research : The 
Journal of Laboratory and Clinical Medicine, 178, 54-62.e6.  
315. Wang, Y., Shen, L., Xu, N., Wang, J.W., Jiao, S.C., Liu, Z.Y. and Xu, J.M. 
(2012) UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and 
fluorouracil. World Journal of Gastroenterology, 18(45), 6635-6644.  
316. Wang, Z., Schuetz, E.G., Xu, Y. and Thummel, K.E. (2013) Interplay between 
vitamin D and the drug metabolizing enzyme CYP3A4. The Journal of Steroid 
Biochemistry and Molecular Biology, 136, 54-58.  
317. Wang, Z., Wong, T., Hashizume, T., Dickmann, L.Z., Scian, M., Koszewski, 




(2014) Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3: 
metabolite structure, kinetics, inducibility, and interindividual variability. 
Endocrinology, 155(6), 2052-2063.  
318. Wardyn, J.D., Ponsford, A.H. and Sanderson, C.M. (2015) Dissecting 
molecular cross-talk between Nrf2 and NF-kappaB response pathways. 
Biochemical Society Transactions, 43(4), 621-626.  
319. Watai, Y., Kobayashi, A., Nagase, H., Mizukami, M., McEvoy, J., Singer, J.D., 
Itoh, K. and Yamamoto, M. (2007) Subcellular localization and cytoplasmic 
complex status of endogenous Keap1. Genes to Cells : Devoted to Molecular & 
Cellular Mechanisms, 12(10), 1163-1178.  
320. Webb, A.R., DeCosta, B.R. and Holick, M.F. (1989) Sunlight regulates the 
cutaneous production of vitamin D3 by causing its photodegradation. The Journal 
of Clinical Endocrinology and Metabolism, 68(5), 882-887.  
321. Weerachayaphorn, J., Mennone, A., Soroka, C.J., Harry, K., Hagey, L.R., 
Kensler, T.W. and Boyer, J.L. (2012) Nuclear factor-E2-related factor 2 is a major 
determinant of bile acid homeostasis in the liver and intestine. American Journal 
of Physiology.Gastrointestinal and Liver Physiology, 302(9), G925-36.  
322. Wong, C.H. and Ko, W.H. (2002) Stimulation of Cl- secretion via membrane-
restricted Ca2+ signaling mediated by P2Y receptors in polarized epithelia. The 
Journal of Biological Chemistry, 277(11), 9016-9021.  
323. Wu, K.C., McDonald, P.R., Liu, J. and Klaassen, C.D. (2014) Screening of 
natural compounds as activators of the keap1-nrf2 pathway. Planta Medica, 80(1), 
97-104.  
324. Wu, R.P., Hayashi, T., Cottam, H.B., Jin, G., Yao, S., Wu, C.C., Rosenbach, 
M.D., Corr, M., Schwab, R.B. and Carson, D.A. (2010) Nrf2 responses and the 
therapeutic selectivity of electrophilic compounds in chronic lymphocytic 
leukemia. Proceedings of the National Academy of Sciences of the United States 
of America, 107(16), 7479-7484.  
325. Xiang, W., Kong, J., Chen, S., Cao, L.P., Qiao, G., Zheng, W., Liu, W., Li, X., 
Gardner, D.G. and Li, Y.C. (2005) Cardiac hypertrophy in vitamin D receptor 
knockout mice: role of the systemic and cardiac renin-angiotensin systems. 





326. Xie, W., Yeuh, M.F., Radominska-Pandya, A., Saini, S.P., Negishi, Y., 
Bottroff, B.S., Cabrera, G.Y., Tukey, R.H. and Evans, R.M. (2003) Control of 
steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and 
constitutive androstane receptor. Proceedings of the National Academy of Sciences 
of the United States of America, 100(7), 4150-4155.  
327. Xu, C., Li, C.Y. and Kong, A.N. (2005) Induction of phase I, II and III drug 
metabolism/transport by xenobiotics. Archives of Pharmacal Research, 28(3), 
249-268.  
328. Xue, D., Zhou, C., Shi, Y., Lu, H., Xu, R. and He, X. (2016) Nuclear 
transcription factor Nrf2 suppresses prostate cancer cells growth and migration 
through upregulating ferroportin. Oncotarget, 7(48), 78804-78812.  
329. Yang, G., Ge, S., Singh, R., Basu, S., Shatzer, K., Zen, M., Liu, J., Tu, Y., 
Zhang, C., Wei, J., Shi, J., Zhu, L., Liu, Z., Wang, Y., Gao, S. and Hu, M. (2017) 
Glucuronidation: driving factors and their impact on glucuronide disposition. Drug 
Metabolism Reviews, 49(2), 105-138.  
330. Yang, H., Magilnick, N., Lee, C., Kalmaz, D., Ou, X., Chan, J.Y. and Lu, S.C. 
(2005) Nrf1 and Nrf2 regulate rat glutamate-cysteine ligase catalytic subunit 
transcription indirectly via NF-kappaB and AP-1. Molecular and Cellular Biology, 
25(14), 5933-5946.  
331. Yang, Y., Zhou, M., Hu, M., Cui, Y., Zhong, Q., Liang, L. and Huang, F. 
(2018) UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with 
irinotecan-induced toxicity: A meta-analysis. Asia-Pacific Journal of Clinical 
Oncology, 14(5), e479-e489.  
332. Yilmaz, L., Borazan, E., Aytekin, T., Baskonus, I., Aytekin, A., Oztuzcu, S., 
Bozdag, Z. and Balik, A. (2015) Increased UGT1A3 and UGT1A7 expression is 
associated with pancreatic cancer. Asian Pacific Journal of Cancer Prevention : 
APJCP, 16(4), 1651-1655.  
333. Yueh, M.F. and Tukey, R.H. (2007) Nrf2-Keap1 signaling pathway regulates 
human UGT1A1 expression in vitro and in transgenic UGT1 mice. The Journal of 
Biological Chemistry, 282(12), 8749-8758.  
334. Zagorski, J.W., Turley, A.E., Dover, H.E., VanDenBerg, K.R., Compton, J.R. 




events following stimulation of Jurkat cells. Toxicological Sciences : An Official 
Journal of the Society of Toxicology, 136(1), 63-71.  
335. Zanardo, V., Golin, R., Amato, M., Trevisanuto, D., Favaro, F., Faggian, D. 
and Plebani, M. (2007) Cytokines in human colostrum and neonatal jaundice. 
Pediatric Research, 62(2), 191-194.  
336. Zella, L.A., Kim, S., Shevde, N.K. and Pike, J.W. (2006) Enhancers located 
within two introns of the vitamin D receptor gene mediate transcriptional 
autoregulation by 1,25-dihydroxyvitamin D3. Molecular Endocrinology 
(Baltimore, Md.), 20(6), 1231-1247.  
337. Zella, L.A., Meyer, M.B., Nerenz, R.D., Lee, S.M., Martowicz, M.L. and Pike, 
J.W. (2010) Multifunctional enhancers regulate mouse and human vitamin D 
receptor gene transcription. Molecular Endocrinology (Baltimore, Md.), 24(1), 
128-147.  
338. Zhang, D.D., Lo, S.C., Cross, J.V., Templeton, D.J. and Hannink, M. (2004) 
Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent 
ubiquitin ligase complex. Molecular and Cellular Biology, 24(24), 10941-10953.  
339. Zhang, L., Huang, M., Blair, I.A. and Penning, T.M. (2013) Interception of 
benzo[a]pyrene-7,8-dione by UDP glucuronosyltransferases (UGTs) in human 
lung cells. Chemical Research in Toxicology, 26(10), 1570-1578.  
340. Zhang, Z.M., Yang, X.Y., Yuan, J.H., Sun, Z.Y. and Li, Y.Q. (2009) 
Modulation of NRF2 and UGT1A expression by epigallocatechin-3-gallate in 
colon cancer cells and BALB/c mice. Chinese Medical Journal, 122(14), 1660-
1665.  
341. Zhao, C., Wang, X., Cong, Y., Deng, Y., Xu, Y., Chen, A. and Yin, Y. (2014) 
Effects of bile acids and the bile acid receptor FXR agonist on the respiratory 
rhythm in the in vitro brainstem medulla slice of neonatal Sprague-Dawley rats. 
PloS One, 9(11), e112212.  
342. Zheng, Z., Park, J.Y., Guillemette, C., Schantz, S.P. and Lazarus, P. (2001) 
Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with 
orolaryngeal cancer risk. Journal of the National Cancer Institute, 93(18), 1411-
1418.  
343. Zhou, C., Poulton, E.J., Grun, F., Bammler, T.K., Blumberg, B., Thummel, 




antagonist of the human steroid and xenobiotic nuclear receptor. Molecular 
Pharmacology, 71(1), 220-229.  
344. Zundorf, G. and Reiser, G. (2011) Calcium dysregulation and homeostasis of 
neural calcium in the molecular mechanisms of neurodegenerative diseases 
provide multiple targets for neuroprotection. Antioxidants & Redox Signaling, 





























































ORAL PRESENTATIONS  
 
21st Vitamin D Workshop, Barcelona, Spain AND Biomedical Science Post 
graduate Society Conference, Coleraine : 
 
• Regulation of Regulation of UDP-glucuronosyltransferase 1A gene family 
members by Vitamin D Receptor. Dube, K.,Goodman, R., Rodriguez E.P., 




• Laboratory Demonstrator to Undergraduate Students of :  
Clinical Biochemistry  
Clinical Haemotology  
Clinical and Molecular Genetics  
 
AWARDS 
• Trainee Travel Award ($500) - 21st Vitamin D Workshop, Barcelona, Spain  
• ILM Level 5 Diploma in Leadership and Management  
• 3MT (3 minute thesis) Semi- Finalist  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
